<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22104291</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>I want it now! Neural correlates of hypersensitivity to immediate reward in hypomania.</ArticleTitle><Pagination><MedlinePgn>530-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2011.10.008</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypomania is associated with impulsive decision making and risk taking, characteristics that may arise from hypersensitivity to reward. To date, the neural dynamics underlying intertemporal reward processing have neither been characterized clinically nor in the general population. Taking vulnerability to hypomania as a surrogate model of impulsivity, we utilized event-related potentials to study the neural mechanisms of delay discounting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the first experiment, 32 participants completed an established Two Choice Impulsivity Paradigm in which free choice between immediate and delayed rewards was used to quantify impulsivity behaviorally. In the second experiment, electroencephalography was recorded while 32 separately recruited participants completed a speeded response task involving gains and losses of monetary incentives to be paid at three different delays after the experiment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the first experiment, the hypomania-prone group made significantly more immediate choices than the control group. In the second experiment, the hypomania-prone group evidenced greater differentiation between delayed and immediate outcomes in early attention-sensitive (N1) and later reward-sensitive (feedback-related negativity) components. Proneness to hypomania was also associated with greater N1 amplitude to rewards per se.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate steeper delay discounting in hypomania at multiple stages of information processing. The N1 modulation by valence and delay suggests an attentional bias to immediate rewards, which may drive subsequent cognitive appraisal of outcomes (feedback-related negativity). These results highlight the early influence of attention on reward processing and provide support for reward dysregulation accounts of bipolar disorder. Potential implications for mindfulness training and other therapeutic interventions are highlighted.</AbstractText><CopyrightInformation>Copyright Â© 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Liam</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, Manchester, United Kingdom. Liam.Mason@manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Noreen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Marianna</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bentall</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>El-Deredy</LastName><ForeName>Wael</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22104291</ArticleId><ArticleId IdType="pii">S0006-3223(11)00966-8</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2011.10.008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22342167</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-622X</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Behaviour research and therapy</Title><ISOAbbreviation>Behav Res Ther</ISOAbbreviation></Journal><ArticleTitle>Positive overgeneralization and Behavioral Approach System (BAS) sensitivity interact to predict prospective increases in hypomanic symptoms: a behavioral high-risk design.</ArticleTitle><Pagination><MedlinePgn>231-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brat.2012.01.003</ELocationID><Abstract><AbstractText>Recent work has identified Behavioral Approach System (BAS) sensitivity as a risk factor for the first onset and recurrence of mood episodes in bipolar disorder, but little work has evaluated risk factors for the prospective development of hypomanic symptoms in individuals at risk for, but without a history of, bipolar disorder. The present study used a prospective behavioral high-risk design to evaluate the impact of positive overgeneralization, a cognitive correlate of risk for hypomania, on hypomanic symptoms in individuals with high vs. moderate BAS sensitivity, but without a history of mood elevation. Hierarchical linear regressions indicated that upward positive overgeneralization and BAS sensitivity interacted to predict increased levels of hypomanic symptoms at follow-up, controlling for initial hypomanic symptoms. The pattern of this interaction was such that positive overgeneralization predicted higher levels of hypomanic symptoms among high-BAS, but not moderate-BAS, individuals. Thus, the self-reported tendency to experience grandiose increases in confidence following success may confer additional risk for mood elevation among individuals already at risk for developing bipolar disorder. Potential implications for prevention and treatment are discussed.</AbstractText><CopyrightInformation>Copyright ÃÂ© 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stange</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Temple University, Philadelphia, PA 19122, United States. jstange@temple.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molz</LastName><ForeName>Ashleigh R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Chelsea L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Shapero</LastName><ForeName>Benjamin G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Bacelli</LastName><ForeName>Joanna M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Abramson</LastName><ForeName>Lyn Y</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Alloy</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH077908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077908-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 77908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Res Ther</MedlineTA><NlmUniqueID>0372477</NlmUniqueID><ISSNLinking>0005-7967</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="Y">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>01</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22342167</ArticleId><ArticleId IdType="pii">S0005-7967(12)00015-0</ArticleId><ArticleId IdType="doi">10.1016/j.brat.2012.01.003</ArticleId><ArticleId IdType="pmc">PMC3315156</ArticleId><ArticleId IdType="mid">NIHMS352899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 2005 Jun;35(6):855-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15997605</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2001 Feb;21(1):63-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11148896</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15023494</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Dir Psychol Sci. 2010 Jun 1;19(3):189-194</Citation><ArticleIdList><ArticleId IdType="pubmed">20606725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jun;47(6):511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2350203</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Res Pers. 2010 Dec;44(6):698-703</Citation><ArticleIdList><ArticleId IdType="pubmed">21769159</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Nov;134(1-3):438-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21683449</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1055-103</Citation><ArticleIdList><ArticleId IdType="pubmed">17064429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Emot. 2003 Mar;17(2):241-261</Citation><ArticleIdList><ArticleId IdType="pubmed">29715724</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Sep;42(11):920-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18082182</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2009 Jun 1;16(2):206-226</Citation><ArticleIdList><ArticleId IdType="pubmed">20161008</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):807-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15289279</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Sci. 2010 Jul;21(7):1021-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20519486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):310-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18271911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):459-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19685944</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):19-28</Citation><ArticleIdList><ArticleId IdType="pubmed">16503056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1986 Aug;95(3):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3745642</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Mar;30(2):467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10824667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 Feb;121(1):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">21668080</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2008 Oct;28(7):1188-205</Citation><ArticleIdList><ArticleId IdType="pubmed">18565633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2009 Dec;33(6):552-569</Citation><ArticleIdList><ArticleId IdType="pubmed">20376291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1997 Feb;106(1):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9103728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2009 Sep;65(9):891-905</Citation><ArticleIdList><ArticleId IdType="pubmed">19455611</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2003 Nov;85(5):909-21</Citation><ArticleIdList><ArticleId IdType="pubmed">14599253</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1981 Jun;90(3):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7288016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 May;122(3):294-300</Citation><ArticleIdList><ArticleId IdType="pubmed">19773086</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2008 Apr;64(4):450-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18327768</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1963 Aug;137:162-72</Citation><ArticleIdList><ArticleId IdType="pubmed">14047823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20888048</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 2004 Jan;41(1):37-45</Citation><ArticleIdList><ArticleId IdType="pubmed">14692999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2008 Aug 1;32(4):507-525</Citation><ArticleIdList><ArticleId IdType="pubmed">20360998</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 1989;40:457-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2648983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Res Pers. 2008 Dec;42(6):1427-1438</Citation><ArticleIdList><ArticleId IdType="pubmed">20376289</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2006;30(3):377-395</Citation><ArticleIdList><ArticleId IdType="pubmed">20198117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2007 Feb;116(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17324021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2008 Oct 1;32(5):702-713</Citation><ArticleIdList><ArticleId IdType="pubmed">20360996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 May;121(2):339-351</Citation><ArticleIdList><ArticleId IdType="pubmed">22004113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2011 Nov;120(4):956-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21553935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Psychol Gen. 1981 Sep;110(3):436-47</Citation><ArticleIdList><ArticleId IdType="pubmed">6457085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Feb;117(1):154-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18266493</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Nov;134(11):1227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">910973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 2001 Sep 1;23(3):133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">21765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jan;35(1):69-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15842030</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cogn Ther. 2009;2(2):176-187</Citation><ArticleIdList><ArticleId IdType="pubmed">20360995</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Addict Behav. 2004 Sep;18(3):275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Sci. 1999 Jun;22(3):491-517; discussion 518-69</Citation><ArticleIdList><ArticleId IdType="pubmed">11301519</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 Feb;25(2):241-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642648</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 15;50(6):468-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11566165</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 2009 Jun;48(Pt 2):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19254445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 1999 Dec 1;21(4):275-292</Citation><ArticleIdList><ArticleId IdType="pubmed">21765591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11195996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2004 Sep;130(5):711-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15367078</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 1988 Jul;25(4):373-91</Citation><ArticleIdList><ArticleId IdType="pubmed">3051073</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jun;35(6):773-82</Citation><ArticleIdList><ArticleId IdType="pubmed">655775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14668941</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0214-0934</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Drug news &amp; perspectives</Title><ISOAbbreviation>Drug News Perspect</ISOAbbreviation></Journal><ArticleTitle>Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice.</ArticleTitle><Pagination><MedlinePgn>453-63</MedlinePgn></Pagination><Abstract><AbstractText>Despite the devastating impact that bipolar disorder has on the lives of millions worldwide, little is known for certain about its etiology or pathophysiology. Whereas research has traditionally focused on biogenic amines, it is becoming increasingly more apparent that intracellular pathways are involved in the etiology and treatment of the disease and that a true understanding of the pathophysiology of bipolar disorder must address its neurobiology at different physiological levels, that is, molecular, cellular, systems and behavioral levels. There is now considerable biochemical evidence that the antimanic agents lithium and valproate robustly activate the ERK signaling cascade in therapeutically relevant paradigms. This raises the possibility that this pathway may play a role in the antimanic effects of these agents. The present paper reviews behavioral studies that may shed light on the involvement of the ERK pathway in affective-like behaviors in animals. The available literature suggests that genetic manipulations of the brain-derived neurotrophic factor (BDNF)-ERK kinase pathway produces a variety of changes in affective-like behaviors, with most changes consistent with manic-like behavior. Thus, overall, mice with targeted mutation of the BDNF gene exhibited increased spontaneous locomotion and increased response to acute amphetamine, altered response to chronic cocaine, increased aggression, increase in risk-taking behavior, as demonstrated by time spent in the center of an open field, and changes in eating patterns. Although it has to be acknowledged that the currently available behavioral data from the BDNF-ERK pathway mutants is less than ideal to offer real substantiation relating this pathway to bipolar disorder, the data still supports the possibility that this pathway modulates manic-like behavior in animals, and perhaps mania in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Einat</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-4405, USA. einath@intra.nimh.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>H K</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Gould</LastName><ForeName>T D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Drug News Perspect</MedlineTA><NlmUniqueID>8809164</NlmUniqueID><ISSNLinking>0214-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14668941</ArticleId><ArticleId IdType="pii">414</ArticleId><ArticleId IdType="doi">10.1358/dnp.2003.16.7.829357</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15950022</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants.</ArticleTitle><Pagination><MedlinePgn>1467-73</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systematic studies of children and adolescents with a diagnosis of bipolar disorder show that rates of attention-deficit/hyperactivity disorder (ADHD) range from 60% to 90%, but the prevalence and implications of ADHD in adults with bipolar disorder are less clear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The first consecutive 1000 adults with bipolar disorder enrolled in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) were assessed for lifetime ADHD. The retrospective course of bipolar disorder, current mood state, and prevalence of other comorbid psychiatric diagnoses were compared for the groups with and without lifetime comorbid ADHD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall lifetime prevalence of comorbid ADHD in this large cohort of bipolar patients was 9.5% (95% confidence interval 7.6%-11.4%); 14.7% of male patients and 5.8% of female patients with bipolar disorder had lifetime ADHD. Patients with bipolar disorder and ADHD had the onset of their mood disorder approximately 5 years earlier. After adjusting for age of onset, those with ADHD comorbidity had shorter periods of wellness and were more frequently depressed. We found that patients with bipolar disorder comorbid with ADHD had a greater number of other comorbid psychiatric diagnoses compared with those without comorbid ADHD, with substantially higher rates of several anxiety disorders and alcohol and substance abuse and dependence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lifetime ADHD is a frequent comorbid condition in adults with bipolar disorder, associated with a worse course of bipolar disorder and greater burden of other psychiatric comorbid conditions. Studies are needed that focus on the efficacy and safety of treating ADHD comorbid with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Depression and Clinical Research Program ACC 812, Boston, Massachusetts 02114, USA. anierenberg@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Pollack</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><CollectiveName>STEP-BD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15950022</ArticleId><ArticleId IdType="pii">S0006-3223(05)00113-7</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2005.01.036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24048399</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder - from endophenotypes to treatment.</ArticleTitle><Pagination><MedlinePgn>284-91</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There are a lot of unresolved issues associated with the classification, diagnosis, clinical management and understanding of the underlying pathogenic mechanisms of bipolar affective disorder.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To search for discrete endophenotypes in BAD.</AbstractText><AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">We studied various bipolar I and II and recurrent depression patient samples and healthy controls using descriptive data, self and clinician-rated scales for neurological and psychopathological symptoms, neurocognitive instruments, and inventories for temperamental and characterological features. We also looked into the efficacy, tolerability and cost/benefit ratio of sodium valproate in the treatment of acute mania.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BAD patients display deficits in the domains of memory, selective attention, working memory and psychomotor speed. Sensory, motor and complex neurological soft signs can be considered part and parcel of the symptomatology of BAD. The evidence linking hyperthymic temperament to the bipolar spectrum is not supported, while cyclothymia seems to be a marker of vulnerability to affective psychopathology. In contrast to others, we found significantly lower self-transcendence in BAD patients compared to controls. Early age of onset, abrupt onset, lability of mood and energy with late-day brightening and activation, discriminate bipolar from unipolar depression. Sodium valproate (especially if started intravenously) is a highly efficacious, cost-effective treatment approach for acute mania.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The discovery of BAD endophenotypes can enhance early diagnosis, prevent errors in treatment and help elucidate the genetic vulnerability for this grave disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hranov</LastName><ForeName>Luchezar G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Second Psychiatric Clinic of the University Hospital for Active Treatment, in Neurology and Psychiatry "Sveti Naum" 1, Dr. Lyuben Russev Street, 1113 Sofia, Bulgaria, lucho.hranov@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinova</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Stoyanova</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pandova</LastName><ForeName>Milena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hranov</LastName><ForeName>Georgi</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="Y">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24048399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7235858</PMID><DateCompleted><Year>1981</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>1981</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The Family Attitudes Questionnaire. Patients' and spouses' views of bipolar illness.</ArticleTitle><Pagination><MedlinePgn>562-8</MedlinePgn></Pagination><Abstract><AbstractText>A newly devised Family Attitudes Questionnaire has been employed to quantify the perceptions of 19 bipolar manic-depressive patients and their well spouses about the etiology, familial risk, and long-term burden of bipolar illness, and to assess their abilities about marriage and childbearing. In this study, 53% of well spouses compared with 5% of patients (P less than .01) would not have had children if they had known more about bipolar illness prior to making these decisions. The overall data suggest that the bipolar patients, compared with his or her spouse, minimizes the burden and denies the heritable/familial nature of affective illness. These findings should be borne in mind for genetic counseling as well as for psychotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Targum</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Dibble</LastName><ForeName>E D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Y B</ForeName><Initials>YB</Initials></Author><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001290" MajorTopicYN="Y">Attitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002668" MajorTopicYN="N">Child Rearing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008393" MajorTopicYN="Y">Marriage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7235858</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1980.01780300074009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16169087</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?</ArticleTitle><Pagination><MedlinePgn>279-85</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The objective of this retrospective chart review was to evaluate the phenomenology and response to divalproex in a sub-population of children admitted to an inpatient setting with severe impairing symptoms of irritability and aggression. In addition, we examined whether the symptomatology of this group was consistent with a pediatric divalproex-responsive bipolar spectrum disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The charts of 46 child and adolescent patients with prominent impulsive aggression with irritability admitted to a crisis stabilization center were assessed retrospectively. Impulsive aggressive symptoms were assessed for admission and discharge severity by two clinicians using the Overt Aggression Scale (OAS) and the Anger-Hostility Subscale of the SCL-90 (SCL-A), with overall functioning changes assessed using the Children's Global Assessment Scale (C-GAS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Statistically significant improvements were obtained for the group in the C-GAS, with significant decreases in the OAS and the SCL-A scores at discharge, following a maximal 14-day stay. No severe side effects were reported. All patients met the criteria for a potential pediatric bipolar phenotype.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This was a retrospective study without randomization or a control group. Additionally, the non-blinded design may have biased the raters concerning the effectiveness of divalproex for impulsive aggression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data are in line with divalproex response in children and adolescents with target symptoms of explosive temper and mood instability. Our data further suggest that such symptoms, coupled with impulsive aggression and irritability, as well as related manic symptoms, constitute a pediatric divalproex-responsive bipolar spectrum disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barzman</LastName><ForeName>Drew H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA. drew.barzman@fuse.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McConville</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Masterson</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sethuraman</LastName><ForeName>Gopalan</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Krissell</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kahwaty</LastName><ForeName>Ann-Marie</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="Y">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>06</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16169087</ArticleId><ArticleId IdType="pii">S0165-0327(05)00226-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.08.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16190786</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2005</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Comorbid anxiety in phenotypes of pediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>534-48</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There has been limited research on anxiety in pediatric bipolar disorder (BPD). Adult BPD studies suggest comorbid anxiety disorders are common and impact treatment outcome. We explored the association of comorbid anxiety with two phenotypes of pediatric BPD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied two groups of children. The first group (BPD; N = 31) represents the "narrow phenotype" of pediatric BPD, meeting stringent DSM-IV criteria for mania, including duration and elevated/expansive mood. The second group (ED; N = 32) exhibited chronic, non-episodic irritability without elation or grandiosity ("broad phenotype").</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both samples demonstrate high prevalence of anxiety (BPD 77.4%; ED 46.9%). In the BPD sample, anxiety predates BPD onset, and those with comorbid anxiety have earlier age of onset of BPD than those without. Children with BPD plus anxiety have more hospitalizations than those without anxiety. ED subjects with and without comorbid anxiety did not differ with respect to onset of ED symptoms or number of hospitalizations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Narrow and broad phenotype BPD children have high rates of comorbid anxiety, although only in the narrow phenotype group is comorbid anxiety associated with greater functional impairment BPD plus comorbid anxiety may represent a particularly severe phenotype of pediatric BPD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickstein</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Mood and Anxiety Disorders Program, Pediatrics and Developmental Neuropsychiatry Branch, National Institute of Mental Health, Bethesda, Maryland 20892-1255, USA. Dicksted@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Brendan A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Binstock</LastName><ForeName>Anna B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Pradella</LastName><ForeName>Anne G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Towbin</LastName><ForeName>Kenneth E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Pine</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16190786</ArticleId><ArticleId IdType="doi">10.1089/cap.2005.15.534</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24247478</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2072</ISSN><JournalIssue CitedMedium="Internet"><Volume>231</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>Antidepressant-induced mania or hypomania in DSM-5.</ArticleTitle><Pagination><MedlinePgn>315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-013-3358-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terao</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Faculty of Medicine, Oita University, Idaigaoka 1-1, Hasamamachi, Yufu, Oita, 879-5593, Japan, terao@med.oita-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Teruaki</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24247478</ArticleId><ArticleId IdType="doi">10.1007/s00213-013-3358-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):32-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14996139</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Nov;134(1-3):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">21742381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14504992</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>253</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Recurrence of bipolar disorders and major depression. A life-long perspective.</ArticleTitle><Pagination><MedlinePgn>236-40</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">It is not known whether the risk of recurrence declines with time in bipolar disorders and in major depression. This study describes the life-long recurrence risk of bipolar I, bipolar II and major depressive disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">160 bipolar-I, 60 bipolar-II and 186 depressive patients hospitalised between 1959 and 1963 were followed up every five years from 1965 to 1985. The course prior to the index hospitalisation was assessed in retrospect. The recurrence risk was computed by the multiplicative intensity model (Aalen et al. 1980).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cumulative intensity curves for the transition from states of remission to new episodes remained linear over 30 to 40 years after onset, indicating a constant risk of recurrence over the life-span up to the age of 70 or more. The recurrence risk of bipolar disorders (0.40 episodes per year) was about twice that of depression (0.20 episodes per year); BP-II disorders had only a slightly higher recurrence risk than BP-I disorders. There were no significant gender differences in the course of either bipolar or depressive disorders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">If long-term trials confirm its efficacy, these results support lifelong prophylactic treatment of severe types of mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zurich University Psychiatric Hospital, Lenggstrasse 31, 8029 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamma</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sellaro</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lavori</LastName><ForeName>Philip W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Heping</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="Y">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14504992</ArticleId><ArticleId IdType="doi">10.1007/s00406-003-0437-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10760562</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Social support and self-esteem predict changes in bipolar depression but not mania.</ArticleTitle><Pagination><MedlinePgn>79-86</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Our own and other research has suggested that social support predicts course of bipolar disorder, with particularly strong effects on depressive symptoms. Within this paper, we examine which components of social support appear most powerful.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-one individuals with Bipolar I disorder were followed longitudinally for 9 months. Participants completed a standardized symptom severity interview monthly, and at a 2-month follow-up, they completed the Interpersonal Support Evaluation List. At a 6-month follow-up, they completed the Rosenberg Self-Esteem Inventory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Self-esteem support appeared to the most important predictor of change in depression across a 6-month follow-up, and multiple regression analyses suggested that social support effects were mediated through self-esteem. LIMITATIONS AND IMPLICATIONS: Although the small sample size suggests a need for replication, current results highlight the importance of psychosocial variables in the course of bipolar depression. Self-esteem may be a particularly important target for clinical interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Miami, PO Box 249229, Coral Gables, FL, USA. sjohnson@maimi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Winett</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH55950</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="Y">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="Y">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10760562</ArticleId><ArticleId IdType="pii">S0165-0327(99)00133-0</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(99)00133-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16263839</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Secondary mania in older adults.</ArticleTitle><Pagination><MedlinePgn>2033-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>John O</ForeName><Initials>JO</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA. johnbrooks@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoblyn</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>H1250JIK0A</RegistryNumber><NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017291" MajorTopicYN="N">Clarithromycin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16263839</ArticleId><ArticleId IdType="pii">162/11/2033</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17714370</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9630</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of child psychology and psychiatry, and allied disciplines</Title><ISOAbbreviation>J Child Psychol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dynamic mapping of cortical development before and after the onset of pediatric bipolar illness.</ArticleTitle><Pagination><MedlinePgn>852-62</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There are, to date, no pre-post onset longitudinal imaging studies of bipolar disorder at any age. We report the first prospective study of cortical brain development in pediatric bipolar illness for 9 male children, visualized before and after illness onset.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We contrast this pattern with that observed in a matched group of healthy children as well as in a matched group of 8 children with 'atypical psychosis' who had similar initial presentation marked by mood dysregulation and transient psychosis (labeled as 'multi-dimensionally impaired' (MDI)) as in the bipolar group, but have not, to date, developed bipolar illness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dynamic maps, reconstructed by applying novel cortical pattern matching algorithms, for the children who became bipolar I showed subtle, regionally specific, bilaterally asymmetrical cortical changes. Cortical GM increased over the left temporal cortex and decreased bilaterally in the anterior (and sub genual) cingulate cortex. This was seen most strikingly after the illness onset, and showed a pattern distinct from that seen in childhood onset schizophrenia. The bipolar neurodevelopmental trajectory was generally shared by the children who remained with MDI diagnosis without converting to bipolar I, suggesting that this pattern of cortical development may reflect affective dysregulation (lability) in general.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These dynamic trajectories of cortical development may explain age-related disparate findings from cross-sectional studies of bipolar illness, and suggest the importance of mood disordered non-bipolar control group in future studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gogtay</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Child Psychiatry Branch, NIMH, Bethesda, MD 20892, USA. gogtayn@intra.nimh.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ordonez</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Kiralee M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Greenstein</LastName><ForeName>Deanna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vaituzis</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lenane</LastName><ForeName>Marge</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Clasen</LastName><ForeName>Liv</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Giedd</LastName><ForeName>Jay N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nugent</LastName><ForeName>Tom F</ForeName><Initials>TF</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 MH060482</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Child Psychol Psychiatry</MedlineTA><NlmUniqueID>0375361</NlmUniqueID><ISSNLinking>0021-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17714370</ArticleId><ArticleId IdType="pii">JCPP1747</ArticleId><ArticleId IdType="doi">10.1111/j.1469-7610.2007.01747.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11481189</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><Issue>8</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium discontinuation: uncovering latent bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>1337-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faedda</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2000 Sep;157(9):1429-35</RefSource><PMID Version="1">10964859</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11481189</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.158.8.1337-a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15654936</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>African-American participants in a bipolar disorder registry: clinical and treatment characteristics.</ArticleTitle><Pagination><MedlinePgn>82-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The goal of this paper was to compare clinical characteristics and treatment history of African-American and Caucasian participants in a bipolar disorder registry.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Western Pennsylvania Bipolar Disorder Registry used several recruitment methods to reach individuals self-identified as having bipolar disorder. Individuals who contacted and joined the registry completed an interviewer-administered questionnaire on clinical characteristics and treatment history. A sample of 2,718 registry participants was analyzed in order to compare these characteristics and history by race.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">African-Americans in the registry reported a greater number of inpatient hospitalizations (9.8 versus 4.4) than Caucasians, as well as a higher suicide attempt rate (64% versus 49%). African-American participants were more likely to report a family member with schizophrenia. With respect to psychotropic medication, African-Americans were less likely to report taking antimanic medication or benzodiazepines, but more likely to report taking antipsychotics than Caucasians.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present findings reinforce previous reports regarding the chronicity and severity of bipolar disorder among African-Americans. They also support previous studies that found high rates of attempted suicide among African-Americans with bipolar disorder. These findings provide further impetus for specific community and mental health services delivery efforts to reduce barriers to early accurate diagnosis and to appropriate ambulatory treatment for bipolar disorder.</AbstractText><CopyrightInformation>Copyright (c) 2005, Blackwell Munksgaard.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. kupferdj@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grochocinski</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010414" MajorTopicYN="N" Type="Geographic">Pennsylvania</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15654936</ArticleId><ArticleId IdType="pii">BDI163</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00163.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2282683</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-1769</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>12</Issue><PubDate><Year>1990</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Zhonghua hu li za zhi = Chinese journal of nursing</Title><ISOAbbreviation>Zhonghua Hu Li Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Experience in the care of mental patients with suicide attempts].</ArticleTitle><Pagination><MedlinePgn>627-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Hu Li Za Zhi</MedlineTA><NlmUniqueID>8201928</NlmUniqueID><ISSNLinking>0254-1769</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2282683</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5831875</PMID><DateCompleted><Year>1965</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>1965</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychopharmacologia</Title><ISOAbbreviation>Psychopharmacologia</ISOAbbreviation></Journal><ArticleTitle>[Urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) in 20 atypical cycloid-type psychoses].</ArticleTitle><Pagination><MedlinePgn>266-71</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Constantinidis</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dejaiffe</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>ExcrÃ©tion urinaire de l'acide 5-hydroxyindoleacÃ©tique (5-HIAA) de 20 psychoses atypiques de type cycloÃ¯de.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacologia</MedlineTA><NlmUniqueID>7609417</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>54-16-0</RegistryNumber><NameOfSubstance UI="D006897">Hydroxyindoleacetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006897" MajorTopicYN="N">Hydroxyindoleacetic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014556" MajorTopicYN="N">Urine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1965</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1965</Year><Month>3</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1965</Year><Month>3</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5831875</ArticleId><ArticleId IdType="doi">10.1007/BF00403693</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Presse Med. 1962 Jun 2;70:1352-4</Citation><ArticleIdList><ArticleId IdType="pubmed">13921382</ArticleId></ArticleIdList></Reference><Reference><Citation>Presse Med. 1963 May 4;71:1116-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14016979</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7848047</PMID><DateCompleted><Year>1995</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients.</ArticleTitle><Pagination><MedlinePgn>114-23</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given the therapeutic and prognostic importance of the unipolar-bipolar dichotomy, predicting which patients will become bipolar subsequent to index diagnosis of major depressive disorder (MDD) is of paramount clinical significance. We sought to characterize the profile of patients with MDD who would convert to the more subtle bipolar subtype (known as BPII) on the basis of clinical and personality variables obtained during MDD episodes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 559 patients, comprehensively evaluated with the Schedule of Affective Disorders and Schizophrenia and "unipolar" MDD at entry, were administered 17 self-report personality measures. Hypomanic and manic episodes were systematically recorded over a prospective observation period of up to 11 years. We compared 48 converters to BPII (8.6%) with 22 converters to bipolar I (BPI) (3.9%) and the remaining larger group of unipolar patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Except for greater acuteness, severity, and psychotic symptomatology, BPI converters were essentially similar to MDD nonconverters. By contrast, BPII converters were robustly distinguished from those with MDD who remained unipolar on the basis of self-report measures along the newly derived factors of Mood Lability, Energy-Activity, and Daydreaming. This profile was associated with early age at onset of MDD and pleomorphic psychopathology beyond the usual affective realm, high rates of substance abuse, as well as educational, marital, and occupational disruption and minor antisocial acts prior to discrete hypomanic episodes. Overall, BPII switchers had a more protracted and tempestuous course with shorter well intervals. "Habitual self" descriptions of temperamental instability during MDD episodes provided useful clinical information for predicting which depressed patients will switch to BPII, attaining a sensitivity of 91% for all three factors combined (23 items); Mood Lability alone (nine items) was the most specific predictor (86%), though of lower sensitivity (42%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The BPII subtype is best understood by such lability intruding into, and possibly its accentuation during, depressive episodes, thereby creating an intimate interweaving of trait and state. Clinicians must note that the foregoing temperamental profile appears more fundamental in defining the affective dysregulation of the BPII subtype than hypomanic episodes emphasized in DSM-IV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health (NIMH), Collaborative Program on the Psychobiology of Depression (Clinical Studies), Rockville, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maser</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Zeller</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Coryell</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Warshaw</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH025478</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1995.03950140032004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7325027</PMID><DateCompleted><Year>1982</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-5062</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>5</Issue><PubDate><MedlineDate>1981 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Actas luso-espanolas de neurologia, psiquiatria y ciencias afines</Title><ISOAbbreviation>Actas Luso Esp Neurol Psiquiatr Cienc Afines</ISOAbbreviation></Journal><ArticleTitle>[Evaluation of the HLA system in a sample of patients with endogenous depression].</ArticleTitle><Pagination><MedlinePgn>363-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campillo</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Duque del RÃ­o</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fuentenebro de Diego</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Llorente</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>MÃ©ndez Barroso</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>ValoraciÃ³n del sistema HLA en una muestra de pacientes con depresiÃ³n endÃ³gena.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Luso Esp Neurol Psiquiatr Cienc Afines</MedlineTA><NlmUniqueID>0355573</NlmUniqueID><ISSNLinking>0300-5062</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7325027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25454116</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>225</Volume><Issue>1-2</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Relationship between atypical depression and social anxiety disorder.</ArticleTitle><Pagination><MedlinePgn>79-84</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(14)00836-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2014.10.014</ELocationID><Abstract><AbstractText>In this study, we aimed to investigate the effects of atypical and non-atypical depression comorbidity on the clinical characteristics and course of social anxiety disorder (SAD). A total of 247 patients with SAD were enrolled: 145 patients with a current depressive episode (unipolar or bipolar) with atypical features, 43 patients with a current depressive episode with non-atypical features and 25 patients without a lifetime history of depressive episodes were compared regarding sociodemographic and clinical features, comorbidity rates, and severity of SAD, depression and functional impairment. Thirty four patients with a past but not current history of major depressive episodes were excluded from the comparisons. 77.1% of current depressive episodes were associated with atypical features. Age at onset of SAD and age at initial major depressive episode were lower in the group with atypical depression than in the group with non-atypical depression. History of suicide attempts and bipolar disorder comorbidity was more common in the atypical depression group as well. Atypical depression group has higher SAD and depression severity and lower functionality than group with non-atypical depression. Our results indicate that the presence of atypical depression is associated with more severe symptoms and more impairment in functioning in patients with SAD. </AbstractText><CopyrightInformation>Copyright Â© 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koyuncu</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bahat Group Hospitals, Psychiatry Unit, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin</LastName><ForeName>Erhan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical Faculty, Psychiatry Department, Istanbul, Turkey. Electronic address: erhanert76@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin</LastName><ForeName>Banu AslantaÅ</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Istanbul Bilim University, Medical Faculty, Psychiatry Department, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binbay</LastName><ForeName>Zerrin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Kanuni Sultan SÃ¼leyman Hospital, Psychiatric Clinic, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>YÃ¼ksel</LastName><ForeName>ÃaÄrÄ±</ForeName><Initials>Ã</Initials><AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical Faculty, Psychiatry Department, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveci</LastName><ForeName>Erdem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bezmialem Vakif University, Medical Faculty, Psychiatry Department, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>TÃ¼kel</LastName><ForeName>RaÅit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical Faculty, Psychiatry Department, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atypical depression</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Mood disorders</Keyword><Keyword MajorTopicYN="N">Social anxiety disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25454116</ArticleId><ArticleId IdType="pii">S0165-1781(14)00836-1</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2014.10.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28365865</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-8491</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study.</ArticleTitle><Pagination><MedlinePgn>169-177</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00406-017-0791-0</ELocationID><Abstract><AbstractText>Bipolar disorders (BDs) are prevalent, comorbid and disabling conditions, associated with the highest suicide risk among psychiatric illnesses. In the last few years, new efforts to better characterize the socio-demographic and clinical profiles of BD type I vs II have been documented by several reports, with novel and insightful findings in the field. The present multicenter study aimed to provide a comprehensive and reliable representation of the Italian reality, through the analysis of the largest national sample of bipolar patients collected so far. A total of 1500 patients (BD I nâ=â963 and BD II nâ=â537) from different psychiatric departments, participating in the Italian Chapter of the "International Society of Bipolar Disorders" (ISBD), were assessed and divided into two groups on the basis of their diagnostic subtype, and different socio-demographic and clinical variables were compared between the two subgroups. Chi-squared tests for categorical variables and t tests for continuous variables were performed for group comparison. Furthermore, a multivariable logistic regression was performed, considering diagnostic bipolar subtype (type I or II) as dependent variable, and socio-demographic/clinical characteristics as independent variables. BD I vs II patients showed an overall less favorable socio-demographic and clinical profile. In addition, the multivariable logistic regression showed that BD II vs BD I was predicted by the absence of lifetime suicide attempts (ORâ=â1.58, pâ=â0.01), a later age of diagnosis (ORâ=â1.03, pâ&lt;â0.01), less hypomanic episodes in the last year (ORâ=â2.29, pâ&lt;â0.0001) and absence of psycho-educational interventions in the last year (ORâ=â0.51, pâ&lt;â0.01). BD I and II patients were found to significantly differ in relation to specific clinical variables, which should be considered within updated diagnostic-therapeutic algorithms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altamura</LastName><ForeName>A Carlo</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buoli</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-3359-3191</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy. massimiliano.buoli@unimi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cesana</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of Biostatistics and Biomathematics, University of Brescia, Viale Europa 11, 25123, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Osso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tacchini</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Psychiatric Unit, Department of Neuroscience, S. Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Mental Health, University of Siena Medical Center, Siena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Siena Medical Center, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bartolomeis</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Psychiatry and Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology, School of Medicine, University "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maina</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Psychiatric Unit, Department of Neuroscience, S. Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchetti</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Psychiatric Unit, School of Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BD type I</Keyword><Keyword MajorTopicYN="N">BD type II</Keyword><Keyword MajorTopicYN="N">Bipolar disorder (BD)</Keyword><Keyword MajorTopicYN="N">Clinical variables</Keyword><Keyword MajorTopicYN="N">Socio-demographic features</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28365865</ArticleId><ArticleId IdType="doi">10.1007/s00406-017-0791-0</ArticleId><ArticleId IdType="pii">10.1007/s00406-017-0791-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 2015 Nov;132(5):324-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26367266</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2003;17(7):491-511</Citation><ArticleIdList><ArticleId IdType="pubmed">12751919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Jul 1;179:114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25863906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Jun;17(4):349-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25594775</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2010 Jan;25(1):47-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19926262</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2011 Feb;41(1):6-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21309819</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):667-73, ix-x</Citation><ArticleIdList><ArticleId IdType="pubmed">10550861</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):48-52</Citation><ArticleIdList><ArticleId IdType="pubmed">25912537</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2016 May;76:94-100</Citation><ArticleIdList><ArticleId IdType="pubmed">26921874</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jun;73(6):778-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22225677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):531-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17680925</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 May 20;10(5):e0126530</Citation><ArticleIdList><ArticleId IdType="pubmed">25992560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Aug;71(8):1000-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20361912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Dec;64(12):1483-94</Citation><ArticleIdList><ArticleId IdType="pubmed">14728111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Mar;60(3):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Jun;6(2):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12890308</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2016 Sep;18(9):88</Citation><ArticleIdList><ArticleId IdType="pubmed">27542851</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2016 Jun 14;38(4):270-274</Citation><ArticleIdList><ArticleId IdType="pubmed">27304255</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2005 Dec;7(6):462-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16318825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11869765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):548-56</Citation><ArticleIdList><ArticleId IdType="pubmed">24127825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Nov;66(11):1456-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16420084</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Feb;166(2):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19122008</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Dec;61(1-2):13-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11099736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1997 Mar-Apr;38(2):98-101</Citation><ArticleIdList><ArticleId IdType="pubmed">9056128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Apr;138(1-2):46-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22284021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1976 Feb;11(1):31-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1260075</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Mar;64(3):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12716276</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Psychiatry Psychother. 2015 Jul-Sep;37(3):152-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26630406</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Suicide Res. 2005;9(3):279-300</Citation><ArticleIdList><ArticleId IdType="pubmed">16020171</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Jun;6(2):127-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12890306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Dec 1;188:257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">26378735</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2004 Mar-Apr;45(2):77-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14999656</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2013 Dec;263(8):663-73</Citation><ArticleIdList><ArticleId IdType="pubmed">23370488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):343-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21843274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Aug 15;182:70-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25978716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Feb;12(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20148862</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2010 May;25(3):172-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20305566</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Oct;11(9 Suppl):S271-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16232009</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2009 Dec;11(6):494-502</Citation><ArticleIdList><ArticleId IdType="pubmed">19909673</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Mar;133(3):174-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26555604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jan;152-154:250-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24200153</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1985 Jan-Feb;8(1):17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3156908</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">11869754</ArticleId></ArticleIdList></Reference><Reference><Citation>Iran J Psychiatry Behav Sci. 2016 Aug 14;10 (3):e2298</Citation><ArticleIdList><ArticleId IdType="pubmed">27822276</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jun;131(1-3):59-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21195482</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2005;6(3):198-205</Citation><ArticleIdList><ArticleId IdType="pubmed">16166029</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2013;(442):11-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23581788</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2014 Apr;48(4):314-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24610031</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2017 Aug;22(4):325-332</Citation><ArticleIdList><ArticleId IdType="pubmed">26905615</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Obstet Gynecol. 2015 Dec;213(6):876</Citation><ArticleIdList><ArticleId IdType="pubmed">26264825</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2008 Feb;4(1):311-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18728801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10507518</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>The conflict of the nosologists: views on schizophrenia and manic-depressive illness in the early part of the 20th century.</ArticleTitle><Pagination><MedlinePgn>95-100; discussion 159</MedlinePgn></Pagination><Abstract><AbstractText>The distinction between schizophrenia (dementia praecox) and bipolar disorder (manic-depressive insanity), proposed by Kraepelin in 1896, was the subject of vigorous debate in the first decades of this century. The debate addressed fundamental questions about the principles underlying the nosology of psychiatric disorders, and the issues raised remain as relevant today as at the time they were formulated. A meta-analysis of a sample of Kraepelin's primary data suggests that his original classification was consistent with the empirical evidence. However, heeding his critics, Kraepelin modified considerably his earlier views and proposed a conceptual model of the pathogenesis of schizophrenia and affective psychosis that is consonant with present-day ideas arising out of neuroscience and genetics. The lesson to be drawn is that nosological arguments should be put on hold until basic understanding is gained of the specific mechanisms of syndromogenesis across diagnostic boundaries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jablensky</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, University of Western Australia, Perth, Australia. assen@cyllene.uwa.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>Q</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002965" MajorTopicYN="N">Classification</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Kraepelin</LastName><ForeName>E</ForeName><Initials>E</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10507518</ArticleId><ArticleId IdType="pii">S0920996499001061</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(99)00106-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18507483</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Acute treatment of patients with bipolar mixed episodes.</ArticleTitle><Pagination><MedlinePgn>e10</MedlinePgn></Pagination><Abstract><AbstractText>Managing bipolar mixed states should start by establishing a diagnosis, assessing for comorbidities, and clarifying targets for therapy. Differentiating between unipolar and bipolar disorder is important because these conditions have dissimilar efficacious pharmacotherapeutic options. To treat mixed states, atypical antipsychotics or divalproex have been shown to be effective, and antidepressants should generally be avoided. Because of the complexity of mixed episodes, monotherapy may be insufficient and patients may require combination treatment. As more medications become available in the treatment of bipolar disorder, algorithms can help clinicians make the appropriate treatment choices by offering recommendations for sequencing agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18507483</ArticleId><ArticleId IdType="doi">10.4088/jcp.0408e10</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18242583</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task.</ArticleTitle><Pagination><MedlinePgn>162-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2007.12.001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BPD) features cycling mood states ranging from depression to mania with intermittent phases of euthymia. Bipolar disorder subjects often show excessive goal-directed and pleasure-seeking behavior during manic episodes and reduced hedonic capacity during depressive episodes, indicating that BPD might involve altered reward processing. Our goal was to test the hypothesis that BPD is characterized by impairments in adjusting behavior as a function of prior reinforcement history, particularly in the presence of residual anhedonic symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighteen medicated BPD subjects and 25 demographically matched comparison subjects performed a probabilistic reward task. To identify putative dysfunctions in reward processing irrespective of mood state, primary analyses focused on euthymic BPD subjects (n = 13). With signal-detection methodologies, response bias toward a more frequently rewarded stimulus was used to objectively assess the participants' propensity to modulate behavior as a function of reinforcement history.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative to comparison subjects, euthymic BPD subjects showed a reduced and delayed acquisition of response bias toward the more frequently rewarded stimulus, which was partially due to increased sensitivity to single rewards of the disadvantageous stimulus. Analyses considering the entire BPD sample revealed that reduced reward learning correlated with self-reported anhedonic symptoms, even after adjusting for residual manic and anxious symptoms and general distress.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study provides preliminary evidence indicating that BPD, even during euthymic states, is characterized by dysfunctional reward learning in situations requiring integration of reinforcement information over time and thus offers initial insights about the potential source of dysfunctional reward processing in this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pizzagalli</LastName><ForeName>Diego A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Psychology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iosifescu</LastName><ForeName>Dan V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH068376-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH068376-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH068376-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH068376-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH068376-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH068376</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH68376</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001245" MajorTopicYN="N">Association Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="N">Discrimination Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010364" MajorTopicYN="N">Pattern Recognition, Visual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011337" MajorTopicYN="Y">Probability Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012055" MajorTopicYN="N">Reinforcement Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18242583</ArticleId><ArticleId IdType="pii">S0006-3223(07)01205-X</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2007.12.001</ArticleId><ArticleId IdType="pmc">PMC2464620</ArticleId><ArticleId IdType="mid">NIHMS56990</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1975-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16199850</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Oct;158(10):1605-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11578991</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Feb 15;57(4):319-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15705346</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Aug 1;119(3):243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12914895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S89-S101</Citation><ArticleIdList><ArticleId IdType="pubmed">15571794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2007 Feb;116(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17324021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jul 15;60(2):93-105</Citation><ArticleIdList><ArticleId IdType="pubmed">16406007</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 Feb;25(2):241-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642648</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(434):41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17688462</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1999 Nov;22(11):521-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10529820</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 15;60(10):1147-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16806107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Mar;63(1-3):179-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11246094</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1009-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):536-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16403179</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Jul 15;50(2):71-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11526998</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jan 1;55(1):32-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14706422</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2007 Jul;45(7):1609-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16959211</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1995 Feb;104(1):3-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7897050</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2001 Feb;110(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11261398</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):601-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12796223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct 15;82(2):203-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15488248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 2007 Jun;38(2):168-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17107657</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 1989;40:457-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2648983</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):225-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16449475</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 1;63(7):693-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17919457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 2001 Sep 1;23(3):133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">21765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1028-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11195996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 May;3(3):220-6, 190-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9672897</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Jun;9(6):557-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15098002</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2001 Dec;124(Pt 12):2550-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11701607</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Anal Behav. 1979 Nov;32(3):373-86</Citation><ArticleIdList><ArticleId IdType="pubmed">512570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Psychol. 1999 Sep;28(3):366-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10446686</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2008 Feb;196(2):221-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17909750</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 May;31(4):679-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11352370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">22464935</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The impact of the CACNA1C risk allele on limbic structures and facial emotions recognition in bipolar disorder subjects and healthy controls.</ArticleTitle><Pagination><MedlinePgn>94-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.03.014</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Impairments in facial emotion recognition (FER) have been reported in bipolar disorder (BD) during all mood states. FER has been the focus of functional magnetic resonance imaging studies evaluating differential activation of limbic regions. Recently, the Î±1-C subunit of the L-type voltage-gated calcium channel (CACNA1C) gene has been described as a risk gene for BD and its Met allele found to increase CACNA1C mRNA expression. In healthy controls, the CACNA1C risk (Met) allele has been reported to increase limbic system activation during emotional stimuli and also to impact on cognitive function. The aim of this study was to investigate the impact of CACNA1C genotype on FER scores and limbic system morphology in subjects with BD and healthy controls.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Thirty-nine euthymic BD I subjects and 40 healthy controls were submitted to a FER recognition test battery and genotyped for CACNA1C. Subjects were also examined with a 3D 3-Tesla structural imaging protocol.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CACNA1C risk allele for BD was associated to FER impairment in BD, while in controls nothing was observed. The CACNA1C genotype did not impact on amygdala or hippocampus volume neither in BD nor controls.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Sample size.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present findings suggest that a polymorphism in calcium channels interferes FER phenotype exclusively in BD and doesn't interfere on limbic structures morphology.</AbstractText><CopyrightInformation>Copyright Â© 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soeiro-de-Souza</LastName><ForeName>MÃ¡rcio Gerhardt</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Mood disorders Unit (GRUDA), Department and Institute of Psychiatry, School of Medicine, University of Sao Paulo, GRUDA IPq-FMUSP, Brazil. mgss@usp.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otaduy</LastName><ForeName>Maria ConcepciÃ³n Garcia</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Carolina Zadres</ForeName><Initials>CZ</Initials></Author><Author ValidYN="Y"><LastName>Bio</LastName><ForeName>Danielle S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Ricardo Alberto</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22464935</ArticleId><ArticleId IdType="pii">S0165-0327(12)00202-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.03.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17785956</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-8727</ISSN><JournalIssue CitedMedium="Print"><Volume>213</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Tohoku journal of experimental medicine</Title><ISOAbbreviation>Tohoku J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>79-87</MedlinePgn></Pagination><Abstract><AbstractText>The changes in antioxidant-oxidant balance play important roles in the pathophysiology of neuropsychiatric conditions. Bipolar disorder (BD) is a psychiatric condition with recurrent mood disturbances. This study evaluates the effects of treatment with lithium, alone or in combination with antipsychotic olanzapine, on oxidant-antioxidant status and atherogenic character in patients with BD. The blood samples from 15 patients were tested before the treatment (pre-treatment phase) and at the ends of two consecutive treatment periods: period I, treatment with lithium and an antipsychotic drug, olanzapine (first 6 months) and period II, treatment with only lithium (6 months following period I). We measured serum atherogenic lipids (total cholesterol, triglycerides, and LDL-cholesterol), plasma lipid peroxides (thiobarbituric acid-reactive substances), antioxidant enzymes (glutathione peroxidase, superoxide dismutase, and catalase) in neutrophils and lymphocytes, and total antioxidant status in plasma. Compared with pre-treatment phase, the lipid parameters were increased with each treatment; especially, LDL-cholesterol was significantly increased only with lithium treatment. These findings alert to be cautious about use of lithium in patients with atherogenic conditions. Moreover, plasma lipid peroxides were decreased significantly after the combination therapy and further decreased with lithium treatment. Antioxidant enzyme activities in lymphocytes were decreased after both types of treatment. Importantly, plasma total antioxidant status was increased only with lithium treatment. Thus, treatment with lithium alone decreases already up-set oxidant status in BD. In conclusion, the combination therapy with olanzapine is better in terms of atherogenic profile, while lithium alone produces better antioxidant status in patients with BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>AliyazicioÄlu</LastName><ForeName>Rezzan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vocational School of Health Sciences, Karadeniz Technical University, 61080 Trabzon, Turkey. rezzanaoglu@mynet.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kural</LastName><ForeName>BirgÃ¼l</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Colak</LastName><ForeName>Meltem</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Karahan</LastName><ForeName>S Caner</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Ayvaz</LastName><ForeName>Sibel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>DeÄer</LastName><ForeName>Orhan</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Tohoku J Exp Med</MedlineTA><NlmUniqueID>0417355</NlmUniqueID><ISSNLinking>0040-8727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017392" MajorTopicYN="N">Thiobarbituric Acid Reactive Substances</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17785956</ArticleId><ArticleId IdType="pii">JST.JSTAGE/tjem/213.79</ArticleId><ArticleId IdType="doi">10.1620/tjem.213.79</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17688458</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1591</ISSN><JournalIssue CitedMedium="Print"><Issue>434</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica. Supplementum</Title><ISOAbbreviation>Acta Psychiatr Scand Suppl</ISOAbbreviation></Journal><ArticleTitle>Depot antipsychotic medications in bipolar disorder: a review of the literature.</ArticleTitle><Pagination><MedlinePgn>3-16</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the literature on the efficacy and safety of depot formulations of first- and second-generation antipsychotic medications (FGAs and SGAs) in patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a computer-aided MEDLINE search using the search terms 'depot antipsychotic', 'bipolar disorder' and 'compliance.'</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified eight published reports in bipolar patients regarding the use of depot FGAs, and six preliminary reports on the use of depot SGAs. These studies suggest that depots FGAs are efficacious in preventing manic episodes during the maintenance treatment of bipolar disorder. Several studies, however, indicate that depot FGAs may be associated with increased time with depressive symptoms, particularly in patients with a predominantly depressive course of illness. Preliminary data on the role of depot formulations of SGAs suggest that they reduce the frequency of both manic and depressive episodes during maintenance treatment, and are well tolerated by patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">After a careful risk-benefit analysis, depot antipsychotics may be considered for the long-term control of mood episodes in bipolar patients who have relapsed due to medication non-adherence or who have failed to respond to standard therapies. Depot FGAs should be avoided in patients with a high burden of illness from depressive symptoms and particularly in those judged to be at high risk of suicide. The available data on depot formulations of SGAs indicate that they are efficacious in the maintenance treatment of bipolar illness without increasing the burden of the depressive pole of the illness, but further systematic studies are required to definitively assess this.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Mood Disorders Clinical Research Unit, The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratoomsri</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Psychiatr Scand Suppl</MedlineTA><NlmUniqueID>0370365</NlmUniqueID><ISSNLinking>0065-1591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>61</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17688458</ArticleId><ArticleId IdType="pii">ACP1054</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2007.01054.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25180527</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1559-3126</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatric rehabilitation journal</Title><ISOAbbreviation>Psychiatr Rehabil J</ISOAbbreviation></Journal><ArticleTitle>Every family has a north star: family healing and recovery.</ArticleTitle><Pagination><MedlinePgn>261-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1037/prj0000094</ELocationID><Abstract><AbstractText Label="TOPIC" NlmCategory="OBJECTIVE">This contribution describes a personal recovery journey and the creation of an organization focused on rebuilding relationships between members of families living with a parent(s) with psychiatric disabilities.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Adults living with serious mental illnesses have the same hopes and dreams of being successful and resourceful parents to their children and contributing family members as other parents. Specific suggestions highlight ways in which mental health and psychiatric rehabilitation practitioners can support and promote recovery for families.</AbstractText><AbstractText Label="SOURCES USED" NlmCategory="METHODS">Personal data and resource information available on the Child and Family Connections website located at http://www.childfamilyconnections.org.</AbstractText><AbstractText Label="CONCLUSIONS AND IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">Practical guidelines are offered to engage and work with parents living with mental illnesses. Improving our understanding and capacity to better meet the needs of parents with psychiatric disabilities will more likely enhance their roles as parents.</AbstractText><CopyrightInformation>(PsycINFO Database Record (c) 2014 APA, all rights reserved).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Child and Family Connections, Inc.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D062210">Personal Narrative</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Rehabil J</MedlineTA><NlmUniqueID>9601800</NlmUniqueID><ISSNLinking>1095-158X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005219" MajorTopicYN="Y">Father-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25180527</ArticleId><ArticleId IdType="pii">2014-35506-002</ArticleId><ArticleId IdType="doi">10.1037/prj0000094</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32498603</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Bipolar Disorder Among Patients Diagnosed With Frontotemporal Dementia.</ArticleTitle><Pagination><MedlinePgn>376-384</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.20010003</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Previous studies have documented manic and hypomanic symptoms in behavioral variant frontotemporal dementia (bvFTD), suggesting a relationship between bipolar disorder and bvFTD.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The investigators conducted a literature review as well as a review of the psychiatric histories of 137 patients with bvFTD, and patients with a prior diagnosis of bipolar disorder were identified. The clinical characteristics of patients' bipolar disorder diagnosis, family history, features of bvFTD, and results from fluorodeoxyglucose positron emission tomography (FDG-PET), as well as autopsy findings, were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 137 patients, 14 (10.2%) had a psychiatric diagnosis of bipolar disorder, eight of whom met criteria for bipolar disorder (type I, N=6; type II, N=2) 6-12 years preceding onset of classic symptoms of progressive bvFTD. Seven of the eight patients with bipolar disorder had a family history of mood disorders, four had bitemporal predominant hypometabolism on FDG-PET, and two had a tauopathy involving temporal lobes on autopsy. Three additional patients with late-onset bipolar I disorder proved to have a nonprogressive disorder mimicking bvFTD. The remaining three patients with bvFTD had prior psychiatric symptoms that did not meet criteria for a diagnosis of bipolar disorder. The literature review and the findings for one patient further suggested a shared genetic mutation in some patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Manic or hypomanic episodes years before other symptoms of bvFTD may be a prodrome of this dementia, possibly indicating anterior temporal involvement in bvFTD. Other patients with late-onset bipolar disorder exhibit the nonprogressive frontotemporal dementia phenocopy syndrome. Finally, a few patients with bvFTD have a genetic predisposition for both disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Departments of Neurology (Mendez, Parand, Akhlaghipour) and Psychiatry and Biobehavioral Sciences (Mendez), David Geffen School of Medicine, University of California at Los Angeles; and VA Greater Los Angeles Healthcare System (Mendez, Parand).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parand</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departments of Neurology (Mendez, Parand, Akhlaghipour) and Psychiatry and Biobehavioral Sciences (Mendez), David Geffen School of Medicine, University of California at Los Angeles; and VA Greater Los Angeles Healthcare System (Mendez, Parand).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akhlaghipour</LastName><ForeName>Golnoush</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departments of Neurology (Mendez, Parand, Akhlaghipour) and Psychiatry and Biobehavioral Sciences (Mendez), David Geffen School of Medicine, University of California at Los Angeles; and VA Greater Los Angeles Healthcare System (Mendez, Parand).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG050967</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087122" MajorTopicYN="Y">Mania</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar Disorder Dementia</Keyword><Keyword MajorTopicYN="N">Frontotemporal Dementia</Keyword><Keyword MajorTopicYN="N">Mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32498603</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.20010003</ArticleId><ArticleId IdType="pmc">PMC7606722</ArticleId><ArticleId IdType="mid">NIHMS1624694</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 2016 Jan 30;235:200-2</Citation><ArticleIdList><ArticleId IdType="pubmed">26723138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2020 Jun;22(4):356-359</Citation><ArticleIdList><ArticleId IdType="pubmed">31742842</ArticleId></ArticleIdList></Reference><Reference><Citation>Funct Neurol. 2012 Jul-Sep;27(3):193-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23402681</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2013 Nov;19(6):498-500</Citation><ArticleIdList><ArticleId IdType="pubmed">24241504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2016 May;87(5):501-11</Citation><ArticleIdList><ArticleId IdType="pubmed">26216940</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2018 Feb 26;14:657-662</Citation><ArticleIdList><ArticleId IdType="pubmed">29520145</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Mar 9;62(5):742-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15007124</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2013 Jan;28(1):82-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22407730</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Feb;18(1):63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26876913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Sep/Oct;78(8):e940-e946</Citation><ArticleIdList><ArticleId IdType="pubmed">28749089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2017 Apr;25(4):357-362</Citation><ArticleIdList><ArticleId IdType="pubmed">28161155</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Mar 1;246:595-602</Citation><ArticleIdList><ArticleId IdType="pubmed">30605878</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Apr 1;75(7):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24629669</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatr Psychol Neuropsychiatr Vieil. 2019 Jun 1;17(2):179-188</Citation><ArticleIdList><ArticleId IdType="pubmed">31162118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 May;18(3):205-20</Citation><ArticleIdList><ArticleId IdType="pubmed">27112231</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2010 Dec;23(6):628-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20962637</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Sep;134(Pt 9):2456-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2016 Feb;21(1):23-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24411553</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2016 Dec 6;55(3):973-979</Citation><ArticleIdList><ArticleId IdType="pubmed">27802240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2019 Feb;25(2):184-194</Citation><ArticleIdList><ArticleId IdType="pubmed">30458895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Apr;23(4):932-942</Citation><ArticleIdList><ArticleId IdType="pubmed">28461699</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathology. 2015 Jun;35(3):245-53</Citation><ArticleIdList><ArticleId IdType="pubmed">25819679</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2017 Oct;205(10):743-756</Citation><ArticleIdList><ArticleId IdType="pubmed">28961594</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Apr;125(4):309-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21848702</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2019 Sep;24(9):1296-1318</Citation><ArticleIdList><ArticleId IdType="pubmed">30279458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1662-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15548477</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Dir Assoc. 2015 Jun 1;16(6):504-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25737262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;27(4):791-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21891869</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Dec;164(12):1811-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18056235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):286-296</Citation><ArticleIdList><ArticleId IdType="pubmed">28335872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Dec;27(6):722-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18004150</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2019 Mar 18;126:159-169</Citation><ArticleIdList><ArticleId IdType="pubmed">28219620</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2000 Oct;2(5):440-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11122994</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2018 Dec;26(12):1191-1201</Citation><ArticleIdList><ArticleId IdType="pubmed">30392777</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2008 Dec;34(6):606-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19081458</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):624-626</Citation><ArticleIdList><ArticleId IdType="pubmed">28664756</ArticleId></ArticleIdList></Reference><Reference><Citation>W V Med J. 2012 Jul-Aug;108(4):16-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22872960</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Dec;47(12):1955-66</Citation><ArticleIdList><ArticleId IdType="pubmed">24070910</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1999 Jul;56(7):817-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10404983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Dec;169 Suppl 1:S3-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25533912</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):93</Citation><ArticleIdList><ArticleId IdType="pubmed">31773397</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2013 Apr;25(2):159-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23611346</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Aug;209(2):121-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27482038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Nov;15(7):787-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23992521</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Nov;63(11):1627-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17101833</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2015 Sep;17(9):75</Citation><ArticleIdList><ArticleId IdType="pubmed">26257147</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychogeriatrics. 2011 Mar;11(1):60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21447111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Feb;72(2):126-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21382304</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Mar 15;229:125-134</Citation><ArticleIdList><ArticleId IdType="pubmed">29306692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2018 Jan;84:162-170</Citation><ArticleIdList><ArticleId IdType="pubmed">29162519</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2018 Oct 16;91(16):e1498-e1507</Citation><ArticleIdList><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):326-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23551834</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2009;21(4):323-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20374147</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2003 Feb;18(1):32-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12648894</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Mar;202(3):177-86</Citation><ArticleIdList><ArticleId IdType="pubmed">23457181</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2016 Sep 07;12:2207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">27660450</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2010 Jun;23(2):75-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20101069</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Mar;76(3):e342-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25830456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;31(2):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22571983</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Nov 15;78(10):684-92</Citation><ArticleIdList><ArticleId IdType="pubmed">25958088</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2014 Winter;26(1):E35</Citation><ArticleIdList><ArticleId IdType="pubmed">24515704</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Case Rep. 2011 Feb 02;2011:</Citation><ArticleIdList><ArticleId IdType="pubmed">22714610</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:269-283</Citation><ArticleIdList><ArticleId IdType="pubmed">31014945</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2013 Jun 14;9:88-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23878613</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Dec;47(16):2753-2766</Citation><ArticleIdList><ArticleId IdType="pubmed">28585513</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:157-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24548785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Oct 1;257:166-172</Citation><ArticleIdList><ArticleId IdType="pubmed">31301619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2013 Apr;260(4):1155-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23314407</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2006 Winter;18(1):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16525077</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Oct 24;9(10):e107829</Citation><ArticleIdList><ArticleId IdType="pubmed">25343370</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2020 May;28(5):530-541</Citation><ArticleIdList><ArticleId IdType="pubmed">31761661</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17417815</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2007</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9762</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of clinical psychology</Title><ISOAbbreviation>J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Psychotherapy through the phases of bipolar disorder: evidence for general efficacy and differential effects.</ArticleTitle><Pagination><MedlinePgn>491-506</MedlinePgn></Pagination><Abstract><AbstractText>The obstacle facing pharmacotherapy for bipolar disorder is that almost half of the patients do not achieve recovery over the duration of treatment. Although the reason for this disappointing clinical outcome remains unclear, structured psychotherapy has helped to fill these gaps in the treatment of bipolar disorder. Psychoeducation, family-focused therapy, interpersonal and social rhythm therapy, and cognitive behavior therapy have all received attention in the research literature. In this review, by assessing the outcomes from randomized control trials across the phases of bipolar disorder, we demonstrate that psychotherapy is an effective adjunctive treatment. We also show that the use of psychotherapy for bipolar disorder has differential results depending on when and under what conditions it is administered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizvi</LastName><ForeName>Sakina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Head Cognitive Behavior Therapy Clinic, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaretsky</LastName><ForeName>Ari E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychol</MedlineTA><NlmUniqueID>0217132</NlmUniqueID><ISSNLinking>0021-9762</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>80</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17417815</ArticleId><ArticleId IdType="doi">10.1002/jclp.20370</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18582347</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Correlates of subjective and objective burden among caregivers of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>49-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-0447.2008.01201.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examined the relationship between mood symptoms and episodes in patients with bipolar disorder and burden reported by their primary caregivers.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data on subjective and objective burden reported by 500 primary caregivers for 500 patients with bipolar disorder participating in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) were collected using semistructured interviews. Patient data were collected prospectively over 1 year. The relationship between patient course and subsequent caregiver burden was examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Episodes of patient depression, but not mood elevation, were associated with greater objective and subjective caregiver burden. Burden was associated with fewer patient days well over the previous year. Patient depression was associated with caregiver burden even after controlling for days well.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patient depression, after accounting for chronicity of symptoms, independently predicts caregiver burden. This study underscores the important impact of bipolar depression on those most closely involved with those whom it affects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Bipolar Clinic and Research Program, Boston, MA, and Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA. mostacher@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>A A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Iosifescu</LastName><ForeName>D V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Eidelman</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lund</LastName><ForeName>H G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Ametrano</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Kaczynski</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Perlick</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><CollectiveName>STEP-BD Family Experience Collaborative Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01MH-8001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH-65015</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Jodi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Culver</LastName><ForeName>Jenifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fosse</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marangell</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Jayendra</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chessick</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18582347</ArticleId><ArticleId IdType="pii">ACP1201</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2008.01201.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28527265</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>0</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>[Profile of lithium carbonate use in patients with bipolar disorder in Colombia].</ArticleTitle><Pagination><MedlinePgn>43-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.v37i1.2815</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lithium is the drug of choice for the treatment of bipolar affective disorder.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define lithium therapeutic profile and adverse reactions to its use in patients with bipolar affective disorder in Colombia.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted an observational retrospective cohort study between January 1 and December 31, 2013, which included patients with a diagnosis of bipolar disorder treated with lithium carbonate in 25 Colombian cities; we evaluated socio-demographic variables, lithium dose, co-medication, drug interactions and adverse reactions. A multivariate analysis was done using SPSS 22.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 331 patients had an average age of 44.5 Â± 13.9 years; 59.2% were women. The mean dose of lithium was 898 Â± 294 mg/day; 22% received doses lower than recommended, and patients had received lithium for 38.0 Â± 39.5 months (range: 12-159 months). Lithium levels in blood had been measured only in 13.5% of patients; 71.3% of them had received adjuvant therapy for bipolar disorder with other drugs, especially clozapine (16.6%) and valproic acid (16.6%). The main comorbidities were hypothyroidism (18.1%) and hypertension (12.7%); 390 potentially toxic drug interactions were found, and adverse reactions were reported in 1.2% of patients. A statistically significant association was found between a lower risk of combination therapy and receiving treatment in the cities of BogotÃ¡ (OR=0.4, p=0.025), Cartagena (OR=0.3, p=0.015) and IbaguÃ© (OR=0.3, p=0.025).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lithium was generally used at recommended doses and intervals, but a significant percentage of patients received lower doses than those recommended, and it was not possible to compare with lithium levels in blood. Adverse reactions and blood lithium levels reporting should be improved in patients with bipolar disorder in Colombia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Machado-Duque</LastName><ForeName>Manuel Enrique</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n en FarmacoepidemiologÃ­a y Farmacovigilancia, Universidad TecnolÃ³gica de Pereira-Audifarma, S. A., Pereira, Colombia. m_machado91@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzate-Carvajal</LastName><ForeName>Catalina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zapata-CastaÃ±eda</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Machado-Alba</LastName><ForeName>Jorge Enrique</ForeName><Initials>JE</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="Y">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder/therapy</Keyword><Keyword MajorTopicYN="N">Colombia</Keyword><Keyword MajorTopicYN="N">drug interactions</Keyword><Keyword MajorTopicYN="N">lithium carbonate</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28527265</ArticleId><ArticleId IdType="doi">10.7705/biomedica.v37i1.2815</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18635718</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2008</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-8811</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Commentary on the paper of Smith, et al.</ArticleTitle><Pagination><MedlinePgn>404-5; discussion 408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0269881108089874</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zurich University Psychiatric Hospital, Lenggstrasse, Zurich, Switzerland. jules.angst@bli.uzh.ch</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Psychopharmacol. 2008 Jun;22(4):397-400</RefSource><PMID Version="1">18635715</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18635718</ArticleId><ArticleId IdType="pii">22/4/404</ArticleId><ArticleId IdType="doi">10.1177/0269881108089874</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31822292</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>12</Month><Day>10</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Peripheral blood metabolome predicts mood change-related activity in mouse model of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-019-0527-3</ELocationID><Abstract><AbstractText>Bipolar disorder is a major mental illness characterized by severe swings in mood and activity levels which occur with variable amplitude and frequency. Attempts have been made to identify mood states and biological features associated with mood changes to compensate for current clinical diagnosis, which is mainly based on patients' subjective reports. Here, we used infradian (a cycle &gt; 24âh) cyclic locomotor activity in a mouse model useful for the study of bipolar disorder as a proxy for mood changes. We show that metabolome patterns in peripheral blood could retrospectively predict the locomotor activity levels. We longitudinally monitored locomotor activity in the home cage, and subsequently collected peripheral blood and performed metabolomic analyses. We then constructed cross-validated linear regression models based on blood metabolome patterns to predict locomotor activity levels of individual mice. Our analysis revealed a significant correlation between actual and predicted activity levels, indicative of successful predictions. Pathway analysis of metabolites used for successful predictions showed enrichment in mitochondria metabolism-related terms, such as "Warburg effect" and "citric acid cycle." In addition, we found that peripheral blood metabolome patterns predicted expression levels of genes implicated in bipolar disorder in the hippocampus, a brain region responsible for mood regulation, suggesting that the brain-periphery axis is related to mood-change-associated behaviors. Our results may serve as a basis for predicting individual mood states through blood metabolomics in bipolar disorder and other mood disorders and may provide potential insight into systemic metabolic activity in relation to mood changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hagihara</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9602-9518</Identifier><AffiliationInfo><Affiliation>Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horikawa</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6524-9398</Identifier><AffiliationInfo><Affiliation>Department of Neuroinformatics, ATR Computational Neuroscience Laboratories, Kyoto, 619-0288, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irino</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Evidence-based Laboratory Medicine, Kobe University, Graduate School of Medicine, Kobe, 650-0017, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Hironori K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umemori</LastName><ForeName>Juzoh</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2595-7362</Identifier><AffiliationInfo><Affiliation>Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Metabolomics Research, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamitani</LastName><ForeName>Yukiyasu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9300-8268</Identifier><AffiliationInfo><Affiliation>Department of Neuroinformatics, ATR Computational Neuroscience Laboratories, Kyoto, 619-0288, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Informatics, Kyoto University, Kyoto, 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyakawa</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0137-8200</Identifier><AffiliationInfo><Affiliation>Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. miyakawa@fujita-hu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056930">ARNTL Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C538961">Arntl protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056930" MajorTopicYN="N">ARNTL Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071217" MajorTopicYN="N">Infradian Rhythm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31822292</ArticleId><ArticleId IdType="doi">10.1186/s13041-019-0527-3</ArticleId><ArticleId IdType="pii">10.1186/s13041-019-0527-3</ArticleId><ArticleId IdType="pmc">PMC6902552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Investig. 2018 Jul;15(7):695-700</Citation><ArticleIdList><ArticleId IdType="pubmed">29969852</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2010 Oct;16(5):578-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20889967</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2017 Mar;74(Pt A):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">28093238</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2015 Dec 30;19(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">26721951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11256685</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Jul 29;351(5):476-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15282355</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Nov 5;527(7576):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Jun;15(4):405-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23560889</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2018 Feb;43(3):459-468</Citation><ArticleIdList><ArticleId IdType="pubmed">28776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Mar;42(3):295-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3977549</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2011 Sep 08;5:100</Citation><ArticleIdList><ArticleId IdType="pubmed">21927594</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2011 Mar;33(6):1152-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21395859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23663953</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2006 Mar;5(2):150-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16507006</ArticleId></ArticleIdList></Reference><Reference><Citation>BBA Clin. 2016 Apr 03;5:151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27114925</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacol Rep. 2019 Jun;39(2):78-89</Citation><ArticleIdList><ArticleId IdType="pubmed">30772953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Mar 15;193:109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">26773901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2004 Sep;5(9):763-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15340383</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Jun 15;75(12):920-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24286759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Dec;21(12):1696-1709</Citation><ArticleIdList><ArticleId IdType="pubmed">26903267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Mar 15;47(6):475-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10715353</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2008 Jan 15;44(2):224-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18191758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vis Exp. 2009 Nov 17;(33):null</Citation><ArticleIdList><ArticleId IdType="pubmed">19920804</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 Jan;33(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17619145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Aug;116(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19251324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2018 Jan 4;11(1):1</Citation><ArticleIdList><ArticleId IdType="pubmed">29301575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2016 Mar 29;14(12):2784-96</Citation><ArticleIdList><ArticleId IdType="pubmed">27028761</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Monit. 2006 May;12(5):RA79-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16641887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1954 Aug 21;267(6834):365-7</Citation><ArticleIdList><ArticleId IdType="pubmed">13184682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Nov;21(11):1504-1510</Citation><ArticleIdList><ArticleId IdType="pubmed">26782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2019 Sep;73(9):526-540</Citation><ArticleIdList><ArticleId IdType="pubmed">31021488</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Jul 10;2:e135</Citation><ArticleIdList><ArticleId IdType="pubmed">22781168</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2013;2013:318596</Citation><ArticleIdList><ArticleId IdType="pubmed">23840971</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1047-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18228528</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494</Citation><ArticleIdList><ArticleId IdType="pubmed">29762782</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Mar 25;13(4):501-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11930170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jan;34(1):173-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18843269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2008 Sep 10;1:6</Citation><ArticleIdList><ArticleId IdType="pubmed">18803808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2019 Aug;115:165-175</Citation><ArticleIdList><ArticleId IdType="pubmed">31150948</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Apr 5;141B(3):234-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16528748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Feb;14(2):156-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18301394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Jun;16(4):337-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24372893</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Behav Neurosci. 2011;5:187-200</Citation><ArticleIdList><ArticleId IdType="pubmed">25236556</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2009 Aug;35(2):165-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19303440</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3576-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25730879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2011 Dec;31(6):685-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22020358</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE J Biomed Health Inform. 2016 Apr 20;20(4):1034-1043</Citation><ArticleIdList><ArticleId IdType="pubmed">28113920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7551964</PMID><DateCompleted><Year>1995</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-8829</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Association study of bipolar disorder using a functional polymorphism (Ser311--&gt;Cys) in the dopamine D2 receptor gene.</ArticleTitle><Pagination><MedlinePgn>63-5</MedlinePgn></Pagination><Abstract><AbstractText>Several pieces of evidence are consistent with the involvement of dopamine neurotransmission in the aetiology of bipolar disorder. We have tested the hypothesis that the functional mutation Ser311--&gt;Cys of the dopamine D2 receptor gene confers susceptibility to bipolar disorder. There was no increased frequency of the mutation in 82 bipolar probands compared with 72 controls, showing that this mutation is not involved in the pathogenesis of (at least) the vast majority of cases of bipolar disorder. Our findings are consistent with other evidence from linkage and association studies against the involvement of the dopamine D2 receptor in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>McGuffin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003062">Codon</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003062" MajorTopicYN="N">Codon</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7551964</ArticleId><ArticleId IdType="doi">10.1097/00041444-199522000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21381300</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>112</Volume><Issue>12</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[History of bipolar disorder: a consideration on ancient western literature].</ArticleTitle><Pagination><MedlinePgn>1253-60</MedlinePgn></Pagination><Abstract><AbstractText>We can find the description suggesting pathological shift from melancholia to mania in Diseases I (4th century BC) of Corpus Hippocraticum. However, it was 2nd century that detailed account concerning bipolar disorder in modern sense was supposed to appear. Especially the text of Aretaeus of Cappadocia contained several paragraphs indicating this disease. Thereafter in 6th century, Alexander of Tralles clearly mentioned the transition from melancholia to mania. In ancient world, both melancholia and mania embodied vast area of general mental derangement on the one hand, they had restricted meaning of depressive and manic state respectively in modern sense on the other. The situation mentioned above formed the heterogeneity of ancient madness as a whole.</AbstractText></Abstract><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076145" MajorTopicYN="N">Greece, Ancient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049690" MajorTopicYN="N">History, Ancient</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21381300</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23123133</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Socio-emotional processing and functioning of youth at high risk for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>112-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.08.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00585-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The goal of this study was to investigate differences in socio-emotional processing and functioning in children and adolescents at high risk for bipolar disorder (BD) and healthy control participants.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Children and adolescents with a parent with bipolar disorder, who had mood dysregulation but not fully syndromal BD (high risk, HR, n=24), were compared to participants with no personal or family history of psychopathology (healthy control, HC, n=27) across several neuropsychological domains. Social reciprocity was measured by the Social Responsiveness Scale, theory of mind was measured by use of the NEPSY, and affect recognition was measured by the NEPSY and the Diagnostic Test of Nonverbal Accuracy 2 (DANVA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The HR group demonstrated significant impairment in social reciprocity, including impairments in social awareness, social cognition, social communication, social motivation, and autistic mannerisms. There were no significant group differences in performance on theory of mind or affect recognition tasks.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Lack of impairment in tasks associated with theory of mind or affect recognition indicate that social functioning difficulties are not likely due to impairments in these areas, or that the measures employed were not sufficiently sensitive to detect group differences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Youth at high risk for BD demonstrated impairments in numerous social domains, which may be due to innate differences in brain development governing socio-emotional functioning or may be due to disruptions in normal development caused by mood regulation difficulties.</AbstractText><CopyrightInformation>Copyright Â© 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whitney</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Bipolar Disorders Program, Stanford University, Stanford, CA 94305-5540, United States. jane.whitney@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shoemaker</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sherrie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Marie Sanders</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dijamco</LastName><ForeName>Cheri</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Acquaye</LastName><ForeName>Tenah</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Manpreet</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH085919</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23MH085919</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23123133</ArticleId><ArticleId IdType="pii">S0165-0327(12)00585-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.08.016</ArticleId><ArticleId IdType="pmc">PMC3644339</ArticleId><ArticleId IdType="mid">NIHMS408354</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1070-1079</Citation><ArticleIdList><ArticleId IdType="pubmed">17667485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 2003 Aug;33(4):427-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12959421</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 Jun;47(6):652-661</Citation><ArticleIdList><ArticleId IdType="pubmed">18434923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2005 Jun;15(3):452-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16092910</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 May;58(5):510-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11343533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11314571</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2003 Feb 28;358(1430):345-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12639332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">21320254</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 May;33(3):703-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17478437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2006 Dec;1094:235-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17347355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Jul-Aug;37(4):297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12765852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6715741</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Jun;38(6):791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">18208632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1998 Dec;28(6):479-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9932234</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Dec;62(12):1322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16330720</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16135623</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):174-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18715651</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1990 Mar;20(1):115-28</Citation><ArticleIdList><ArticleId IdType="pubmed">2324051</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2008 Spring;20(2):529-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18423093</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Mar;167(3):321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20080982</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):385-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18245180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 Dec;47(12):1455-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19034190</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2007 Sep;48(9):863-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17714371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Sep;133(1-2):204-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21463899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1023-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17064427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 2007 May;150(5):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17452221</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jun;160(6):1172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12777278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19708034</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-0657</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of methods in psychiatric research</Title><ISOAbbreviation>Int J Methods Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Berkson's bias and the mood dimensions of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>279-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mpr.290</ELocationID><Abstract><AbstractText>In this paper we examined whether manic and depressive dimensions independently contribute to mental health service use and determined the degree of comorbidity between manic and depressive dimensions in individuals with and without mental health service use. If both depressive and manic episodes independently influence help-seeking behaviour, a higher level of comorbidity between these dimensions would be found in clinical as compared to non-clinical samples (i.e. Berkson's Bias). Data were derived from the Netherlands Mental Health Survey and Incidence Study (NEMESIS), a prospective epidemiological survey in a representative sample of the Dutch population (N = 7076). Dimensions of depression and mania and mental health service use (MHSU) were assessed with the Composite International Diagnostic Interview (CIDI) at baseline, and prospectively one and three years later. Logistic regression was used to test whether depressive and manic dimensions both had independent effects on mental health service use. The degree of mania-comorbidity given the presence of depressive dimension was assessed as a function of MHSU, both retrospectively and prospectively. Manic and depressive dimensions contributed independently to mental health service use. Mania-comorbidity given the presence of depressive dimension was significantly higher in individuals with mental health service use than in those without, both retrospectively (16.7% versus 7.1%, p = 0.000) and prospectively (10.8% versus 6.6%, p = 0.017). We conclude that the bipolar phenotype consists of manic and depressive dimensions that may be much more loosely associated than (Berkson) biased clinical observations suggest. A dimension-specific approach may be more productive in clarifying the aetiology of mood dysregulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Regeer</LastName><ForeName>E J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Altrecht Institute for Mental Health Care, Utrecht, The Netherlands. e.regeer@altrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krabbendam</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Graaf</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Have</LastName><ForeName>M Ten</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Van Os</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Methods Psychiatr Res</MedlineTA><NlmUniqueID>9111433</NlmUniqueID><ISSNLinking>1049-8931</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001244" MajorTopicYN="N">Association</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="Y">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19708034</ArticleId><ArticleId IdType="doi">10.1002/mpr.290</ArticleId><ArticleId IdType="pmc">PMC6878283</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 2001 Jul;179:39-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11435267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):71-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15023482</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 1999 Sep;1(1):31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11256653</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1998 Dec;33(12):587-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9857791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Oct;7(5):418-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16176434</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Jul;187:87-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15994577</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Nov;110(5):374-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15458561</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 May;109(5):325-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15049768</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2002 Dec;25(4):685-98</Citation><ArticleIdList><ArticleId IdType="pubmed">12462855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Aug;7(4):344-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16026487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Dec;45(12):1069-77</Citation><ArticleIdList><ArticleId IdType="pubmed">2848472</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Neurol Sci. 1987;236(4):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3582430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):183-97</Citation><ArticleIdList><ArticleId IdType="pubmed">12507751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Sep;10(9):811-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15970930</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1946 Jun;2(3):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21001024</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1994 Jan-Feb;28(1):57-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8064641</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Nov;35(11):1333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">757997</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Apr;63(4):366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16585465</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Nov;159:645-53, 658</Citation><ArticleIdList><ArticleId IdType="pubmed">1756340</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2000 Dec 1;152(11):1039-47</Citation><ArticleIdList><ArticleId IdType="pubmed">11117613</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Oct;62(10):1089-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16203954</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 15;58(4):307-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16005437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 1999 Sep;1(1):25-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11256651</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2004 Aug;39(8):600-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15300369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2006 Jan;32(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16319375</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Oct;34(7):1177-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15697044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Aug;45(1-2):31-9; discussion 39-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9268773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jan;160(1):4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12505793</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Nov;159:653-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1756341</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 May;36(5):619-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16438739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Mar;2(1):3-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11254017</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1998 Dec;33(12):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9857790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7648847</PMID><DateCompleted><Year>1995</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>3</Issue><PubDate><MedlineDate>1995 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric morbidity in travelers to Honolulu, Hawaii.</ArticleTitle><Pagination><MedlinePgn>224-8</MedlinePgn></Pagination><Abstract><AbstractText>To investigate the phenomenon of acute psychiatric decompensation in travelers, charts of all psychiatric-emergency patients with a history of recent travel involving time-zone changes were reviewed at a major medical center in Honolulu, HI. Charts of a control group with no history of travel were also reviewed. Significantly more travelers than controls showed symptoms of depression and mania (P &lt; .012). East-bound travelers were significantly more likely to show symptoms of mania than controls (P &lt; .001). In an eastbound-versus-westbound comparison, significantly more eastbound travelers showed symptoms of mania, whereas significantly more westbound travelers showed symptoms of depression (P &lt; .05). These findings support the phase-advance hypothesis of depression. Psychosocial and biologic factors that may contribute to psychiatric decompensation in travelers are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu 96813, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004637" MajorTopicYN="N">Emergency Services, Psychiatric</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006254" MajorTopicYN="N">Hawaii</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009949" MajorTopicYN="N">Orientation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014195" MajorTopicYN="Y">Travel</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7648847</ArticleId><ArticleId IdType="pii">0010-440X(95)90086-B</ArticleId><ArticleId IdType="doi">10.1016/0010-440x(95)90086-b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30343458</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-6660</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>12</Month></PubDate></JournalIssue><Title>Neuropsychology review</Title><ISOAbbreviation>Neuropsychol Rev</ISOAbbreviation></Journal><ArticleTitle>Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.</ArticleTitle><Pagination><MedlinePgn>509-533</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11065-018-9388-2</ELocationID><Abstract><AbstractText>Individuals with disorders that include psychotic symptoms (i.e. psychotic disorders) experience broad cognitive impairments in the chronic state, indicating a dimension of abnormality associated with the experience of psychosis. These impairments negatively impact functional outcome, contributing to the disabling nature of schizophrenia, bipolar disorder, and psychotic depression. The robust and reliable nature of cognitive deficits has led researchers to explore the timing and profile of impairments, as this may elucidate different neurodevelopmental patterns in individuals who experience psychosis. Here, we review the literature on cognitive deficits across the life span of individuals with psychotic disorder and psychotic-like experiences, highlighting the dimensional nature of both psychosis and cognitive ability. We identify premorbid generalized cognitive impairment in schizophrenia that worsens throughout development, and stabilizes by the first-episode of psychosis, suggesting a neurodevelopmental course. Research in affective psychosis is less clear, with mixed evidence regarding premorbid deficits, but a fairly reliable generalized deficit at first-episode, which appears to worsen into the chronic state. In general, cognitive impairments are most severe in schizophrenia, intermediate in bipolar disorder, and the least severe in psychotic depression. In all groups, cognitive deficits are associated with poorerÂ functional outcome. Finally, while the generalized deficit is the clearest and most reliable signal, data suggests specific deficits in verbal memory across all groups, specific processing speed impairments in schizophrenia and executive functioning impairments in bipolar disorder. Cognitive deficits are a core feature of psychotic disorders that provide a window into understanding developmental course and risk for psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Julia M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave S, Nashville, TN, 37212, USA. Julia.sheffield@vumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karcher</LastName><ForeName>Nicole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Psychological &amp; Brain Sciences, Washington University St. Louis, 1 Brookings Dr., St. Louis, MO, 63130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barch</LastName><ForeName>Deanna M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Psychological &amp; Brain Sciences, Washington University St. Louis, 1 Brookings Dr., St. Louis, MO, 63130, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 MH108309</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014677</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA041120</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychol Rev</MedlineTA><NlmUniqueID>9009029</NlmUniqueID><ISSNLinking>1040-7308</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Cognitive Impairment</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Development</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30343458</ArticleId><ArticleId IdType="doi">10.1007/s11065-018-9388-2</ArticleId><ArticleId IdType="pii">10.1007/s11065-018-9388-2</ArticleId><ArticleId IdType="pmc">PMC6475621</ArticleId><ArticleId IdType="mid">NIHMS1012771</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2007 Jun;64(6):633-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17548746</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Dec 15;72(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15531406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Nov;34(6):1024-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18156637</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Apr;61(4):354-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15066893</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Mar;126(1-3):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20965697</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychology. 1998 Jul;12(3):426-45</Citation><ArticleIdList><ArticleId IdType="pubmed">9673998</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Jan;45(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25065902</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2018 Apr 19;19(Suppl 1):22</Citation><ArticleIdList><ArticleId IdType="pubmed">29745862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Aug;157(1-3):33-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24888526</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jan;167(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19952077</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Apr;38(4):424-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7212972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Oct 1;238:297-304</Citation><ArticleIdList><ArticleId IdType="pubmed">29902733</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Jul 1;56(1-2):171-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12084431</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jul;157(7):1095-100</Citation><ArticleIdList><ArticleId IdType="pubmed">10873917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18232725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Dec 15;65(2-3):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">14630303</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2010 Feb;196(2):109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20118454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jan 1;225:250-255</Citation><ArticleIdList><ArticleId IdType="pubmed">28841488</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Jul;44(7):660-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3606332</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 Jan;42(1):77-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26231719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2004 Jan;38(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">14690768</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Feb;58(2):158-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11177117</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jan;37(1):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19443616</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Mar 30;226(1):23-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25618475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):272-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23521608</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jul;195(1):67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19567899</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Sep;35(5):1022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18495643</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jul;167(7):748-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20595427</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):532-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17485605</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 Jul;33(4):877-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17548842</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Oct;123(1):59-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20716479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):103-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17391354</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):699-711</Citation><ArticleIdList><ArticleId IdType="pubmed">29164332</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Nov;1(6):498-506</Citation><ArticleIdList><ArticleId IdType="pubmed">27833940</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 May;118(1-3):54-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20171849</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Aug;159(8):1395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">12153834</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2002 Oct;17(6):311-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12457741</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Apr;71(4):366-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24499990</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Mar;70(3):261-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23325066</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Dec;115(2-3):121-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19786339</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1999 May 4;37(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10227104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):323-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19419389</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Sep;36(5):919-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20566491</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Jul;205(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24764544</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1987 Jan;75(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">3577843</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 Jan;42(1):87-95</Citation><ArticleIdList><ArticleId IdType="pubmed">26101305</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 May;121(5):377-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20199494</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Nov;70(11):1133-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24006090</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Aug 08;4:87</Citation><ArticleIdList><ArticleId IdType="pubmed">23964248</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2005 Jul;112(1):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15952944</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychol. 2016 Apr 02;4:14</Citation><ArticleIdList><ArticleId IdType="pubmed">27039372</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1997 May 3;25(1):21-31</Citation><ArticleIdList><ArticleId IdType="pubmed">9176924</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jan;64(1):86-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12590629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Dec;127(1-3):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20231037</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Nov 29;145(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17045658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Feb;90(1-3):338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17123787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 May;14(3):227-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22548896</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2016 Oct 30;244:394-402</Citation><ArticleIdList><ArticleId IdType="pubmed">27525830</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Mar;194(3):243-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19252155</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1996 Aug;94(2):87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">8883568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Jan;43(1):119-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22575089</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 May;118(1-3):6-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20194004</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2012 Aug;201:124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22743845</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 Jul;41(4):940-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25194139</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Mar;163(3):418-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16513862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2013 Oct;27(5):652-79</Citation><ArticleIdList><ArticleId IdType="pubmed">22928856</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;164:130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24856566</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 Jul;31(5):915-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11459389</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2001;27(2):269-79</Citation><ArticleIdList><ArticleId IdType="pubmed">11354594</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2018 Jul;127(5):513-528</Citation><ArticleIdList><ArticleId IdType="pubmed">29781658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Mar 1;43(2):397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">27306316</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Feb;39(2):179-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18606047</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Nov;189:463-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17077440</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Aug;166(1-3):316-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26070411</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1904-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16199837</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1993;19(4):797-804</Citation><ArticleIdList><ArticleId IdType="pubmed">8303228</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2014 Jul;55(5):1212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24666714</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Feb;41(2):225-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20836900</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2000 Nov 1;4(11):417-423</Citation><ArticleIdList><ArticleId IdType="pubmed">11058819</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychology. 2009 May;23(3):315-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19413446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Feb;71(2):201-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19925749</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Aug;38(8):1133-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17988422</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2013 Apr 22;2:590-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24179809</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Jun 1;68(2-3):127-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15099597</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jun;166(6):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19369319</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2017 Mar;51(3):270-277</Citation><ArticleIdList><ArticleId IdType="pubmed">27004487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Mar;50:92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24373930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1995 May;104(2):355-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7790637</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2018 Feb;48(3):392-403</Citation><ArticleIdList><ArticleId IdType="pubmed">28735586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Oct;132(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21763109</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Oct 1;70(2-3):331-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15329308</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Sep;158(1-3):156-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25086658</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Dec 1;78(11):744-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26542742</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Nov;108(5):381-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14531759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2003 Feb;191(2):87-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12586961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Mar;11(2):113-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19267694</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Affect Behav Neurosci. 2014 Mar;14(1):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24037621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Mar;16(2):159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">24636366</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2012 Jan;16(1):27-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22169777</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2009;78(5):285-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19602917</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Oct;188:151-157</Citation><ArticleIdList><ArticleId IdType="pubmed">28143678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15117401</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Dec;88(1-3):26-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16930949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2000 Jul;41(5):561-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10946749</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Dec;159(12):2021-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12450951</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2010 Apr;260(3):225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19768481</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2017 Oct;23(9-10):881-892</Citation><ArticleIdList><ArticleId IdType="pubmed">29198285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Apr;22(4):527-536</Citation><ArticleIdList><ArticleId IdType="pubmed">27528460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Nov;47(11):1564-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23907000</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Dec;133(1-3):250-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21996268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Dec;17(12):1228-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22488257</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Aug;109(3):286-99</Citation><ArticleIdList><ArticleId IdType="pubmed">18289698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2018 May;20(3):184-194</Citation><ArticleIdList><ArticleId IdType="pubmed">29345040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May;147(1-3):441-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23141631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Feb;136(3):1188-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22209188</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Jan 1;53(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11728836</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Jan;45(2):381-94</Citation><ArticleIdList><ArticleId IdType="pubmed">25065268</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2014 Oct;13(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25273286</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2017 Mar;249:286-292</Citation><ArticleIdList><ArticleId IdType="pubmed">28142102</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409</Citation><ArticleIdList><ArticleId IdType="pubmed">15925493</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Jan;208(1):87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26541692</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Jan 1;121(3):303-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14675749</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Dec;47(16):2844-2853</Citation><ArticleIdList><ArticleId IdType="pubmed">28587688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1995;245(2):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7654790</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 May 1;43(3):546-556</Citation><ArticleIdList><ArticleId IdType="pubmed">27521348</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Dec 1;78(11):786-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25863361</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1994 Oct;54(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7701028</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Oct;70(10):1107-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23925787</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):672-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9585720</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Dec;133(1-3):212-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21996265</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Apr;121(4):273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19694626</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Feb;167(2):160-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20048021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Mar;50:100-105</Citation><ArticleIdList><ArticleId IdType="pubmed">24398256</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(434):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17688459</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Apr 1;67(2-3):115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14984870</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Mar;131(3):185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25597383</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2008 Nov;18(11):787-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18725178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Feb;227:109-116</Citation><ArticleIdList><ArticleId IdType="pubmed">29055258</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2006 Jun;194(6):422-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16772859</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">23771174</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Nov;132(2-3):220-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21764562</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Aug;170(8):852-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23511717</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 May;84(1):100-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16563699</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2006 Apr;32(2):250-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16221995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Nov;14(7):749-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22998105</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Sep 1;60(5):472-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16483550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 2016 Jan;102:39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25152315</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Oct 21;43(6):1176-1189</Citation><ArticleIdList><ArticleId IdType="pubmed">29045744</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):144-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22101961</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1984;10(3):430-59</Citation><ArticleIdList><ArticleId IdType="pubmed">6382590</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 May;118(1-3):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20153140</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 May 1;59(9):863-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16325151</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Jan;171(1):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24030246</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1988 Jan-Feb;29(1):12-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2893689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1976 Jun;44(3):363-75</Citation><ArticleIdList><ArticleId IdType="pubmed">932265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Oct;168(1-2):213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26305063</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res Cogn. 2016 Aug 17;6:1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">28740818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Nov 19;344(8934):1398-402</Citation><ArticleIdList><ArticleId IdType="pubmed">7968076</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2016 Aug;175(1-3):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">27050475</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Nov 1;79(1):127-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16107309</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2006 Apr;28(3):370-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16618626</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):94-102</Citation><ArticleIdList><ArticleId IdType="pubmed">25912542</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2017 May;30(3):171-175</Citation><ArticleIdList><ArticleId IdType="pubmed">28230631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Mar;18(2):136-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26990158</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1996 Jun;168(6):679-87</Citation><ArticleIdList><ArticleId IdType="pubmed">8773809</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 May;165(5):579-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18413704</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Oct;158(10):1612-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11578992</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Mar 15;229:125-134</Citation><ArticleIdList><ArticleId IdType="pubmed">29306692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Nov 1;64(9):823-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18472089</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 May;33(3):761-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17412711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Nov;222:169-176</Citation><ArticleIdList><ArticleId IdType="pubmed">28709024</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):71-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15625204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:580-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25560194</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Sep;157(9):1416-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10964857</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Sep;113(2-3):167-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19450952</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):468-77</Citation><ArticleIdList><ArticleId IdType="pubmed">17680917</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2018 Jun;28(2):216-231</Citation><ArticleIdList><ArticleId IdType="pubmed">29680959</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2016 Dec 1;73(12):1239-1248</Citation><ArticleIdList><ArticleId IdType="pubmed">27806157</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Mar;126(1-3):124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21159492</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2006;75(2):72-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16508342</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16762369</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jul;159(7):1183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12091197</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 May 1;68(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15037336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):537-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22834462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Saudi Med. 2007 Jul-Aug;27(4):273-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17684432</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2007 Sep;133(5):833-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17723032</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Mar 30;196(1):38-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22342122</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Jul;216:30-35</Citation><ArticleIdList><ArticleId IdType="pubmed">28010957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2018 Feb;40(1):84-94</Citation><ArticleIdList><ArticleId IdType="pubmed">28562181</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Apr;42(4):743-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21896236</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 Mar;135(1-3):134-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22130110</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2016 Jan;170(1):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">26645510</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 Sep;41(5):1095-104</Citation><ArticleIdList><ArticleId IdType="pubmed">25616505</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Mar 15;57(6):688-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15780858</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 May;56(5):457-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10232301</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 May;84(1):121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16443348</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Jun;67(6):578-88</Citation><ArticleIdList><ArticleId IdType="pubmed">20530007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 Apr;34(5):670-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20026186</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Behav Neurosci. 2014 Nov 28;8:416</Citation><ArticleIdList><ArticleId IdType="pubmed">25506320</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1997 May 3;25(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9176922</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neurosci. 1977;7(2):59-66</Citation><ArticleIdList><ArticleId IdType="pubmed">893004</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):467-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11018220</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 May;59(5):449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11982449</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Dec 30;170(2-3):150-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19906441</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2015 Jul;21(6):468-72</Citation><ArticleIdList><ArticleId IdType="pubmed">26154947</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J (Clin Res Ed). 1987 Sep 19;295(6600):681-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3117295</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 May;164(1-3):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25802138</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Mar;83(1):41-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16497484</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Jan;38(1):125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22021658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2016 Jul;174(1-3):71-76</Citation><ArticleIdList><ArticleId IdType="pubmed">27197904</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 May;168(5):472-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21406461</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Dec;48(12):1075-81</Citation><ArticleIdList><ArticleId IdType="pubmed">1845225</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Dec;47(16):2753-2766</Citation><ArticleIdList><ArticleId IdType="pubmed">28585513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 May;146(1-3):103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23465966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Mar 1;192:109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26720009</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Jun;69(6):562-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22664547</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:378-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15863741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Apr;130(1-2):180-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21074274</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2010 Jan;10(1):43-57</Citation><ArticleIdList><ArticleId IdType="pubmed">20021320</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2009 Jul;9(7):957-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19589046</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 May 1;68(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15037334</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2015 Apr 25;3:9</Citation><ArticleIdList><ArticleId IdType="pubmed">25914866</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2016 Dec;50(12):1186-1197</Citation><ArticleIdList><ArticleId IdType="pubmed">26698823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2010 Jul;24(7):1037-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19164494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 1999 Summer;11(3):487-508</Citation><ArticleIdList><ArticleId IdType="pubmed">10532621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Jan;36(1):112-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19767349</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Sep;45(9):789-96</Citation><ArticleIdList><ArticleId IdType="pubmed">3046553</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2011 Jun;199(6):367-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21629013</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Sep;157(9):1453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10964862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Dec;97(1-3):25-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17884347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2003 Feb;112(1):132-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12653421</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jun 12;10(6):e0127955</Citation><ArticleIdList><ArticleId IdType="pubmed">26070195</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2018 Mar;28(1):32-72</Citation><ArticleIdList><ArticleId IdType="pubmed">29446012</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Dec;159(12):2027-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12450952</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2013 Feb;23(1):41-2</Citation><ArticleIdList><ArticleId IdType="pubmed">22914618</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2017 Aug 1;74(8):807-814</Citation><ArticleIdList><ArticleId IdType="pubmed">28636694</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Nov;160(11):2060-2</Citation><ArticleIdList><ArticleId IdType="pubmed">14594759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10227110</PMID><DateCompleted><Year>1999</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Differences in cerebellar blood volume in schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>81-9</MedlinePgn></Pagination><Abstract><AbstractText>Brain morphometry has been studied extensively in schizophrenic patients, and among the cortical differences identified two consistent findings are decreased cerebellar vermal volume and increased volume of the fourth ventricle; although contradictory findings are reported as well. Recent cognitive activation studies utilizing PET, SPECT and fMRI have identified both decreased and increased activation in the cerebellum of schizophrenic patients compared with healthy controls. This study used DSC fMRI to map cerebellar blood volume in patients with schizophrenia or bipolar disorder and healthy controls. For all cerebellar regions analyzed, schizophrenic patients had the highest cerebellar blood volume, while bipolars had the lowest blood volume. Morphometric measurements were completed and indicated that the ratio of vermis to whole CBL tissue volume was 24% less for the schizophrenic population than controls, whereas the subjects with bipolar disorder had a ratio that was non-significantly smaller than controls by 19%. Comparison of morphometric data with blood volume data did not reveal any statistically significant correlations among the study groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loeber</LastName><ForeName>R T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>McLean Brain Imaging Center, Belmont, MA 02178, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Renshaw</LastName><ForeName>P F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Yurgelun-Todd</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10227110</ArticleId><ArticleId IdType="pii">S0920-9964(98)00137-6</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(98)00137-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8456169</PMID><DateCompleted><Year>1993</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3182</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><MedlineDate>1993 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Psychosomatics</Title><ISOAbbreviation>Psychosomatics</ISOAbbreviation></Journal><ArticleTitle>Bipolar and pure mania disorders precipitated by head trauma.</ArticleTitle><Pagination><MedlinePgn>194-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burstein</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychosomatics</MedlineTA><NlmUniqueID>0376506</NlmUniqueID><ISSNLinking>0033-3182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Psychosomatics. 1993 Sep-Oct;34(5):462</RefSource><PMID Version="1">8140201</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8456169</ArticleId><ArticleId IdType="pii">S0033-3182(93)71920-9</ArticleId><ArticleId IdType="doi">10.1016/S0033-3182(93)71920-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2084774</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4-6</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of cycloid psychosis.</ArticleTitle><Pagination><MedlinePgn>228-32</MedlinePgn></Pagination><Abstract><AbstractText>The incidence and risk of cycloid psychosis were investigated in the 1947 cohort of the Lundby Study. No male cases were found. For women the incidence rate (per 100 observation years) was 0.016%. The cumulative probability, i.e. risk up to 60 years of age, was 0.7%. These figures are about half of those for schizophrenia in women in the same population. It is concluded that cycloid psychosis constitutes a substantial part of psychotic disorders among women.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindvall</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Lund University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagnell</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ohman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2084774</ArticleId><ArticleId IdType="doi">10.1159/000284665</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20029406</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Replication of GWAS of bipolar disorder: association of SNPs near CDH7 with bipolar disorder and visual processing.</ArticleTitle><Pagination><MedlinePgn>4-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2009.86</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soronen</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ollila</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Antila</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Silander</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Palo</LastName><ForeName>O M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>KieseppÃ¤</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>LÃ¶nnqvist</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Peltonen</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tuulio-Henriksson</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Partonen</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Paunio</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121291">CDH7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015820">Cadherins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20029406</ArticleId><ArticleId IdType="pii">mp200986</ArticleId><ArticleId IdType="doi">10.1038/mp.2009.86</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2975294</PMID><DateCompleted><Year>1989</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3</Issue><PubDate><MedlineDate>1988 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Manic symptoms in a non-referred adolescent population.</ArticleTitle><Pagination><MedlinePgn>219-26</MedlinePgn></Pagination><Abstract><AbstractText>Using a structured interview with 150 randomly selected 14-16-year-olds and their parents, we found 20 who endorsed four or more manic symptoms of at least 2 days duration. Compared to the rest of the sample, these teenagers had significantly higher rates of attention deficit, conduct, and anxiety disorders and psychotic symptoms, and were seen as needing treatment by the interviewers. However, most of the pathology was endorsed by teenagers rather than parents. Other assessments confirmed this group as dysphoric, impulsive and emotionally labile. We discuss the normative and diagnostic implications of these findings though long-term follow-up is necessary to draw more certain conclusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>G A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, State University of New York, Stony Brook 11794-8790.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashani</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="N">Manuals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2975294</ArticleId><ArticleId IdType="pii">0165-0327(88)90019-5</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(88)90019-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9381957</PMID><DateCompleted><Year>1997</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-5062</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>3</Issue><PubDate><MedlineDate>1997 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Actas luso-espanolas de neurologia, psiquiatria y ciencias afines</Title><ISOAbbreviation>Actas Luso Esp Neurol Psiquiatr Cienc Afines</ISOAbbreviation></Journal><ArticleTitle>[Bipolar II disorder: course and suicidal behavior].</ArticleTitle><Pagination><MedlinePgn>147-51</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Bipolar II disorder seems to be more than a mild form of classic manic-depressive illness. Differences with bipolar I concern genetic, biological, clinical and pharmacological aspects. Nevertheless, studies on suicidal behavior in both groups have resulted in inconsistent results</AbstractText><AbstractText Label="PATIENTS AND METHOD" NlmCategory="METHODS">Twenty-two patients fulfilling Research Diagnostic Criteria for the diagnosis of bipolar II disorder and 38 bipolar I were evaluated with the Schedule for Affective Disorders and Schizophrenia by two independent interviewers, and compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar II patients had significantly more previous episodes (p = 0.001), including both depressive (p = 0.003) and hypomanic switches (p = 0.006), but had been hospitalized (p = 0.001) and presented psychotic symptoms (p &lt; 0.001) less frequently.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There were no significant differences between both groups regarding suicidal behavior variables. These results suggest that bipolar II disorder is less severe than bipolar I regarding symptoms intensity, but more severe with respect to episodes frequency, and that suicide attempts rates are not useful to discriminate between both groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>SubdivisiÃ³n de PsiquiatrÃ­a y PsicologÃ­a ClÃ­nica Hospital ClÃ­nic, Barcelona, EspaÃ±a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>GastÃ³</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nieto</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Otero</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Trastorno bipolar II: curso y conducta suicida.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Luso Esp Neurol Psiquiatr Cienc Afines</MedlineTA><NlmUniqueID>0355573</NlmUniqueID><ISSNLinking>0300-5062</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9381957</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9861474</PMID><DateCompleted><Year>1999</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>1998</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Shortened REM latency as a psychobiological marker for psychotic depression? An age-, gender-, and polarity-controlled study.</ArticleTitle><Pagination><MedlinePgn>1314-20</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous reports suggest that the clinical dichotomy separating psychotic and nonpsychotic depression corresponds to different neurobiological profiles. The aim of the present study is to further investigate the psychobiological correlates of these two particular depressive subtypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thyroid-stimulating hormone response to thyrotropin-releasing hormone postdexamethasone cortisol levels, and electroencephalgraphic sleep characteristics of 44 psychotic major depressive patients were compared to those of 44 nonpsychotic depressives matched for age, gender, and polarity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Some biological disturbances usually associated with depression (increased wakefulness, diminished rapid eye movement latency, hypercortisolism, blunted thyroid-stimulating hormone response to thyrotropin-releasing hormone stimulation) seemed to be significantly more pronounced in the psychotic depressed group as a reflection of greater illness severity; however, shortened REM latency was not influenced by severity and seemed to be more specifically related to the co-occurrence of psychotic and depressive symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data provide further support for the validity of the clinical dichotomy separating psychotic and nonpsychotic major depression independently of severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stefos</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, CHU Saint-Pierre Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staner</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kerkhofs</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hubain</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Linkowski</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012895" MajorTopicYN="N">Sleep, REM</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="N">Thyrotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9861474</ArticleId><ArticleId IdType="pii">S0006-3223(98)00009-2</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(98)00009-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17126406</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>1-3</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Enhanced creativity in bipolar disorder patients: a controlled study.</ArticleTitle><Pagination><MedlinePgn>31-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Associations between eminent creativity and bipolar disorders have been reported, but there are few data relating non-eminent creativity to bipolar disorders in clinical samples. We assessed non-eminent creativity in euthymic bipolar (BP) and unipolar major depressive disorder (MDD) patients, creative discipline controls (CC), and healthy controls (HC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">49 BP, 25 MDD, 32 CC, and 47 HC (all euthymic) completed four creativity measures yielding six parameters: the Barron-Welsh Art Scale (BWAS-Total, and two subscales, BWAS-Dislike and BWAS-Like), the Adjective Check List Creative Personality Scale (ACL-CPS), and the Torrance Tests of Creative Thinking--Figural (TTCT-F) and Verbal (TTCT-V) versions. Mean scores on these instruments were compared across groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BP and CC (but not MDD) compared to HC scored significantly higher on BWAS-Total (45% and 48% higher, respectively) and BWAS-Dislike (90% and 88% higher, respectively), but not on BWAS-Like. CC compared to MDD scored significantly higher (12% higher) on TTCT-F. For all other comparisons, creativity scores did not differ significantly between groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found BP and CC (but not MDD) had similarly enhanced creativity on the BWAS-Total (driven by an increase on the BWAS-Dislike) compared to HC. Further studies are needed to determine the mechanisms of enhanced creativity and how it relates to clinical (e.g. temperament, mood, and medication status) and preclinical (e.g. visual and affective processing substrates) parameters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santosa</LastName><ForeName>Claudia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, CA 94305-5723, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strong</LastName><ForeName>Connie M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Nowakowska</LastName><ForeName>Cecylia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Po W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Rennicke</LastName><ForeName>Courtney M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="Y">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>07</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17126406</ArticleId><ArticleId IdType="pii">S0165-0327(06)00452-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.10.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15960566</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Does recovery from substance use disorder matter in patients with bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>730-5; quiz 808-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the potential impact of recovery from substance use disorder (SUD) on the course of bipolar disorder among patients diagnosed with both bipolar and substance use disorders according to DSM-IV criteria.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">As part of the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), we examined bipolar disorder status (i.e., whether the patient is recovering or recovered), role functioning, and quality of life in the first 1000 patients to enter the STEP-BD study. We compared patients with no history of SUD, current SUD, and past SUD (i.e., lifetime SUD, but no current SUD) on these parameters. Data were collected between November 1999 and April 2001.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A current clinical status of recovering or recovered from bipolar disorder was less likely among patients with current or past SUD compared to patients with no SUD (p &lt; .002). Recovering/recovered status did not differ significantly between patients with current SUD versus past SUD. All 3 groups differed significantly on measures of role functioning as assessed by the Longitudinal Interval Follow-Up Evaluation-Range of Impaired Functioning Tool (LIFE-RIFT), with poorest role functioning among patients with current SUD, followed by patients with past SUD (p = .0002). Patients with current or past SUD reported significantly lower quality of life as measured by the LIFE-RIFT and the Quality of Life Enjoyment and Satisfaction Questionnaire and more lifetime suicide attempts (p &lt; .001) than patients without an SUD; patients with past versus current SUD did not differ significantly on these measures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results suggest that patients with bipolar disorder who experience sustained remission from an SUD fare better than patients with current SUD, but not as well as subjects with no history of SUD; differences among the 3 groups appear greatest in the area of role functioning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Roger D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, USA. rweiss@mclean.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Fossey</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Pollack</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Salloum</LastName><ForeName>Ihsan M</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Naomi M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><CollectiveName>for STEP-BD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 DA00326</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA15968</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="N">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15960566</ArticleId><ArticleId IdType="doi">10.4088/jcp.v66n0609</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30286842</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2530-3120</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>4</Issue><PubDate><MedlineDate>2018 Oct - Dec</MedlineDate></PubDate></JournalIssue><Title>Revista Colombiana de psiquiatria (English ed.)</Title><ISOAbbreviation>Rev Colomb Psiquiatr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Relationship Between Cognitive Function and Clinical Features in Patients With Bipolar I Disorder.</ArticleTitle><Pagination><MedlinePgn>204-210</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0034-7450(17)30068-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rcp.2017.05.012</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Previous studies suggest that the severity of alterations in cognitive functions in people with a diagnosis of bipolar I disorder (BP-I) are directly related to the deterioration in overall functioning and life quality. Altered cognitive function is associated with a worse prognosis of BP-I, however little is known about the relationship between cognitive functions and the clinical features of BP-I.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To establish possible associations between cognitive function and the clinical and socio-demographic characteristics of patients with BP-I.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cognitive function was evaluated by applying a neuropsychological battery to a group of patients with a BP-I diagnosis, who did not have affective episodes for at least 6Â months, and who were outpatients treated at the San Juan de Dios Clinic in Manizales. The statistical analysis involved using clustering methocology in order to divide those patients with the best and worst cognitive function and it was later correlated with the clinical and socio-demographic variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A statistically significant corrrelation was found between the number of years of education and the age the disorder started with alterations in the level of cognitive function (P=.002 and P=.017 respectively). No significant correlations were found with other variables.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An early onset of the pathology and fewer years of education seems to be risk factors associated with poorer cognitive function in patients with BP-I.</AbstractText><CopyrightInformation>Copyright Â© 2017 AsociaciÃ³n Colombiana de PsiquiatrÃ­a. Publicado por Elsevier EspaÃ±a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>CastaÃ±o RamÃ­rez</LastName><ForeName>Oscar Mauricio</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n Salud Mental y Comportamiento Humano, Universidad de Caldas, Manizales, Colombia. Electronic address: oscar.castano@ucaldas.edu.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>GÃ³mez Montoya</LastName><ForeName>Sandra Milena</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n Salud Mental y Comportamiento Humano, Universidad de Caldas, Manizales, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemos Buitrago</LastName><ForeName>RocÃ­o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n Salud Mental y Comportamiento Humano, Universidad de Caldas, Manizales, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valderrama SÃ¡nchez</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n Salud Mental y Comportamiento Humano, Universidad de Caldas, Manizales, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro Navarro</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Grupo de InvestigaciÃ³n Salud Mental y Comportamiento Humano, Universidad de Caldas, Manizales, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>RelaciÃ³n del funcionamiento cognitivo conÂ variables clÃ­nicas enÂ pacientes conÂ trastorno bipolar tipoÂ I.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Rev Colomb Psiquiatr (Engl Ed)</MedlineTA><NlmUniqueID>101778593</NlmUniqueID><ISSNLinking>2530-3120</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">CogniciÃ³n</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Cognition disorders</Keyword><Keyword MajorTopicYN="N">Neuropsychological tests</Keyword><Keyword MajorTopicYN="N">Pruebas neuropsicolÃ³gicas</Keyword><Keyword MajorTopicYN="N">Trastorno bipolar</Keyword><Keyword MajorTopicYN="N">Trastornos de la cogniciÃ³n</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30286842</ArticleId><ArticleId IdType="pii">S0034-7450(17)30068-9</ArticleId><ArticleId IdType="doi">10.1016/j.rcp.2017.05.012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6731641</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>7</Issue><PubDate><Year>1984</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Is delusional depression related to bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>892-3</MedlinePgn></Pagination><Abstract><AbstractText>In a family study of major depression, the prevalence of bipolar illness was nearly six times as high among the relatives of delusionally depressed probands as among the relatives of nondelusionally depressed probands or of controls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Prusoff</LastName><ForeName>B A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Merikangas</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-28274</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6731641</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.7.892</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11353454</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0148-7299</ISSN><JournalIssue CitedMedium="Print"><Volume>105</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>American journal of medical genetics</Title><ISOAbbreviation>Am J Med Genet</ISOAbbreviation></Journal><ArticleTitle>Identification of three polymorphisms in the translated region of PLC-gamma1 and their investigation in lithium responsive bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>301-5</MedlinePgn></Pagination><Abstract><AbstractText>Recently, we have found an association between bipolar disorder patients who are excellent responders to lithium prophylaxis and a polymorphic marker located in the first intron of the phospholipase C-gamma1 gene (PLC-gamma1) [Turecki et al., 1998: Mol Psychiatry 3:534-538]. As this variant is not known to be functional, we searched for other markers within the coding region, using single-strand conformational polymorphism (SSCP) analysis. We have identified three polymorphic sites localized in three different exons of the PLC-gamma1 gene (exons 9, 26, 31). Variation studies of these potentially functional sites in a group of 133 bipolar patients with an excellent response to lithium prophylaxis and a comparison group of 99 healthy controls showed no difference in genotype distributions for exon 9 (chi-square = 1.41, df = 2, P = 0.49), exon 26 (chi-square = 2.26, df = 2, P = 0.13), or exon 31 (chi-square = 1.41, df = 2, P = 0.49). Similar results were observed for allele distributions. These results suggest that our previous findings were not the result of linkage disequilibrium with these variants.</AbstractText><CopyrightInformation>Copyright 2001 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ftouhi-Paquin</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Douglas Hospital Research Institute, Douglas Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grof</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chretien</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Turecki</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet</MedlineTA><NlmUniqueID>7708900</NlmUniqueID><ISSNLinking>0148-7299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.-</RegistryNumber><NameOfSubstance UI="D010738">Type C Phospholipases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.3</RegistryNumber><NameOfSubstance UI="D051966">Phospholipase C gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016366" MajorTopicYN="N">Open Reading Frames</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051966" MajorTopicYN="N">Phospholipase C gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018807" MajorTopicYN="N">Polymorphism, Single-Stranded Conformational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010738" MajorTopicYN="N">Type C Phospholipases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>16</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11353454</ArticleId><ArticleId IdType="pii">10.1002/ajmg.1326</ArticleId><ArticleId IdType="doi">10.1002/ajmg.1326</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17497717</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4825</ISSN><JournalIssue CitedMedium="Print"><Volume>143A</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part A</Title><ISOAbbreviation>Am J Med Genet A</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder associated with 11q24.2 disruption--a second report.</ArticleTitle><Pagination><MedlinePgn>1263-7</MedlinePgn></Pagination><Abstract><AbstractText>A recent report identified bipolar affective disorder in a patient with a de novo deletion 11q24.2. We record a further instance involving this cytogenetic region and bipolar affective disorder in a patient with a balanced translocation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reardon</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland. willie.reardon@olhsc.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Blennerhassett</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet A</MedlineTA><NlmUniqueID>101235741</NlmUniqueID><ISSNLinking>1552-4825</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002880" MajorTopicYN="N">Chromosomes, Human, Pair 11</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014178" MajorTopicYN="Y">Translocation, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17497717</ArticleId><ArticleId IdType="doi">10.1002/ajmg.a.31749</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26576693</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Early-onset and very-early-onset bipolar disorder: distinct or similar clinical conditions?</ArticleTitle><Pagination><MedlinePgn>814-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12346</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to examine differences in the clinical presentation of very-early-onset (VEO) and early-onset (EO) bipolar disorder (BD) not fully explored previously.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We selected two groups of subjects with BD from the Maritime Bipolar Registry based on age at onset of first major mood episode (VEO with onset prior to age 15 years; EO ranging from 15 to 18Â years) and compared them with a reference group (onset after 18Â years of age). There were 363 subjects (240 with bipolar I disorder and 123 with bipolar II disorder; mean age 44.2Â Â±Â 12.8 (SD)Â years), with 41 subjects in the VEO and 95 in the EO groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In comparison with the EO and reference groups, more subjects in the VEO group developed major depression as an index episode (88% for the VEO group versus 61% for the EO group and 54% for the reference group), and had an unremitting clinical course (65% versus 42% and 42%, respectively), rapid cycling (54% versus 34% and 28%, respectively), and comorbid attention-deficit hyperactivity disorder (17% versus 1% and 3%, respectively); a higher proportion of the VEO group had first-degree relatives with affective disorders compared with the EO and reference groups (0.41 versus 0.32 and 0.29, respectively), and they had lower scores on the Global Assessment of Functioning scale (mean scores of 64 versus 70 and 70). Overall, the EO group was similar to the reference group on most measures, except for increased suicidal behavior VEO 53%, EO 44% and reference group 25%). The results of polychotomous logistic regression also support the view that VEO BD represents a rather specific subtype of BD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest the recognized correlates of early-onset BD may be driven by subjects at the lowest end of the age at onset spectrum.</AbstractText><CopyrightInformation>Â© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Propper</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaney</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Capital Health Addictions and Mental Health Program, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnham</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Capital Health Addictions and Mental Health Program, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruzickova</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Queens University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calkin</LastName><ForeName>Cynthia V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajek</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>64410</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">childhood ADHD</Keyword><Keyword MajorTopicYN="N">early course</Keyword><Keyword MajorTopicYN="N">early onset</Keyword><Keyword MajorTopicYN="N">first mood episode</Keyword><Keyword MajorTopicYN="N">rapid cycling</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26576693</ArticleId><ArticleId IdType="doi">10.1111/bdi.12346</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3961033</PMID><DateCompleted><Year>1986</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>1986</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Premenstrual changes: a comparison of five populations.</ArticleTitle><Pagination><MedlinePgn>77-85</MedlinePgn></Pagination><Abstract><AbstractText>Several studies have suggested that a special relationship exists between premenstrual and major affective disorders. The present report describes the incidence of reported premenstrual symptoms in women with and without prospectively confirmed premenstrual syndrome, women with bipolar or seasonal affective disorder, and controls. The inability of reported symptoms to differentiate women with and without confirmed premenstrual syndrome, as well as the reduced prevalence of reported premenstrual changes in our affective populations relative to previous reports, is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roy-Byrne</LastName><ForeName>P P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Rubinow</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Hoban</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>N E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Nurnberger</LastName><ForeName>J I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011293" MajorTopicYN="N">Premenstrual Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3961033</ArticleId><ArticleId IdType="pii">0165-1781(86)90062-4</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(86)90062-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10550856</PMID><DateCompleted><Year>1999</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0193-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Psychiatric clinics of North America</Title><ISOAbbreviation>Psychiatr Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Anxious-bipolar comorbidity. Diagnostic and treatment challenges.</ArticleTitle><Pagination><MedlinePgn>565-83, viii</MedlinePgn></Pagination><Abstract><AbstractText>This article describes multiple anxiety comorbidity in the setting of unstable bipolar syndromes, associated with alcohol and substance abuse. Also described are panic attacks during mania, social phobia followed by hypomania as well as bipolar disorder manifesting as episodic obsessive-compulsive disorder. The use of psychotropic combinations is necessary because of the syndromic complexity and the contrasting effects of pharmacologic treatments. The identification of differential patterns of comorbidity may provide important information in distinguishing more homogeneous clinical subtypes of affective disorders from the genetic, temperamental, and therapeutic point of view. The pattern of complex relationships among these disorders requires better-designed prospective observations. This is also true for putative temperamental (e.g. cyclothymia, interpersonal sensitivity) and personality (e.g. histrionic and borderline) factors, which might play a predisposing role in several clinically comorbid syndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Pisa, Italy. g.perugi@psico.med.unipi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Clin North Am</MedlineTA><NlmUniqueID>7708110</NlmUniqueID><ISSNLinking>0193-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>86</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>11</Month><Day>7</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>7</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10550856</ArticleId><ArticleId IdType="pii">S0193-953X(05)70096-4</ArticleId><ArticleId IdType="doi">10.1016/s0193-953x(05)70096-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32172610</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>04</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.</ArticleTitle><Pagination><MedlinePgn>373-383</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14737175.2020.1743684</ELocationID><Abstract><AbstractText><b>Introduction</b>: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.<b>Areas covered</b>: The authors review the effect of pregnancy and the postpartum period on the course of bipolar disorder, describe adverse pregnancy and birth outcomes, and discuss the pharmacotherapy of bipolar disorder during and after pregnancy.<b>Expert opinion</b>: When treating women with bipolar disorder of childbearing age, clinicians should consider the possibility of pregnancy. Pre-conception counseling should be an integral part of the overall plan to manage bipolar disorder during and after pregnancy. Peripartum management of bipolar disorder is challenging and requires balancing of risks associated with the use of drugs and the potentially deleterious effects of untreated bipolar disorder on the fetus/child. Formulation of personalized treatment requires knowledge of both current (episode type, symptom severity, psychiatric comorbidity, and safety concerns) and historical (episode frequency, response to drugs and psychotherapy, and the effect of reproductive events including pregnancy and postpartum period) factors. Close monitoring is essential for early detection and management of mood episodes. Routine safety assessments are necessary to identify women at risk of harming themselves or the newborn.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Verinder</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Obstetrics &amp; Gynecology, University of Western Ontario, London, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Parkwood Institute Mental Health, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Schulich School of Medicine and Dentistry, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Sapna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058725" MajorTopicYN="Y">Peripartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="Y">Postpartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antidepressants</Keyword><Keyword MajorTopicYN="Y">antipsychotics</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">breastfeeding</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">lithium</Keyword><Keyword MajorTopicYN="Y">mood stabilizers</Keyword><Keyword MajorTopicYN="Y">postpartum</Keyword><Keyword MajorTopicYN="Y">pregnancy</Keyword><Keyword MajorTopicYN="Y">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32172610</ArticleId><ArticleId IdType="doi">10.1080/14737175.2020.1743684</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33547595</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1866-3370</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Current topics in behavioral neurosciences</Title><ISOAbbreviation>Curr Top Behav Neurosci</ISOAbbreviation></Journal><ArticleTitle>New Pharmacological Interventions in Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>303-324</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/7854_2020_181</ELocationID><Abstract><AbstractText>The biological bases of bipolar disorder include aspects related, among others, to neurohormonal pathways, neurotransmission, signal transduction, regulation of gene expression, oxidative stress, neuroplasticity, and changes in the immune system. There is still a gap in understanding its complex neurobiology and, consequently, developing new treatments. Multiple factors probably interact in this complex equation of pathophysiology of bipolar disorder, such as genetic, biochemical, psychosocial, and environmental stress events, correlating with the development and severity of the bipolar disorder. These mechanisms can interact to exacerbate inflammation, impair neurogenesis, and increase oxidative stress damage, cellular mitochondrial dysfunction, changes in neurotrophins and in epigenetic mechanisms, neuroendocrine dysfunction, activation of neuronal death pathways, and dysfunction in neurotransmission systems. In this review, we explore the up-to-date knowledge of the neurobiological underpinnings of bipolar disorders. The difficulty in developing new drugs for bipolar disorder is very much associated with the lack of knowledge about the precise pathophysiology of this disorder. Pharmacological treatment for bipolar patients is vital; to progress to effective medications, it is essential to understand the neurobiology in bipolar patients better and identify novel therapeutic targets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Juruena</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Mario.Juruena@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jelen</LastName><ForeName>Luke A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Allan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleare</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Curr Top Behav Neurosci</MedlineTA><NlmUniqueID>101535383</NlmUniqueID><ISSNLinking>1866-3370</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009446" MajorTopicYN="N">Neurobiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009490" MajorTopicYN="N">Neurosecretory Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Targets</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33547595</ArticleId><ArticleId IdType="doi">10.1007/7854_2020_181</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams WK, Levesque DL, Cocker PJ, Kaur S, Bodnar TS, Young AH, Winstanley CA (2020) Decreased motor impulsivity following chronic lithium treatment in male rats is associated with reduced levels of pro-inflammatory cytokines in the orbitofrontal cortex. Brain Behav Immun 89:339â349</Citation></Reference><Reference><Citation>Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, Ghosh S (2012) Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 14:64â70</Citation><ArticleIdList><ArticleId IdType="pubmed">22329473</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreazza AC, Kapczinski F, Kauer-SantâAnna M, Walz JC, Bond DJ, GonÃ§alves CA et al (2009) 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34(4):263â271</Citation><ArticleIdList><ArticleId IdType="pubmed">19568477</ArticleId><ArticleId IdType="pmcid">2702443</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreazza AC, Shao L, Wang JF, Young LT (2010) Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67(4):360â368</Citation><ArticleIdList><ArticleId IdType="pubmed">20368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S (2015) Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord 17(6):606â614</Citation><ArticleIdList><ArticleId IdType="pubmed">26291962</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL (2014) Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014:360481</Citation><ArticleIdList><ArticleId IdType="pubmed">25313338</ArticleId><ArticleId IdType="pmcid">4172873</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudry M, Greget R, Pernot F, Bouteiller JM, Xiaoning B (2012) Roles of group I metabotropic glutamate receptors under physiological conditions and in neurodegeneration. WIREs Membr Transp Signal 1(4):523â532</Citation></Reference><Reference><Citation>Bavaresco DV, Colonetti T, Grande AJ, Colom F, Valvassori SS, Quevedo J, da Rosa MI (2019) Efficacy of celecoxib adjunct treatment on bipolar disorder: systematic review and meta-analysis. CNS Neurol Disord Drug Targets 18:19â28</Citation><ArticleIdList><ArticleId IdType="pubmed">30398124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17:4â31</Citation><ArticleIdList><ArticleId IdType="pubmed">20236142</ArticleId><ArticleId IdType="pmcid">6493865</ArticleId></ArticleIdList></Reference><Reference><Citation>Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33(9):2175â2186</Citation><ArticleIdList><ArticleId IdType="pubmed">18033238</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468â475</Citation><ArticleIdList><ArticleId IdType="pubmed">18534556</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011a) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135:389â394</Citation><ArticleIdList><ArticleId IdType="pubmed">21719110</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al (2011b) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804â817</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, Waterdrinker A, Smith D, Dean OM (2019) A randomized controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17:18</Citation><ArticleIdList><ArticleId IdType="pubmed">30678686</ArticleId><ArticleId IdType="pmcid">6346513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti F, Rintala J, Seemann R, Rosenberger TA, Contreras MA, Rapoport SI, Chang MC (2002) Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 7(8):845â850</Citation><ArticleIdList><ArticleId IdType="pubmed">12232777</ArticleId></ArticleIdList></Reference><Reference><Citation>Brietzke E, Kapczinski F (2008) TNF-alpha as a molecular target in bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 32:1355â1361</Citation></Reference><Reference><Citation>Brown ES, Bobadilla L, Rush AJ (2001) Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord 3:23â29</Citation><ArticleIdList><ArticleId IdType="pubmed">11256460</ArticleId></ArticleIdList></Reference><Reference><Citation>Burket JA, Deutsch SI (2019) Metabotropic functions of the NMDA receptor and an evolving rationale for exploring NR2A-selective positive allosteric modulators for the treatment of autism spectrum disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 90:142â160</Citation></Reference><Reference><Citation>Burt T, Sachs GS, Demopulos C (1999) Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 45:959â964</Citation><ArticleIdList><ArticleId IdType="pubmed">10386177</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese JR, Guelfi JD, Perdrizet-Chevallier C, Agomelatine Bipolar Study Group (2007) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 9:628â635</Citation><ArticleIdList><ArticleId IdType="pubmed">17845278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC (2006) Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 63:741â747</Citation><ArticleIdList><ArticleId IdType="pubmed">16818863</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord 148(1):136â140</Citation><ArticleIdList><ArticleId IdType="pubmed">23200297</ArticleId></ArticleIdList></Reference><Reference><Citation>Claustrat B, Brun J, Chazot G (2005) The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9:11â24</Citation><ArticleIdList><ArticleId IdType="pubmed">15649735</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle JT, Duman RS (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38:157â160</Citation><ArticleIdList><ArticleId IdType="pubmed">12718851</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle CM, Laws KR (2015) The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 30:152â163</Citation><ArticleIdList><ArticleId IdType="pubmed">25847818</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis D, Vine AE, McQuillin A, Bass NJ, Pereira A, Kandaswamy R, Lawrence J, Anjorin A, Choudhury K, Datta SR, Puri V, Krasucki R, Pimm J, Thirumalai S, Quested D, Gurling HM (2011) Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes. Psychiatr Genet 21(1):1â4</Citation><ArticleIdList><ArticleId IdType="pubmed">21057379</ArticleId><ArticleId IdType="pmcid">3024533</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Berger PA, Hollister LE, Defraites E (1978) Physostigmine in mania. Arch Gen Psychiatry 35:119â122</Citation><ArticleIdList><ArticleId IdType="pubmed">339869</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Fuente-Sandoval C, LeÃ³n-Ortiz P, AzcÃ¡rraga M, Stephano S, Favila R, DÃ­az-Galvis L, Alvarado-Alanis P, RamÃ­rez-BermÃºdez J, Graff-Guerrero A (2013) Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiat 70(10):1057â1066</Citation></Reference><Reference><Citation>de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, Forlenza OV, Gattaz WF, Machado-Vieira R (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494(1):54â56</Citation><ArticleIdList><ArticleId IdType="pubmed">21362460</ArticleId></ArticleIdList></Reference><Reference><Citation>Descamps-Latscha B, DrÃ¼eke T, Witko-Sarsat V (2001) Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 14(3):193â199</Citation><ArticleIdList><ArticleId IdType="pubmed">11422926</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R (2014) Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28:536â544</Citation><ArticleIdList><ArticleId IdType="pubmed">24699062</ArticleId></ArticleIdList></Reference><Reference><Citation>Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793â802</Citation><ArticleIdList><ArticleId IdType="pubmed">20679587</ArticleId><ArticleId IdType="pmcid">3000408</ArticleId></ArticleIdList></Reference><Reference><Citation>Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC et al (2010) Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 13(10):1369â1381</Citation><ArticleIdList><ArticleId IdType="pubmed">20633309</ArticleId></ArticleIdList></Reference><Reference><Citation>Duman RS, Malberg J, Nakagawa S, Dâas C (2000) Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48(8):732â739</Citation><ArticleIdList><ArticleId IdType="pubmed">11063970</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G (2006) A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 8:75â80</Citation><ArticleIdList><ArticleId IdType="pubmed">16411983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick FA (2004) Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 10(6):577â588</Citation><ArticleIdList><ArticleId IdType="pubmed">14965321</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey BN, Valvassori SS, RÃ©us GZ, Martins MR, Petronilho FC, Bardini K et al (2006) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31(5):326â332</Citation><ArticleIdList><ArticleId IdType="pubmed">16951735</ArticleId><ArticleId IdType="pmcid">1557682</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158:100â106</Citation><ArticleIdList><ArticleId IdType="pubmed">11685390</ArticleId></ArticleIdList></Reference><Reference><Citation>Furey ML, Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63:1121â1129</Citation><ArticleIdList><ArticleId IdType="pubmed">17015814</ArticleId><ArticleId IdType="pmcid">3250308</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 1:CD005168</Citation></Reference><Reference><Citation>Gartside SE, Leitch MM, Young AH (2003) Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology 28(9):1572â1578</Citation><ArticleIdList><ArticleId IdType="pubmed">12784107</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JR, Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381(9878):1672â1682</Citation><ArticleIdList><ArticleId IdType="pubmed">23663953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons AS, Scarr E, McLean C, Sundram S, Dean B (2009) Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 116:184â191</Citation><ArticleIdList><ArticleId IdType="pubmed">19103464</ArticleId></ArticleIdList></Reference><Reference><Citation>Giridharan VV, Sayana P, Pinjari OF, Ahmad N, da Rosa MI, Quevedo J, Barichello T (2019) Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review. Mol Psychiatry 25(1):94â113</Citation><ArticleIdList><ArticleId IdType="pubmed">31249382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin MJ, Swendsen J, Heller TL, Hammen C (1995) Relapse and impairment in bipolar disorder. Am J Psychiatry 152(11):1635â1640</Citation><ArticleIdList><ArticleId IdType="pubmed">7485627</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaer E (2014) Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 171:3604â3619</Citation><ArticleIdList><ArticleId IdType="pubmed">24724693</ArticleId><ArticleId IdType="pmcid">4128060</ArticleId></ArticleIdList></Reference><Reference><Citation>Guloksuz S, Altinbas K, Aktas Cetin E, Kenis G, Bilgic Gazioglu S, Deniz G, Oral ET, van Os J (2012) Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord 143(1â3):148â152</Citation><ArticleIdList><ArticleId IdType="pubmed">22749155</ArticleId></ArticleIdList></Reference><Reference><Citation>Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J (2020) Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord 261:145â152</Citation><ArticleIdList><ArticleId IdType="pubmed">31630035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallahan B (n.d.) Scopolamine in bipolar depression (SCOPE-BD). https://clinicaltrials.gov/ct2/show/NCT04211961</Citation></Reference><Reference><Citation>Hendler NH (1978) Spironolactone prophylaxis in manic-depressive disease. J Nerv Ment Dis 166(7):517â520</Citation><ArticleIdList><ArticleId IdType="pubmed">670960</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrobin DF, Lieb J (1981) A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system. Med Hypotheses 7(7):891â905</Citation><ArticleIdList><ArticleId IdType="pubmed">6270514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Yu X, Yang F, Si T, Wang W, Tan Y, Zhou D, Wang H, Chen D (2010) The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 26(2):121â125</Citation><ArticleIdList><ArticleId IdType="pubmed">19935088</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain MI, Chaudhry IB, Hamirani MM, Minhas FA, Kazmi A, Hodsoll J, Haddad PM, Deakin JF, Husain N, Young AH (2016) Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatr Dis Treat 13:1â8</Citation><ArticleIdList><ArticleId IdType="pubmed">28031712</ArticleId><ArticleId IdType="pmcid">5182039</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain MI, Strawbridge R, Stokes PR, Young AH (2017) Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol 31:1137â1148</Citation></Reference><Reference><Citation>Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, Naqvi HA, Minhas FA, Carvalho AF, Meyer JH, Deakin B, Mulsant BH, Husain N, Young AH (2020) Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomized controlled trial. Lancet Psychiatry 7(6):515â527</Citation><ArticleIdList><ArticleId IdType="pubmed">32445690</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai H, Nakagawa Y (2003) Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 34(2):145â169</Citation><ArticleIdList><ArticleId IdType="pubmed">12521597</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2:632â635</Citation><ArticleIdList><ArticleId IdType="pubmed">4116781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, Lyoo IK (2014) Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol 23:28â35</Citation><ArticleIdList><ArticleId IdType="pubmed">24737937</ArticleId><ArticleId IdType="pmcid">3984954</ArticleId></ArticleIdList></Reference><Reference><Citation>Juruena MF (2014) Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav 38:148â159</Citation><ArticleIdList><ArticleId IdType="pubmed">24269030</ArticleId></ArticleIdList></Reference><Reference><Citation>Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS (2009) Improved residual symptoms in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J Psychopharmacol 23(8):985â987</Citation><ArticleIdList><ArticleId IdType="pubmed">18583441</ArticleId></ArticleIdList></Reference><Reference><Citation>Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2009a) Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 194:342â349</Citation><ArticleIdList><ArticleId IdType="pubmed">19336786</ArticleId></ArticleIdList></Reference><Reference><Citation>Juruena MF, Ottoni G, Machado-Vieira R, Carneiro R, Weingarthner N, Fleig SS, Broilo L, Busnello ED (2009b) Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuro-Psychopharmacol Biol Psychiatry 33:94â99</Citation></Reference><Reference><Citation>Kargar M, Yousefi A, Mojtahedzadeh M, Akhondzadeh S, Artounian V, Abdollahi A, Ahmadvand A, Ghaeli P (2014) Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly 144:w13880</Citation><ArticleIdList><ArticleId IdType="pubmed">24554598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T (2007) Mitochondrial dysfunction as themolecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21(1):1â11</Citation><ArticleIdList><ArticleId IdType="pubmed">17190525</ArticleId></ArticleIdList></Reference><Reference><Citation>Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr (2009) Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 32:199â204</Citation><ArticleIdList><ArticleId IdType="pubmed">19620854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew JN, Kemp JA (2005) Ionotropic andmetabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179(1):4â29</Citation><ArticleIdList><ArticleId IdType="pubmed">15731895</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairova R, Pawar R, Salvadoran G, Juruena MF, De Sousa RT, Soeiro-de-Souza MG, Salvador M, Zarate CA, Gattaz WF, Machado-Vieira R (2012) Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 5:680â682</Citation><ArticleIdList><ArticleId IdType="pubmed">22200861</ArticleId></ArticleIdList></Reference><Reference><Citation>Laeng P, Pitts RL, Lemire AL, Drabik CE, Weiner A, Tang H, Thyagarajan R, Mallon BS, Altar CA (2004) The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem 91:238â251</Citation><ArticleIdList><ArticleId IdType="pubmed">15379904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanfumey L, Mongeau R, Hamon M (2013) Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol Ther 138:176â184</Citation><ArticleIdList><ArticleId IdType="pubmed">23348014</ArticleId></ArticleIdList></Reference><Reference><Citation>Leach MJ, Baxter MG, Critchley MA (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia 32(2):4â8</Citation></Reference><Reference><Citation>Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141(1):1â10</Citation><ArticleIdList><ArticleId IdType="pubmed">22497876</ArticleId><ArticleId IdType="pmcid">3498820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, Yeh TL, Yang YK, Hong JS, Lu RB (2014) The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. J Clin Psychopharmacol 34:337â343</Citation><ArticleIdList><ArticleId IdType="pubmed">24717258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessmann V, Gottmann K, Malcangio M (2003) Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 69:341â374</Citation><ArticleIdList><ArticleId IdType="pubmed">12787574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ketter TA, Frye MA (2002) Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 69(1â3):1â14</Citation><ArticleIdList><ArticleId IdType="pubmed">12103447</ArticleId></ArticleIdList></Reference><Reference><Citation>LÃ³pez-MuÃ±oz F, Shen WW, DâOcon P, Romero A, Ãlamo C (2018) A history of the pharmacological treatment of bipolar disorder. Int J Mol Sci 19(7):E2143</Citation><ArticleIdList><ArticleId IdType="pubmed">30041458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund C, Tomlinson M, De Silva M, Fekadu A, Shidhaye R, Jordans M, Petersen I, Bhana A, Kigozi F, Prince M, Thornicroft G, Hanlon C, Kakuma R, McDaid D, Saxena S, Chisholm D, Raja S, Kippen-Wood S, Honikman S, Fairall L, Patel V (2012) Prime. A programme to reduce the treatment gap for mental disorders in five low- and middle-income countries. PLoS Med 9(12):e1001359</Citation><ArticleIdList><ArticleId IdType="pubmed">23300387</ArticleId><ArticleId IdType="pmcid">3531506</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr (2012) Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100(4):678â687</Citation><ArticleIdList><ArticleId IdType="pubmed">21971560</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):664â675</Citation></Reference><Reference><Citation>Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Braz J Psychiatry 33:374â378</Citation><ArticleIdList><ArticleId IdType="pubmed">22189927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahableshwarkar AR, Calabrese JR, Macek TA, Budur K, Adefuye A, Dong X, Hanson E, Sachs GS (2017) Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial. J Affect Disord 221:275â282</Citation><ArticleIdList><ArticleId IdType="pubmed">28662460</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, Porter R, Singh AB (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 49(12):1087â1206</Citation><ArticleIdList><ArticleId IdType="pubmed">26643054</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH (2007) Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127(1):108â118</Citation><ArticleIdList><ArticleId IdType="pubmed">17113057</ArticleId></ArticleIdList></Reference><Reference><Citation>McElroy SL, Winstanley EL, Martens B, Patel NC, Mori N, Moeller D, McCoy J, Keck PE Jr (2011) A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 26:48â53</Citation><ArticleIdList><ArticleId IdType="pubmed">20861739</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD, Robbins MJ, Benzel IM, Maycox PR, Holmes E, Bahn S (2009) Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 8(4):1943â1952</Citation><ArticleIdList><ArticleId IdType="pubmed">19714815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL (2013) Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698(1â3):6â18</Citation><ArticleIdList><ArticleId IdType="pubmed">23123057</ArticleId></ArticleIdList></Reference><Reference><Citation>Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013) Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74(1):15â25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, Mohammadinejad P, Gholamian F, Mohammadi MR, Zeinoddini A, Akhondzadeh S (2017) Randomized double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J Child Adolesc Psychopharmacol 27:494â500</Citation><ArticleIdList><ArticleId IdType="pubmed">28409660</ArticleId></ArticleIdList></Reference><Reference><Citation>Moylan S, Maes M, Wray N, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18:595â606</Citation><ArticleIdList><ArticleId IdType="pubmed">22525486</ArticleId></ArticleIdList></Reference><Reference><Citation>Murck H, SchÃ¼ssler P, Steiger A (2012) Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry 45(3):83â95</Citation><ArticleIdList><ArticleId IdType="pubmed">22290200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539â7547</Citation><ArticleIdList><ArticleId IdType="pubmed">7472505</ArticleId><ArticleId IdType="pmcid">6578063</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris ER, Karen B, Correll JR, Zemanek KJ, Lerman J, Primelo RA, Kaufmann MW (2013) A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 144:141â147</Citation><ArticleIdList><ArticleId IdType="pubmed">22963894</ArticleId></ArticleIdList></Reference><Reference><Citation>OâBrien PM, Craven D, Selby C, Symonds EM (1979) Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 86(2):142â147</Citation><ArticleIdList><ArticleId IdType="pubmed">371663</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevas GP, Triantafyllou NI, Kapaki E, Limpitaki G, Petropoulou O, Vassilopoulos D (2006) Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: relation to treatment response. Epilepsy Res 70(2â3):184â189</Citation><ArticleIdList><ArticleId IdType="pubmed">16762531</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LT, Lener MS, Hopkins M, Iadorola N, Machado-Vieira R, Ballard E, Nugent A, Zarate CA Jr (2017) A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression. J Clin Psychopharmacol 37:355â358</Citation><ArticleIdList><ArticleId IdType="pubmed">28338546</ArticleId><ArticleId IdType="pmcid">5392145</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira C, Chavarria V, Vian J, Ashton MM, Berk M, Marx W, Dean OM (2018) Mitochondrial agents for bipolar disorder. Int J Neuropsychopharmacol 21:550â569</Citation><ArticleIdList><ArticleId IdType="pubmed">29596661</ArticleId><ArticleId IdType="pmcid">6007750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rantamaki T, Knuuttila JEA, Hokkanen ME, CastrÃ©n E (2006) The effects of acute and long-term lithium treatments on TrkB neurotrophin receptor activation in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology 50:421â427</Citation><ArticleIdList><ArticleId IdType="pubmed">16300803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao JS, Rapoport SI (2009) Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2:207â214</Citation><ArticleIdList><ArticleId IdType="pubmed">20021459</ArticleId><ArticleId IdType="pmcid">2825027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao JS, Lee HJ, Rapoport SI, Bazinet RP (2008) Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry 13(6):585â596</Citation><ArticleIdList><ArticleId IdType="pubmed">18347600</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao JS, Harry GJ, Rapoport SI, Kim HW (2010) Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 15(4):384â392</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapaport MH, Manji HK (2001) The effects of lithium on ex vivo cytokine production. Biol Psychiatry 50(3):217â224</Citation><ArticleIdList><ArticleId IdType="pubmed">11513821</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel G, Platt B, Micheau J (2003) Glutamate receptor function in learning and memory. Behav Brain Res 140:1â47</Citation><ArticleIdList><ArticleId IdType="pubmed">12644276</ArticleId></ArticleIdList></Reference><Reference><Citation>Roitman S, Green T, Osher Y, Karni N, Levine J (2007) Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disord 9:754â758</Citation><ArticleIdList><ArticleId IdType="pubmed">17988366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa AR, Frey BN, Andreazza AC, Cereser KM, Cunha AB, Quevedo J, Santin A, Gottfriend C, GonÃ§alves CA, Vieta E, Kapczinski F (2006) Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 407(2):146â150</Citation><ArticleIdList><ArticleId IdType="pubmed">16959421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, Churchill GC, Geddes JR, Goodwin GM (2014) Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med 44:2409â2418</Citation><ArticleIdList><ArticleId IdType="pubmed">24467931</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasaio A, Nawa H, Aloyz EP, Castren E (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant induced behavioral effects. J Neurosci 23:349â357</Citation><ArticleIdList><ArticleId IdType="pubmed">12514234</ArticleId><ArticleId IdType="pmcid">6742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarris J, Mischoulon D, Schweitzer I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73:81â86</Citation><ArticleIdList><ArticleId IdType="pubmed">21903025</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH (2018) Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2x2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry 8:27</Citation><ArticleIdList><ArticleId IdType="pubmed">29362444</ArticleId><ArticleId IdType="pmcid">5802452</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaini G, Fries GR, Valvassori SS, Zeni CP, Zunta-Soares G, Berk M et al (2017) Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. Transl Psychiatry 7(5):e1111</Citation><ArticleIdList><ArticleId IdType="pubmed">28463235</ArticleId><ArticleId IdType="pmcid">5534951</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheefhals N, MacGillavry HD (2018) Functional organization of postsynaptic glutamate receptors. Mol Cell Neurosci 91:82â94</Citation><ArticleIdList><ArticleId IdType="pubmed">29777761</ArticleId><ArticleId IdType="pmcid">6276983</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao L, Young LT, Wang JF (2005) Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58:879â884</Citation><ArticleIdList><ArticleId IdType="pubmed">16005436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitges M, Chiu LM, Guarneros A, Nekrassov V (2007) Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52:598â605</Citation><ArticleIdList><ArticleId IdType="pubmed">17070874</ArticleId></ArticleIdList></Reference><Reference><Citation>Soczynska JK, Kennedy SH, Alsuwaidan M, Mansur RB, Li M, McAndrews MP, Brietzke E, Woldeyohannes HO, Taylor VH, McIntyre RS (2017) A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord 19:198â213</Citation><ArticleIdList><ArticleId IdType="pubmed">28599348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sourial-Bassillious N, Rydelius PA, Aperia A, Aizman O (2009) Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 161(4):1126â1134</Citation></Reference><Reference><Citation>Tatay-Manteiga A, BalanzÃ¡-MartÃ­nez V, Bristot G, TabarÃ©s-Seisdedos R, Kapczinski F, Cauli O (2017) Clinical staging and serum cytokines in bipolar patients during euthymia. Prog Neuropsychopharmacol Biol Psychiatry 77:194â201</Citation><ArticleIdList><ArticleId IdType="pubmed">28445689</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniolo RA, Silva M, Fernandes FBF, Amaral J, Dias RDS, Lafer B (2018) A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. J Neural Transm 125:247â257</Citation><ArticleIdList><ArticleId IdType="pubmed">29177955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, HammarbÃ¤ck S, Lindhe BA, BÃ¤ckstrÃ¶m T (1995) Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 74(10):803â808</Citation><ArticleIdList><ArticleId IdType="pubmed">8533564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Hron 11(5):523â529</Citation></Reference><Reference><Citation>Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH (2004) Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184:496â502</Citation><ArticleIdList><ArticleId IdType="pubmed">15172943</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S, North-East Mood Disorders Clinical Research Group, Young AH, Ferrier IN (2012) A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 72:943â949</Citation><ArticleIdList><ArticleId IdType="pubmed">22770649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernze H (2000) Surprising effect of spironolactone on eating behavior and mood in bulimia nervosa. Psychopharmakotherapie 7:33â39</Citation></Reference><Reference><Citation>Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, Calabrese J, Agomelatine Study Group (2016) Agomelatine or placebo as adjunctive therapy to a mood stabilizer in bipolar I depression: randomized double-blind placebo-controlled trial. Br J Psychiatry 208:78â86</Citation><ArticleIdList><ArticleId IdType="pubmed">25999335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF (2009) Decreased glutamate/glutamine levels may mediate cytidineâs efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 34:1810â1818</Citation><ArticleIdList><ArticleId IdType="pubmed">19194376</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29:1538â1545</Citation><ArticleIdList><ArticleId IdType="pubmed">15127079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57(4):430â432</Citation></Reference><Reference><Citation>Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamineâs antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71(11):939â946</Citation><ArticleIdList><ArticleId IdType="pubmed">22297150</ArticleId><ArticleId IdType="pmcid">3343177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8909329</PMID><DateCompleted><Year>1996</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>10</Issue><PubDate><Year>1996</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>441-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gradual discontinuation of lithium may reduce high risk of early morbidity in bipolar disorder patients discontinuing successful long-term maintenance on lithium, but previous small samples have limited analyses of subgroups.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">DSM-IV bipolar disorder patients (N = 161) were pooled from similar samples maintained on lithium for 4.2 +/- 3.1 years. Effects of discontinuing treatment abruptly (1-14 days) or gradually (15-30 days) were compared by survival analysis in clinically closely similar groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After gradual versus rapid discontinuation, the overall median time to recurrence +/- SE differed by 5.0-fold (20.0 +/- 5.8 vs. 4.0 +/- 0.7 months; p &lt; .0001). After rapid discontinuation, the median time in remission was 2.3 times shorter than the mean cycling interval before lithium (6.3 vs. 14.6 months; p &lt; .0001). The proportion of subjects falling ill/month (recurrence rate) was much higher in the first year after rapid discontinuation (6.5% vs. 2.3%), but similar thereafter (0.4% vs. 0.6%); patients remained stable for 3 years when off lithium treatment 20 times more frequently after gradual than rapid discontinuation (37% vs. 1.8%; p &lt; .0001). Ratios of median survival times after gradual/rapid lithium discontinuation were similar for a first recurrence of mania and depression (4.4 vs. 3.4-fold), insignificantly higher (34%) with rapid or continuous cycling before lithium, and greater in Type II than Type I disorder (9.8- vs. 4.0-fold). The polarity of first off-lithium and first lifetime episodes matched in 70% of cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These pooled results strengthen the concept or a pharmacodynamic stress factor in early relapse after stopping lithium maintenance and support the conclusion that early recurrence risk can be minimized by discontinuing maintenance treatment gradually in both Type I and II bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience Program, Harvard Medical School, Mass, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Faedda</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>T R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Floris</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rudas</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-01221</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-31142</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-47370</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8909329</ArticleId><ArticleId IdType="doi">10.4088/jcp.v57n1001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18450941</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2008</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mood stabilizer discontinuation in pregnant women with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>646-7; author reply 647-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2008.08010036</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazer-Poline</LastName><ForeName>Carrie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rifkin</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Geisler</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Walch</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2007 Dec;164(12):1817-24; quiz 1923</RefSource><PMID Version="1">18056236</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005315" MajorTopicYN="N">Fetal Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011261" MajorTopicYN="N">Pregnancy Trimester, First</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18450941</ArticleId><ArticleId IdType="pii">165/5/646-a</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2008.08010036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15827049</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2005</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0931-0509</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</Title><ISOAbbreviation>Nephrol Dial Transplant</ISOAbbreviation></Journal><ArticleTitle>Disturbed calcium metabolism in a patient with bipolar disorder and impaired renal function.</ArticleTitle><Pagination><MedlinePgn>1752-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caskey</LastName><ForeName>Fergus J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Richard Bright Renal Unit, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK. caskey@t-online.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickett</LastName><ForeName>Tom M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nephrol Dial Transplant</MedlineTA><NlmUniqueID>8706402</NlmUniqueID><ISSNLinking>0931-0509</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002128" MajorTopicYN="N">Calcium Metabolism Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15827049</ArticleId><ArticleId IdType="pii">gfh797</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfh797</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8930025</PMID><DateCompleted><Year>1997</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>1996</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Lymphoblastoid transmembrane potential in bipolar patients, their siblings, and unrelated healthy comparison subjects.</ArticleTitle><Pagination><MedlinePgn>197-201</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar illness appears to be characterized by alterations in ionic homeostasis that are related to mood state. This is reflected by reports of altered intracellular sodium and calcium concentrations, altered sodium pump (Na+,K+-adenosine triphosphatase), and calcium pump (Ca2+-adenosine triphosphatase) activity. Recent ex vivo studies with fresh lymphocytes and in vitro studies with cultured lymphoblasts suggest that there may be an enduring trait-related abnormality in Na+,K+-adenosine triphosphatase as well. We have previously found that the lymphocyte transmembrane potential (TMP) varies with mood state. To examine the question of trait-related changes in TMP, we studied TMP of immortalized lymphoblasts from 14 patients with bipolar illness, nine unaffected siblings, and eight normal subjects. TMP was the same in all three groups. These preliminary data suggest that TMP is a state-- rather than a trait-related marker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buss</LastName><ForeName>T J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, KY 40292-0001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Peiper</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>El-Mallakh</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.2.2.13</RegistryNumber><NameOfSubstance UI="D000254">Sodium-Potassium-Exchanging ATPase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="Y">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000254" MajorTopicYN="N">Sodium-Potassium-Exchanging ATPase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>31</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>31</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8930025</ArticleId><ArticleId IdType="pii">0165-1781(95)02756-4</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(95)02756-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3941059</PMID><DateCompleted><Year>1986</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>1986</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports.</ArticleTitle><Pagination><MedlinePgn>40-1</MedlinePgn></Pagination><Abstract><AbstractText>Three patients with bipolar disorder developed manic symptoms while receiving a combination of isocarboxazid and amitriptyline during an episode of major depression refractory to previous treatments. It is suggested that mania be considered a possible complication of combined treatment with an MAO inhibitor and a tricyclic antidepressant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de la Fuente</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Berlanga</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>LeÃ³n-Andrade</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical><Chemical><RegistryNumber>34237V843T</RegistryNumber><NameOfSubstance UI="D007520">Isocarboxazid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007520" MajorTopicYN="N">Isocarboxazid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3941059</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28523821</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Risk factors for early cardiovascular mortality in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>716-724</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12538</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We attempted to determine risk factors, particularly pathophysiological changes, for early cardiovascular mortality in bipolar disorder (BD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 5416 inpatients with bipolar I disorder were retrospectively followed through record linkage for cause of death. A total of 35 patients dying from cardiovascular disease (CVD; ICD 9: 401-443) before the age of 65âyears were identified. Two living BD patients and two mentally healthy adults were matched with each deceased patient as control subjects according to age (Â±2âyears), sex, and date (Â±3âyears) of the final/index admission or the date of general health screening. Data were obtained through medical record reviews.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty percent of CVD deaths occurred within 10âyears following the index admission. Conditional logistic regression revealed that the variables most strongly associated with CVD mortality were the leukocyte count and heart rate on the first day of the index hospitalization, as the deceased BD patients were compared with the living BD controls. Systolic pressure on the first day of the index hospitalization can be substituted for heart rate as another risk factor for CVD mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is suggested that systemic inflammation and sympathetic overactivity during the acute phase of BD may be risk factors for early CVD mortality.</AbstractText><CopyrightInformation>Â© 2017 The Authors. Psychiatry and Clinical Neurosciences Â© 2017 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shang-Ying</ForeName><Initials>SY</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5662-0055</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chao-Hsien</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Health Business Administration, Meiho University, Pingtung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Pao-Huan</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kuo-Hsuan</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shou-Hung</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Chian-Jue</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taipei City Psychiatric Center, Taipei City Hospital, Songde Branch, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wen-Cheng</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061213" MajorTopicYN="Y">Mortality, Premature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">sympathetic overactivity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28523821</ArticleId><ArticleId IdType="doi">10.1111/pcn.12538</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20334933</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>177</Volume><Issue>1-2</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Correlates of recovery of social functioning in types I and II bipolar disorder patients.</ArticleTitle><Pagination><MedlinePgn>131-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2010.02.020</ELocationID><Abstract><AbstractText>Since bipolar disorder (BPD) patients are often functionally impaired, and factors associated with recovery from disability are largely unknown, we investigated demographic, clinical, and neurocognitive correlates of current social functional recovery in 65 stable participants diagnosed with Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) type I (n=42) or II (n=23) BPD. Regaining highest previous levels of social functioning was rated with the Interpersonal Relationships Questionnaire. We also considered neuropsychological test findings as well as demographic and clinical information including mania and depression symptom-ratings. We examined factors associated with social recovery status using univariate analyses and then multiple logistic regression modeling. Of all subjects, 30 (46%) achieved current social functional recovery and 35 (54%) did not. Younger age (P=0.005) and lesser current depressive symptoms (P=0.02) were associated with social functional recovery, even after controlling for time since the last major mood episode, diagnostic type (II vs. I), co-morbid psychiatric illness, and executive functioning status. The findings are consistent with deleterious effects of even residual depressive symptoms in BPD patients.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Aliza P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA. aliza.wingo@emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Compton</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR025008</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025008-03</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000454</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR-025008</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20334933</ArticleId><ArticleId IdType="pii">S0165-1781(10)00094-6</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2010.02.020</ArticleId><ArticleId IdType="pmc">PMC2859974</ArticleId><ArticleId IdType="mid">NIHMS185979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Compr Psychiatry. 2009 Jan-Feb;50(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19059506</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17728418</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2007 Jun 07;3:5</Citation><ArticleIdList><ArticleId IdType="pubmed">17555558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Dec;62(12):1322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16330720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Mar;11(2):190-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19267701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):183-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17391360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20565439</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 May;150(5):720-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8480816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):401-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19500093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Aug;68(8):1237-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17854249</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Dec;116(6):419-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17997721</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 2004 Mar;19(2):203-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15010086</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 1999 Feb;14(2):167-77</Citation><ArticleIdList><ArticleId IdType="pubmed">14590600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17988364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Jul;14(7):728-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18283278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 May;10(3):413-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18402629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1997 Sep-Oct;31(5):509-17</Citation><ArticleIdList><ArticleId IdType="pubmed">9368193</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Nov;152(11):1635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7485627</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Oct;67(10):1551-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17107246</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1974 Feb;124(579):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4825659</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1780370</PMID><DateCompleted><Year>1992</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>1</Issue><PubDate><MedlineDate>1991 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Social adaptation of patients with bipolar disorder in relation to the problems of alcoholism (pilot studies)].</ArticleTitle><Pagination><MedlinePgn>21-8</MedlinePgn></Pagination><Abstract><AbstractText>89 patients (52 women and 37 men) with bipolar affective disorder was separated on two groups: with alcohol problems (n = 30) and without alcohol problems (n = 59). Both groups were tested using Scale of Adaptation and Activity of PuzyÅski (SAA III). The bipolar affective illness discriminates patient's social functioning (especially married life and emotional relation to the closest relatives). The bipolar patients with alcohol problems did show worse social adaptation than the other group; it concerns mainly masculine patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Habrat</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>II Kliniki Psychiatrycznej Instytutu Psychiatrii i Neurologii w Warszawie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>BidziÅska</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Adaptacja socjalna u osÃ³b z choroba afektywna dwubiegunowa w zaleznoÅci od wystepowania pboblemÃ³w alkoholowych (badania pilotazowe).</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1780370</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19769442</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Myth of evidence-based medicine for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1271-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/ern.09.87</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009229" MajorTopicYN="Y">Mythology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>19</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19769442</ArticleId><ArticleId IdType="doi">10.1586/ern.09.87</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12392349</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63 Suppl 10</Volume><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Long-term treatment of bipolar disorder with lamotrigine.</ArticleTitle><Pagination><MedlinePgn>18-22</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar depression is as debilitating as mania in bipolar disorder, but the treatment of bipolar depression has historically received less attention. To date, there is no mood stabilizer (liberally defined as a medication that decreases episode severity, duration, or frequency in one phase of bipolar illness without producing a negative effect in other phases) that demonstrates similar efficacy in both the depressive and the manic phases of bipolar disorder. However, bipolar depression--which is prevalent, sometimes chronic, and associated with a low quality of life and a high risk of suicide--must be addressed as energetically as mania. Recent research into the long-term treatment of bipolar disorder has raised several questions about the generalizability of early lithium studies, as a result of these studies' designs. Researchers conducting more recent studies of mood stabilizers in the long-term treatment of bipolar disorder have attempted to clarify their results by, for example, performing survival analyses of the data. Until pharmacotherapy has been found that is equally efficacious in the treatment of both manic and depressive episodes in bipolar disorder, the use of combination therapy to manage bipolar disorder is advised. Lithium and divalproex sodium remain the first-line treatments for mania. Lamotrigine has been found to have acute efficacy in treating episodes of bipolar depression without increasing cycling or provoking a switch into mania, as well as a long-term role in delaying relapse and recurrence of depressive episodes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>jrc8@po.cwru.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Melvin D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Rapport</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Elhaj</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>27</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12392349</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24185242</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Reduced white matter integrity in sibling pairs discordant for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1317-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.12111462</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Several lines of evidence indicate that white matter integrity is compromised in bipolar disorder, but the nature, extent, and biological causes remain elusive. To determine the extent to which white matter deficits in bipolar disorder are familial, the authors investigated white matter integrity in a large sample of bipolar patients, unaffected siblings, and healthy comparison subjects.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors collected diffusion imaging data for 64 adult bipolar patients, 60 unaffected siblings (including 54 discordant sibling pairs), and 46 demographically matched comparison subjects. Fractional anisotropy was compared between the groups using voxel-wise tract-based spatial statistics and by extracting mean fractional anisotropy from 10 regions of interest. Additionally, intraclass correlation coefficients were calculated between the sibling pairs as an index of familiality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Widespread fractional anisotropy reductions in bipolar patients (&gt;40,000 voxels) and more subtle reductions in their siblings, mainly restricted to the corpus callosum, posterior thalamic radiations, and left superior longitudinal fasciculus (&gt;2,000 voxels) were observed. Similarly, region-of-interest analysis revealed significant reductions in most white matter regions in patients. In siblings, fractional anisotropy in the posterior thalamic radiation and the forceps was nominally reduced. Significant between-sibling correlations were found for mean fractional anisotropy across the tract-based spatial statistic skeleton, within significant clusters, and within nearly all regions of interest.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings emphasize the relevance of white matter to neuropathology and familiality of bipolar disorder and encourage further use of white matter integrity markers as endophenotypes in genetic studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sprooten</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Brumbaugh</LastName><ForeName>Margaret S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Emma E M</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>D Reese</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cyr</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kochunov</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Anderson M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Glahn</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB015611</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080912</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="Y">Siblings</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24185242</ArticleId><ArticleId IdType="pii">1764123</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.12111462</ArticleId><ArticleId IdType="pmc">PMC4119087</ArticleId><ArticleId IdType="mid">NIHMS578323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Neurosci. 2011 Mar;33(5):933-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21385236</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Jan 1;44(1):83-98</Citation><ArticleIdList><ArticleId IdType="pubmed">18501637</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Aug;94(1-3):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17566708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Apr 1;35(2):467-77</Citation><ArticleIdList><ArticleId IdType="pubmed">17258908</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 Mar;34(4):533-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19896972</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Jun;52(6):471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7771917</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">18076529</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):177-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23036958</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Feb 1;54(3):2308-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20950689</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Jul 1;36(3):630-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17481925</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurosci. 1995;3(2):89-97</Citation><ArticleIdList><ArticleId IdType="pubmed">7583624</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Apr 15;40(3):1044-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18295509</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2008 Nov;11(11):1271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Nov 15;53(3):1109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20117221</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Apr 30;206(2-3):223-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23218918</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e47684</Citation><ArticleIdList><ArticleId IdType="pubmed">23133518</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2007 Jun 30;151(3):179-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17433451</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Feb;66(2):142-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19188536</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jun;194(6):527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19478293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2002;28(4):683-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12795498</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 15;31(4):1487-505</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Mar 15;57(6):633-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15780850</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):443-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15826742</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1249-59, 1259.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">21093774</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Aug 15;70(4):350-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21429475</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Mar 15;73(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Sep 6;362(9386):798-805</Citation><ArticleIdList><ArticleId IdType="pubmed">13678875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15134424</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0098-8421</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Journal of the American Medical Women's Association (1972)</Title><ISOAbbreviation>J Am Med Womens Assoc (1972)</ISOAbbreviation></Journal><ArticleTitle>Women and bipolar disorder across the life span.</ArticleTitle><Pagination><MedlinePgn>91-100</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar I disorder occurs in approximately 1% of the adult population, and it affects women and men equally. Women develop bipolar II disorder, bipolar depression, mixed mania, and a rapid-cycling course of illness more commonly than men and are at greater risk of such comorbid conditions as alcohol use problems, thyroid disease, medication-induced obesity, and migraine headaches. The treatment of bipolar disorder remains challenging. Although lithium reduces symptoms and prevents recurrence with good efficacy, a significant number of patients stop taking it. Furthermore, several anticonvulsants and antidepressants are prescribed off label for acute episodes and prophylaxis despite the lack of adequate research support. Psychotherapy may alleviate mania or depression and improve treatment compliance, yet its ability to prevent relapse remains uncertain. Changes throughout the reproductive cycle also have an impact on the onset and presentation of bipolar symptoms and the choice of treatment. This article provides an overview of common presentations and comorbidities, along with approaches to evaluation and treatment of women with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sit</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, Western Psychiatric Institute and Clinic, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH060335</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060335-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Womens Assoc (1972)</MedlineTA><NlmUniqueID>7503064</NlmUniqueID><ISSNLinking>0098-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="N">Migraine Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="Y">Women's Health</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>131</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15134424</ArticleId><ArticleId IdType="pmc">PMC3107596</ArticleId><ArticleId IdType="mid">NIHMS294416</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2002 Jun;70(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12113916</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002;63 Suppl 10:13-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12392348</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:83-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12504074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jan;60(1):29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12511170</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12656935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):48-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12656938</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):392-400</Citation><ArticleIdList><ArticleId IdType="pubmed">12695317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Apr;74(2):197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">12706522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Apr;64(4):370-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12716236</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003;64 Suppl 6:9-17; discussion 28</Citation><ArticleIdList><ArticleId IdType="pubmed">12720475</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 May;160(5):883-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12727691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Jun 1;61(2-3):157-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12729867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2003 Jun;71(3):482-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12795572</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Jul;108(1):4-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12807371</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jul;160(7):1263-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12832240</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jul;60(7):664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12860770</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2003 Mar-Apr;11(2):99-108</Citation><ArticleIdList><ArticleId IdType="pubmed">12868510</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Aug 1;54(3):307-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12893106</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Aug 1;54(3):376-87</Citation><ArticleIdList><ArticleId IdType="pubmed">12893112</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Nov;60(11):767-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10584766</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Aug;160(8):1428-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12900304</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Sep;160(9):1651-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12944341</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):904-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12963672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):914-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12963673</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Sep 17;290(11):1467-73</Citation><ArticleIdList><ArticleId IdType="pubmed">13129986</ArticleId></ArticleIdList></Reference><Reference><Citation>Headache. 2003 Oct;43(9):940-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14511270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):310-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525551</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14638583</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):421-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14636365</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Jan;161(1):163-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14702267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Dec;64(12):1483-94</Citation><ArticleIdList><ArticleId IdType="pubmed">14728111</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14754766</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Apr;161(4):608-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15056503</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1973 Mar;28(3):337-41</Citation><ArticleIdList><ArticleId IdType="pubmed">4569674</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Psychiatr Nervenkr (1970). 1978 Oct 9;226(1):65-73</Citation><ArticleIdList><ArticleId IdType="pubmed">708228</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Pharmacopsychiatry. 1980;15(2):86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7440098</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1985;317:1-34</Citation><ArticleIdList><ArticleId IdType="pubmed">3861072</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1987 May;150:662-73</Citation><ArticleIdList><ArticleId IdType="pubmed">3651704</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Mar;156(3):426-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10080559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10084633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1999 Mar;187(3):181-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10086475</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 May;56(5):407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10232294</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 May;156(5):702-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10327902</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 May;156(5):811-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10327940</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jan-Mar;52(1-3):239-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10357039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 1999 Aug;19(4):511-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10379423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Jun;11(2):55-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10440521</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Aug;156(8):1164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10450255</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Aug 15;46(4):577-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10459410</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jun 30;86(3):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10482345</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Sep;156(9):1417-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10484954</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 1999 Aug;9 Suppl 4:S109-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10524836</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1999 Feb;50(2):201-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10030478</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):547-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10550855</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):179-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10671384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Feb;61(2):79-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10732654</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 May;57(5):481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10807488</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jun;157(6):982-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10831480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):393-6; quiz 397</Citation><ArticleIdList><ArticleId IdType="pubmed">10847318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Aug;20(4):399-403</Citation><ArticleIdList><ArticleId IdType="pubmed">10917399</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 2001 Summer;35(3):109-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12397882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2000 Sep;12(3):159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10984006</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):558-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11018227</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Mar;45(3):289-92</Citation><ArticleIdList><ArticleId IdType="pubmed">3277580</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1990 Oct;51(10):410-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 Dec;40(4):211-20</Citation><ArticleIdList><ArticleId IdType="pubmed">1811239</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 May;149(5):587-95</Citation><ArticleIdList><ArticleId IdType="pubmed">1575248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1993 Apr;181(4):238-45</Citation><ArticleIdList><ArticleId IdType="pubmed">8097229</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Jun;50(6):448-55</Citation><ArticleIdList><ArticleId IdType="pubmed">8498879</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Jun;50(6):457-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8498880</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Dec;48(12):1082-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1845226</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Feb;151(2):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">8296883</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Apr;164(4):549-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8038948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1994 May;45(5):444-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8045538</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1994 Sep;55(9):391-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7929019</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Nov;32(3):201-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7852662</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Aug;152(8):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7625459</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1995 May-Jun;36(3):187-94</Citation><ArticleIdList><ArticleId IdType="pubmed">7648841</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Nov;152(11):1635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7485627</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Nov;152(11):1641-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7485628</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1995 Nov;30(6):279-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8560330</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Feb;153(2):163-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8561195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):4S-14S</Citation><ArticleIdList><ArticleId IdType="pubmed">8707999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Feb;16(1):87-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8834431</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 1997;5(2):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9262937</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Jan;155(1):30-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9433335</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Fam Med. 1998 Jan-Feb;7(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9443702</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Nov 14;73(1-2):47-56</Citation><ArticleIdList><ArticleId IdType="pubmed">9463838</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1998 Jan;172:29-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9534828</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1998 Apr;18(2):172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1998 May;33(5):211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9604670</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Jun;49(3):189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9629948</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1998 Sep;19(3):206-19</Citation><ArticleIdList><ArticleId IdType="pubmed">9653709</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Oct;155(10):1434-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9766777</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 1998 Nov;39(11):1226-31</Citation><ArticleIdList><ArticleId IdType="pubmed">9821989</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1998 Jun;172:521-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9828994</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):175-86</Citation><ArticleIdList><ArticleId IdType="pubmed">9858077</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Jan 16;318(7177):149-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9888904</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Dec;157(12):1933-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11097953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Dec;61(1-2):13-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11099736</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2001 Jan;52(1):51-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11141528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Feb;3(1):35-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11256462</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Mar;158(3):420-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11229983</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2001 Mar 21;285(11):1466-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11255423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Mar;62(3):212-6; quiz 217</Citation><ArticleIdList><ArticleId IdType="pubmed">11305713</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Behav. 2001 May-Jun;26(3):341-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11436926</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2001;19(5 Pt 1):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11465308</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2001 Sep;104(3):163-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11531653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Sep;108(3):776-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11533352</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jan;159(1):116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11772699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2002 Jan 19;359(9302):241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11812578</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11869757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cephalalgia. 2001 Nov;21(9):894-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11903283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Oct;3(5):245-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11903207</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Feb 15;51(4):288-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11958779</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Feb 15;51(4):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11958781</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 May 1;51(9):745-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11983188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Apr;63(4):284-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12004800</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2002 Mar;14(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12046641</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2002 Jun;47(5):426-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12085677</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23774140</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Differentiation of bipolar I and II disorders by examining for differences in severity of manic/hypomanic symptoms and the presence or absence of psychosis during that phase.</ArticleTitle><Pagination><MedlinePgn>941-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00376-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">DSM-IV criteria for mania/hypomania overlap considerably. We sought to examine the utility of a model differentiating bipolar I and II disorders by weighting the presence or absence of psychosis during manic/hypomanic episodes as opposed to simply weighting symptom severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A set of 632 patients with a so-assigned clinical bipolar I or II disorder diagnosis contributed to the principal analyses, and a subset of 210 was included in a comparative analyses of DSM-assigned diagnoses. We also examined the impact of duration of highs on symptom patterns and the extent to which depressive episodes were psychotic or non-psychotic melancholic in type.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no group differences for bipolar I and II patients (clinical or DSM groups) by age, gender, age of onset or age of formal bipolar diagnosis. Clinically assigned bipolar I patients returned higher severity scores than bipolar II patients on manic/hypomanic symptoms, but such differentiation was limited. Clinically-assigned bipolar I patients were more likely than bipolar II patients to be diagnosed with psychotic depression, and had lower rates of non-melancholic depression. Duration of highs had some impact on the phenomenology of highs, but not on the phenomenology of depression.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">We cannot establish the degree to which clinicians validly differentiated those with bipolar disorder, and accurately judged the lifetime presence of psychotic features and of depressive subtype differentiation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Findings support the utility of an alternative model to DSM-IV in weighting the respective presence or absence of psychotic symptoms during highs in differentiating bipolar I and II disorders.</AbstractText><CopyrightInformation>Â© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, NSW, Australia. g.parker@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>Dusan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McCraw</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Friend</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Differentiation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23774140</ArticleId><ArticleId IdType="pii">S0165-0327(13)00376-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.05.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18328012</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1540-9996</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of women's health (2002)</Title><ISOAbbreviation>J Womens Health (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Are bipolar mood symptoms affected by the phase of the menstrual cycle?</ArticleTitle><Pagination><MedlinePgn>473-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/jwh.2007.0466</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence suggests gender differences may exist in bipolar disorder, and a review of the literature shows that more women than men may experience rapid-cycling bipolar disorder. The issues contributing to these gender differences are unknown; a number of case reports have indicated the possibility of mood changes secondary to hormonal influences during the menstrual cycle. We sought to examine the relationship between bipolar disorder and menstrual cycle-related mood changes. To our knowledge, this is one of the largest samples in the literature addressing this issue.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Outpatient women with bipolar disorder I, bipolar disorder II, and not otherwise specified (NOS), between the ages of 18 and 45, were evaluated. The National Institute of Mental Health Life Chart Method-p (NIMH-LCM-p) was used for daily mood ratings of depression and mania. Repeated measures of ANOVA and t tests were conducted separately for depressive and for manic symptom scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred nineteen women met the age criterion, and only 41 women met the rest of the inclusion criteria. In this sample of 41 women, there was no significant relationship between phases of the menstrual cycle (early and late follicular and early and late luteal phases) and changes in depression or mania. In an exploratory examination, 8 of 41 women showed a numerically higher mean depression score in the luteal phase than in the follicular phase; 5 of 41 women showed a numerically higher mean mania score in the luteal phase than in the follicular phase of the menstrual cycle.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Different phases of the menstrual cycle were unrelated to depression and mania in a heterogeneous group of women with bipolar disorder. Prospective studies are needed to identify a vulnerable subpopulation in a homogeneous clinical sample.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shivakumar</LastName><ForeName>Geetha</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9086, USA. geetha.shivakumar@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Ira H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><CollectiveName>Stanley Foundation Bipolar Network</CollectiveName></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinze</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 UL1 RR024982-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32-MH67543-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Womens Health (Larchmt)</MedlineTA><NlmUniqueID>101159262</NlmUniqueID><ISSNLinking>1540-9996</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005498" MajorTopicYN="N">Follicular Phase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008183" MajorTopicYN="N">Luteal Phase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008597" MajorTopicYN="Y">Menstrual Cycle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008598" MajorTopicYN="N">Menstruation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="Y">Women's Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18328012</ArticleId><ArticleId IdType="doi">10.1089/jwh.2007.0466</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10609421</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-843X</ISSN><JournalIssue CitedMedium="Print"><Volume>108</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of abnormal psychology</Title><ISOAbbreviation>J Abnorm Psychol</ISOAbbreviation></Journal><ArticleTitle>Cognitive styles and life events interact to predict bipolar and unipolar symptomatology.</ArticleTitle><Pagination><MedlinePgn>567-78</MedlinePgn></Pagination><Abstract><AbstractText>This study examined the interaction of cognitive style (as assessed self-report and information-processing battery) and stressful life events in predicting the clinician-rated depressive and manic symptomatology of participants with Research Diagnostic Criteria lifetime diagnoses of bipolar disorder (n = 49), unipolar depression (n = 97), or no lifetime diagnosis (n = 23). Bipolar and unipolar participants' attributional styles, dysfunctional attitudes, and negative self-referent information processing as assessed at Time 1 interacted significantly with the number of negative life events that occurred between Times 1 and 2 to predict increases in depressive symptoms from Time 1 to Time 2. Within the bipolar group, participants' Time 1 attributional styles and dysfunctional attitudes interacted significantly, and their self-referent information processing interacted marginally, with intervening life events to predict increases in manic symptoms from Time 1 to Time 2. These findings provide support for the applicability of cognitive vulnerability-stress theories of depression to bipolar spectrum disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reilly-Harrington</LastName><ForeName>N A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. nhreilly@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloy</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Fresco</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>48216</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>52617</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Abnorm Psychol</MedlineTA><NlmUniqueID>0034461</NlmUniqueID><ISSNLinking>0021-843X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="N">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10609421</ArticleId><ArticleId IdType="doi">10.1037//0021-843x.108.4.567</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7624488</PMID><DateCompleted><Year>1995</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>1995</Year><Month>May</Month></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Frequency of positive family history in bipolar patients in a catchment-area population.</ArticleTitle><Pagination><MedlinePgn>367-73</MedlinePgn></Pagination><Abstract><AbstractText>1. Major family studies of bipolar disorder report the frequency of affective disorder among probands' relatives, but do not usually report the frequency of a positive family history among probands. A single previous study was not population based. 2. The Division of Psychiatry of Ben Gurion University provides virtually all psychiatric services for a catchment area of 300,000 people. The authors reviewed the charts of all 236 treated bipolar I patients in 1991, and interviewed 177 of them with a modified FH-RDC. 3. 48% of probands had a family history of mental illness. 4. However, the present methods of ascertainment may have been insufficiently sensitive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>J R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hadassah Hebrew University School of Medicine, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjamin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lerer</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Belmaker</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH00176</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43979</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7624488</ArticleId><ArticleId IdType="pii">027858469500018Q</ArticleId><ArticleId IdType="doi">10.1016/0278-5846(95)00018-q</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21185427</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 4</Volume><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Screening and management of bipolar disorders: results].</ArticleTitle><Pagination><MedlinePgn>S86-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(10)70037-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llorca</LastName><ForeName>Pierre-Michel</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>pmllorca@chu-clermontferrand.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courtet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Abbar</LastName><ForeName>Mocrane</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gay</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Meynard</LastName><ForeName>Jean-Albert</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>BaylÃ©</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hamon</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>LanÃ§on</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Thibaut</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Guillaume</LastName><ForeName>SÃ©bastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Samalin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><CollectiveName>lâAssociation FranÃ§aise de Psychiatrie Biologique et Neuropsychopharmacologique (AFPBN)</CollectiveName></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>DÃ©pistage et prise en charge du trouble bipolaire : rÃ©sultats.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21185427</ArticleId><ArticleId IdType="pii">S0013-7006(10)70037-3</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(10)70037-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20146919</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0948-6259</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater</Title><ISOAbbreviation>Neuropsychiatr</ISOAbbreviation></Journal><ArticleTitle>[Direct health-related costs of severely mentally ill patients and their informal carers in community care].</ArticleTitle><Pagination><MedlinePgn>42-55</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Within the last few years, a small number of German cost analyses of patients treated in community mental health care settings was presented. None of these studies, however, examined direct health care costs of the patients' close reference persons focusing on costs associated with providing informal care. Therefore, our study aimed to analyse health-related direct costs of severely ill patients suffering from affective or schizophrenic disorders, and of their informal carers during community mental health care; further, we examined if these costs differed between the diagnostic groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">69 patients currently treated by community mental health services of the Dresden region and their closest reference person providing informal care were assessed twice within an interval of 3 months by use of the CSSRI- D. Thus, direct health care costs of patients and their informal carers covering a 6-months-period could be calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">25.35% and 38.24%, respectively, of the closest reference persons' direct health care costs were caused by the situation of acting as informal carer. This was 9.12% and 22.74%, respectively, of the patients' direct health care costs assessed at the same time-points. Patients' costs did not differ between the diagnostic categories, but were influenced by the current severity of psychopathological symptoms. Reference persons' costs were influenced by the severity of the patient's psychopathological symptoms, but also by the social control behaviour of the reference persons themselves as well as by their sense of coherence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While a replication of our findings is urgently needed, they point at the economic significance of direct health-related costs caused by acting as informal carers. Further, therapeutic approaches adequate for minimizing these costs could be suggested, like emphasizing protective factors of mental well-being in psycho-educational programmes for relatives.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kallert</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Klinik fÃ¼r Psychiatrie, Psychosomatik und Psychotherapie, Parkkrankenhaus Leipzig-SÃ¼dost GmbH, Leipzig. thomas.kallert@parkkrankenhaus-leipzig.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsche</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Gesundheitsbezogene Versorgungskosten schwer psychisch erkrankter Patienten und ihrer AngehÃ¶rigen wÃ¤hrend gemeindepsychiatrischer Betreuung.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Neuropsychiatr</MedlineTA><NlmUniqueID>9440588</NlmUniqueID><ISSNLinking>0948-6259</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005102" MajorTopicYN="N">Health Expenditures</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20146919</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23982186</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neural correlates of emotional distractibility in bipolar disorder patients, unaffected relatives, and individuals with hypomanic personality.</ArticleTitle><Pagination><MedlinePgn>1487-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.12081044</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Neuropsychological deficits and emotion dysregulation are present in symptomatic and euthymic patients with bipolar disorder. However, there is little evidence on how cognitive functioning is influenced by emotion, what the neural correlates of emotional distraction effects are, and whether such deficits are a consequence or a precursor of the disorder. The authors used functional MRI (fMRI) to investigate these questions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">fMRI was used first to localize the neural network specific to a certain cognitive task (mental arithmetic) and then to test the effect of emotional distractors on this network. Euthymic patients with bipolar I disorder (N=22), two populations at high risk for developing the disorder (unaffected first-degree relatives of individuals with bipolar disorder [N=17]), and healthy participants with hypomanic personality traits [N=22]) were tested, along with three age-, gender-, and education-matched healthy comparison groups (N=22, N=17, N=24, respectively).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no differences in performance or activation in the task network for mental arithmetic. However, while all participants exhibited slower responses when emotional distractors were present, this response slowing was greatly enlarged in bipolar patients. Similarly, task-related activation was generally increased under emotional distraction; however, bipolar patients exhibited a further increase in right parietal activation that correlated positively with the response slowing effect.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results suggest that emotional dysregulation leads to exacerbated neuropsychological deficits in bipolar patients, as evidenced by behavioral slowing and task-related hyperactivation. The lack of such a deficit in high-risk populations suggests that it occurs only after disease onset, rather than representing a vulnerability marker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanske</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Heissler</LastName><ForeName>Janine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>SchÃ¶nfelder</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Forneck</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wessa</LastName><ForeName>MichÃ¨le</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23982186</ArticleId><ArticleId IdType="pii">1733359</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.12081044</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28535448</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>219</Volume><PubDate><Year>2017</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar postpartum depression: An update and recommendations.</ArticleTitle><Pagination><MedlinePgn>105-111</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(17)30360-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2017.05.014</ELocationID><Abstract><AbstractText Label="BACKGROUND">Over the past few years there has been a surge of interest in the study of bipolar postpartum depression (PPD); however, questions remain about its prevalence, screening, clinical features, and treatment.</AbstractText><AbstractText Label="METHODS">Three electronic databases, MEDLINE/PubMed (1966-2016), PsycINFO (1806-2016), and the Cochrane Database of Systematic Reviews, were searched using a combination of the keywords bipolar, depression, postpartum, peripartum, prevalence, screening, diagnosis, treatment, drugs, and psychotherapy. The reference lists of articles identified were also searched. All relevant articles published in English were included.</AbstractText><AbstractText Label="RESULTS">Depending on the population studied, 21.4-54% of women with PPD have a diagnosis of bipolar disorder (BD). Characteristic clinical features include younger age at illness onset, first onset of depression after childbirth, onset immediately after delivery, atypical depressive symptoms, psychotic features, mixed features, and history of BD in first-degree family members. Treatment should be guided by symptom acuity, safety concerns, the patient's response to past treatments, drug tolerability, and breastfeeding preference. In the absence of controlled treatment data, preference should be given to drugs normally indicated for bipolar depression including lithium, quetiapine and lamotrigine. Although antidepressants have been studied in combination with mood stabilizers in bipolar depression, these drugs should be avoided due to likelihood of elevated risk of induction of manic symptoms in the postpartum period.</AbstractText><AbstractText Label="CONCLUSIONS">In the postpartum period, bipolar PPD is common, can be differentiated from unipolar PPD, and needs to be identified promptly in order to expedite appropriate treatment. Future studies on pharmacotherapy and psychotherapy should focus on the acute and preventative treatment of bipolar PPD.</AbstractText><CopyrightInformation>Copyright Â© 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Verinder</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Western University &amp; Parkwood Institute - London, Ontario, Canada. Electronic address: vsharma@uwo.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doobay</LastName><ForeName>Minakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Western University - London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baczynski</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Parkwood Institute - London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Affect Disord. 2017 Dec 1;223:26-27</RefSource><PMID Version="1">28715725</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019052" MajorTopicYN="N">Depression, Postpartum</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Diagnosis</Keyword><Keyword MajorTopicYN="Y">Drugs</Keyword><Keyword MajorTopicYN="Y">Peripartum</Keyword><Keyword MajorTopicYN="Y">Postpartum</Keyword><Keyword MajorTopicYN="Y">Prevalence</Keyword><Keyword MajorTopicYN="Y">Psychotherapy</Keyword><Keyword MajorTopicYN="Y">Screening</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28535448</ArticleId><ArticleId IdType="pii">S0165-0327(17)30360-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2017.05.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4265814</PMID><DateCompleted><Year>1973</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-1858</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>10</Issue><PubDate><Year>1973</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of the Arkansas Medical Society</Title><ISOAbbreviation>J Ark Med Soc</ISOAbbreviation></Journal><ArticleTitle>Lithium, the hyperactive child and manic depressive illness.</ArticleTitle><Pagination><MedlinePgn>299-300</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hava</LastName><ForeName>F A</ForeName><Initials>FA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Ark Med Soc</MedlineTA><NlmUniqueID>7503069</NlmUniqueID><ISSNLinking>0004-1858</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006948" MajorTopicYN="N">Hyperkinesis</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4265814</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4829316</PMID><DateCompleted><Year>1974</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0079-726X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>1974</Year></PubDate></JournalIssue><Title>La Psychiatrie de l'enfant</Title><ISOAbbreviation>Psychiatr Enfant</ISOAbbreviation></Journal><ArticleTitle>[On infantile depressions].</ArticleTitle><Pagination><MedlinePgn>301-80</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Penot</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Contribution Ã  l'Ã©tude des dÃ©pressions infantiles.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Psychiatr Enfant</MedlineTA><NlmUniqueID>0376466</NlmUniqueID><ISSNLinking>0079-726X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008426" MajorTopicYN="N">Maternal Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="N">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4829316</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12832254</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI.</ArticleTitle><Pagination><MedlinePgn>1345-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study investigated whether the functional abnormalities in prefrontal systems observed in adult bipolar disorder are manifested in adolescents with this illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Ten adolescents with bipolar disorder and 10 healthy comparison subjects participated in a color-naming Stroop task during event-related functional magnetic resonance imaging.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Signal increases in the left putamen and thalamus were significantly greater in the bipolar disorder group than in the healthy group. Age correlated positively with signal increases in the bilateral rostroventral prefrontal cortex and the striatum in the healthy group but not in the bipolar disorder group. In the bipolar disorder subjects, depressive symptoms correlated positively with signal increases in the ventral striatum.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest the presence of dysfunction in the subcortical portions of the frontostriatal circuits in adolescents with bipolar disorder. The absence of the prefrontal abnormalities that were observed previously in adults and the absence of the age-related increases in prefrontal activity observed in normal comparison subjects suggest that a developmental disturbance in prefrontal function may emerge in bipolar disorder over the course of adolescence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blumberg</LastName><ForeName>Hilary P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Diagnostic Radiology and the Yale Child Study Center, Yale University School of Medicine, New Haven, Conn., 06516, USA. hilary.blumberg@yale.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>AndrÃ©s</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Hoi-Chung</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Skudlarski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lacadie</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fulbright</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Gore</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Charney</LastName><ForeName>Dennis S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Krystal</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Bradley S</ForeName><Initials>BS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AA-00261-01</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-01232</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-01792</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-59139</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12832254</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.160.7.1345</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20171742</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Differences in neuroticism and extraversion between patients with bipolar I or II and general population subjects or major depressive disorder patients.</ArticleTitle><Pagination><MedlinePgn>42-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.01.068</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Whether levels of neuroticism or extraversion differ between patients with bipolar disorder (BD), major depressive disorder (MDD) and subjects from the general population, or between BD I and BD II patients, remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">BD patients (n=191) from the Jorvi Bipolar Study, and MDD patients (n=358) from both the Vantaa Depression Study and the Vantaa Primary Care Depression Study cohorts, were interviewed at baseline and at 18 months. A general population comparison group (n=347) was surveyed by mail. BD patients' neuroticism and extraversion scores, measured by Eysenck Personality Inventory, were compared at an index interview, when the levels of depression and mania were lowest, with scores of MDD patients and general population controls. Comparisons were also made between BD I (n=99) and BD II (n=92) patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In multinomial logistic regression, BD patients had higher neuroticism (OR=1.17, p&lt;0.001) and lower extraversion (OR=0.92, p=0.003) than the general population. When entered simultaneously into the model, the effect of extraversion disappeared. In logistic regression, the levels of neuroticism and extraversion did not differ between BD and MDD patients, or between BD I and II patients.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Patients' personality scores were not pre-morbid.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Levels of neuroticism and extraversion are unlikely to differ between BD and MDD patients, or between BD I and II patients. The overall level of neuroticism is moderately higher and extraversion somewhat lower in BD patients than in the general population. High neuroticism may be an indicator of vulnerability to both bipolar and unipolar mood disorders.</AbstractText><CopyrightInformation>2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>JylhÃ¤</LastName><ForeName>Pekka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantere</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Melartin</LastName><ForeName>Tarja</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Suominen</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vuorilehto</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Arvilommi</LastName><ForeName>Petri</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>LeppÃ¤mÃ¤ki</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Valtonen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>RytsÃ¤lÃ¤</LastName><ForeName>Heikki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>IsometsÃ¤</LastName><ForeName>Erkki</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005120" MajorTopicYN="Y">Extraversion, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20171742</ArticleId><ArticleId IdType="pii">S0165-0327(10)00094-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.01.068</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8168791</PMID><DateCompleted><Year>1994</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1597</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>1994</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Hospital &amp; community psychiatry</Title><ISOAbbreviation>Hosp Community Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The relationship between acute psychiatric symptoms, diagnosis, and short-term risk of violence.</ArticleTitle><Pagination><MedlinePgn>133-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Previous research on violence and mental disorder has typically focused on the relationship between diagnosis and risk of violence or between symptoms within a particular diagnostic category and risk of violence. The authors' goal was to evaluate whether the pattern of symptoms associated with short-term risk of violence varies depending on patients' diagnoses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects were 330 patients with a variety of diagnoses who were hospitalized on a university-based, locked psychiatric inpatient unit. At hospital admission, physicians rated patients' symptoms using the Brief Psychiatric Rating Scale. Nurses rated whether patients became violent during hospitalization by completing the Overt Aggression Scale at the end of each shift.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Assaultive patients had different symptom patterns than nonassaultive patients. Symptoms patterns varied significantly across diagnostic groups, and the symptom patterns associated with violence also varied significantly across diagnostic groups. Higher levels of hostile-suspiciousness, agitation-excitement, and thinking disturbance were generally associated with violence, although these symptoms were less predictive of assaultiveness among schizophrenic patients than among patients in other diagnostic groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Symptom profiles represent a useful level of analysis for understanding the relationship between violence and psychopathology. However, the value of particular symptom profiles as indicators of imminent violence varies with diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNiel</LastName><ForeName>D E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S07-RR05755</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hosp Community Psychiatry</MedlineTA><NlmUniqueID>0040250</NlmUniqueID><ISSNLinking>0022-1597</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Hosp Community Psychiatry. 1994 Aug;45(8):830-1</RefSource><PMID Version="1">7982705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003617" MajorTopicYN="Y">Dangerous Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="Y">Violence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8168791</ArticleId><ArticleId IdType="doi">10.1176/ps.45.2.133</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29308715</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1502-4725</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nordic journal of psychiatry</Title><ISOAbbreviation>Nord J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Exploring the relationship between vitamin D and mania: correlations between serum vitamin D levels and disease activity.</ArticleTitle><Pagination><MedlinePgn>221-225</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/08039488.2018.1424238</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several studies suggest an association between hypovitaminosis D and mood disorders including major depressive disorder, seasonal affective disorder and premenstrual dysphoric disorder. On the other hand, there is not enough study about acute manic episode and hypovitaminosis D. This data insufficient zone led us to study on whether vitamin D deficiency is associated with acute manic episode and has an impact on disease activity Methods: Thirty-one patients with bipolar disorder in remission, 26 patients with acute manic episode and 40 healthy controls with no major psychopathology were recruited in this study. Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS) and the Clinical Global Impression - Severety scale (CGI-S) were used to evaluate disease activity. Total vitamin D (D2â+âD3) values were measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients in acute manic episode had significantly lower (pâ=â.002) vitamin D serum concentrations than healthy controls (respectively 15.16âÂ±â7.48 and 22.31âÂ±â8.8) but remission group's serum concentrations (18.40âÂ±â7.30) did not differ significantly from healthy controls or acute manic episode patients (pâ&gt;â.05). We observed negative and moderate correlations between vitamin D levels and YMRS scores (r: -0.641, pâ&lt;â.001), vitamin D levels and CGI scores (r: -0.559, p=â.003).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results contribute to the idea that vitamin D deficiency and acute manic episode may have interactions with many pathways. Future trials may investigate this association with longer follow up. We recommend that serum vitamin D levels should be measured in patients with bipolar disorder especially in long term care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altunsoy</LastName><ForeName>Neslihan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry , Ankara Numune Training and Research Hospital , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>YÃ¼ksel</LastName><ForeName>Rabia Nazik</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry , Ankara Numune Training and Research Hospital , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cingi Yirun</LastName><ForeName>Merve</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry , Ankara Numune Training and Research Hospital , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>KÄ±lÄ±Ã§arslan</LastName><ForeName>AyÅegÃ¼l</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>b Ankara Physical Medicine and Rehabilitation Training and Research Hospital , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aydemir</LastName><ForeName>ÃiÄdem</ForeName><Initials>Ã</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry , Ankara Numune Training and Research Hospital , Ankara , Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nord J Psychiatry</MedlineTA><NlmUniqueID>100927567</NlmUniqueID><ISSNLinking>0803-9488</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-16-2</RegistryNumber><NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004637" MajorTopicYN="N">Emergency Services, Psychiatric</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014808" MajorTopicYN="N">Vitamin D Deficiency</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">25-OH vitamin D</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">acute manic episode</Keyword><Keyword MajorTopicYN="N">vitamin D</Keyword><Keyword MajorTopicYN="N">vitamin D deficiency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29308715</ArticleId><ArticleId IdType="doi">10.1080/08039488.2018.1424238</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12381498</PMID><DateCompleted><Year>2003</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-9338</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Manic episodes: the direct cost of a three-month period following hospitalisation.</ArticleTitle><Pagination><MedlinePgn>278-86</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Few data exist to estimate the burden of manic episodes on healthcare systems or the therapeutic strategies used. This study was undertaken to identify treatment strategies chosen, and to assess the "real-world" direct medical cost of treating manic episodes necessitating hospitalisation.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Case record data were reviewed during the three months following hospitalisation for a manic episode in France. Healthcare resource utilisation was assessed, direct costs calculated, and treatment strategies analysed. A total of 137 patients files (51.8% female; mean age: 35 years) were reviewed and data on 185 hospitalisations collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean duration of hospitalisation was 47 days over the study period. The most common treatment strategy during hospitalisation was the combination of a mood stabilizer with a neuroleptic drug (64% of patients at day 30). Anticonvulsants including valproate (39%) and carbamazepine (20%) were more common than lithium (42%). Treatment received during hospitalisation was generally continued after discharge, with a trend away from neuroleptics and towards mood stabilizers. The mean direct costs incurred over the three-month study period was Euro 22297, with 98.6% of those costs due to hospitalisation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results confirm that the costs of treating a manic episode are high, and overwhelmingly due to the cost of hospitalisation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>OliÃ©</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Centre hospitalier Sainte-Anne, 1, rue Cabanis, 75014, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LÃ©vy</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12381498</ArticleId><ArticleId IdType="pii">S0924933802006806</ArticleId><ArticleId IdType="doi">10.1016/s0924-9338(02)00680-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27269044</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8042</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Pharmacogenomics</Title><ISOAbbreviation>Pharmacogenomics</ISOAbbreviation></Journal><ArticleTitle>COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients.</ArticleTitle><Pagination><MedlinePgn>837-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs-2016-0022</ELocationID><Abstract><AbstractText Label="AIM">We examined the association of COMT haplotypes and plasma metabolites of catecholamines in relation to the clinical response to antipsychotics in schizophrenic and bipolar patients.</AbstractText><AbstractText Label="PATIENTS &amp; METHODS">We studied 165 patients before and after four weeks of treatment, and 163 healthy controls. We assessed four COMT haplotypes and the plasma concentrations of HVA, DOPAC and MHPG.</AbstractText><AbstractText Label="RESULTS">Bipolar patients: haplotypes are associated with age at onset and clinical evolution. In schizophrenic patients, an haplotype previously associated with increased risk, is related to better response of negative symptoms.</AbstractText><AbstractText Label="CONCLUSION">Haplotypes would be good indicators of the clinical status and the treatment response in bipolar and schizophrenic patients. Larger studies are required to elucidate the clinical usefulness of these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>ZumÃ¡rraga</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de InvestigaciÃ³n NeuroquÃ­mica, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ArrÃºe</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de InvestigaciÃ³n NeuroquÃ­mica, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basterreche</LastName><ForeName>Nieves</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Unidad de HospitalizaciÃ³n de Corta Estancia, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de PsiquiatrÃ­a y PsicologÃ­a MÃ©dica, Facultad de Medicina, Universidad del PaÃ­s Vasco, Barrio Sarriena s/n, 48940 Leioa, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacÃ­as</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Unidad de Salud Laboral, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>CatalÃ¡n</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de PsiquiatrÃ­a, Hospital de Basurto, Osakidetza, Avenida de Montevideo 18, 48013 Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madrazo</LastName><ForeName>Arantza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de PsiquiatrÃ­a, Hospital de Basurto, Osakidetza, Avenida de Montevideo 18, 48013 Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de PsiquiatrÃ­a, Hospital de Basurto, Osakidetza, Avenida de Montevideo 18, 48013 Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamalloa</LastName><ForeName>MarÃ­a I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Departamento de InvestigaciÃ³n NeuroquÃ­mica, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erkoreka</LastName><ForeName>Leire</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de PsiquiatrÃ­a y PsicologÃ­a MÃ©dica, Facultad de Medicina, Universidad del PaÃ­s Vasco, Barrio Sarriena s/n, 48940 Leioa, Bizkaia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Salud Mental de Barakaldo, Red de Salud Mental de Bizkaia, Osakidetza, La Felicidad 9, 3. 48901 Barakaldo, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordo</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad de HospitalizaciÃ³n de Corta Estancia, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnaiz</LastName><ForeName>Ainara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de HospitalizaciÃ³n de Corta Estancia, Hospital de Zamudio, Red de Salud Mental de Bizkaia, Osakidetza, Arteaga Auzoa 45, 48170 Zamudio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olivas</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centro de Salud Mental de Gernika, Red de Salud Mental de Bizkaia, Osakidetza, San Juan 1, 48300 Gernika, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroita</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Salud Mental de Barakaldo, Red de Salud Mental de Bizkaia, Osakidetza, La Felicidad 9, 3. 48901 Barakaldo, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MarÃ­n</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital PsiquiÃ¡trico de Bermeo, Tonpoi Bidea s/n. 48370, Bermeo, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>GonzÃ¡lez-Torres</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Departamento de PsiquiatrÃ­a y PsicologÃ­a MÃ©dica, Facultad de Medicina, Universidad del PaÃ­s Vasco, Barrio Sarriena s/n, 48940 Leioa, Bizkaia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de PsiquiatrÃ­a, Hospital de Basurto, Osakidetza, Avenida de Montevideo 18, 48013 Bilbao, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacogenomics</MedlineTA><NlmUniqueID>100897350</NlmUniqueID><ISSNLinking>1462-2416</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="C588010">COMT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="Y">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COMT</Keyword><Keyword MajorTopicYN="Y">antipsychotics</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">haplotypes</Keyword><Keyword MajorTopicYN="Y">plasma metabolites</Keyword><Keyword MajorTopicYN="Y">schizophrenia</Keyword><Keyword MajorTopicYN="Y">symptomatology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27269044</ArticleId><ArticleId IdType="doi">10.2217/pgs-2016-0022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24262639</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study.</ArticleTitle><Pagination><MedlinePgn>110-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.10.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00774-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Poor treatment adherence among patients with bipolar disorder (BD) is a common clinical problem. However, whether adherence is mostly determined by patient characteristics or attitudes, type of treatment or treatment side-effects remains poorly known.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Jorvi Bipolar Study (JoBS) is a naturalistic prospective 18-month study representing psychiatric in- and outpatients with DSM-IV BD I and II in three Finnish cities. During the 18-month follow-up we investigated the continuity of, attitudes towards and adherence to various types of psychopharmacological and psychosocial treatments among 168 psychiatric in- and outpatients with BD I or II.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One-quarter of the patients using mood stabilizers or atypical antipsychotics discontinued medication during at least one treatment phase of the follow-up autonomously, mostly during depression. When pharmacotherapy continued, adherence was compromised in one-third. Rates of non-adherence to mood stabilizers or antipsychotics did not differ, but the predictors did. One-quarter of the patients receiving psychosocial treatments were non-adherent to them.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Serum concentrations were not estimated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More than one-half of BD patients either discontinue pharmacotherapy or use it irregularly. Autonomous discontinuation takes place mostly in depression. Although rates of non-adherence do not necessarily differ between mood-stabilizing medications, the predictors for nonadherence do. Moreover, adherence to one medication does not guarantee adherence to another, nor does adherence at one time-point ensure later adherence. Attitudes towards treatments affect adherence to medications as well as to psychosocial treatments and should be repeatedly monitored. Non-adherence to psychosocial treatment should be given more attention.</AbstractText><CopyrightInformation>Â© 2013 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arvilommi</LastName><ForeName>Petri</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland; Psychiatric and substance abuse services, Helsinki City Department of Social Services and Health Care, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suominen</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland; Psychiatric and substance abuse services, Helsinki City Department of Social Services and Health Care, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantere</LastName><ForeName>Outi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeppÃ¤mÃ¤ki</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland; Finnish Institute of Occupational Health, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valtonen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland; Psychiatric and substance abuse services, Helsinki City Department of Social Services and Health Care, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>IsometsÃ¤</LastName><ForeName>Erkki</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Substance Use, National Institute of Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland; Department of Psychiatry, University of Helsinki, Finland. Electronic address: erkki.isometsa@hus.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Naturalistic study</Keyword><Keyword MajorTopicYN="N">Prospective study</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24262639</ArticleId><ArticleId IdType="pii">S0165-0327(13)00774-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.10.032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4986244</PMID><DateCompleted><Year>1970</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0011-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>1970</Year><Month>May</Month></PubDate></JournalIssue><Title>Current therapeutic research, clinical and experimental</Title><ISOAbbreviation>Curr Ther Res Clin Exp</ISOAbbreviation></Journal><ArticleTitle>Treatment of children of lithium-responding parents.</ArticleTitle><Pagination><MedlinePgn>286-90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dyson</LastName><ForeName>W L</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Barcai</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Ther Res Clin Exp</MedlineTA><NlmUniqueID>0372621</NlmUniqueID><ISSNLinking>0011-393X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>TZ47U051FI</RegistryNumber><NameOfSubstance UI="D003913">Dextroamphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003913" MajorTopicYN="N">Dextroamphetamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1970</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1970</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1970</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4986244</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15762862</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>An investigation of prepulse inhibition in pediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>198-203</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Deficits in prepulse inhibition (PPI), a measure of sensorimotor gating, have been noted in psychopathologies including schizophrenia and adult bipolar disorder (BPD). Sensorimotor gating deficits may contribute to the emotional and behavioral dysregulation characteristic of pediatric BPD. The current study investigated possible PPI deficits in children with BPD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixteen children with BPD (medicated, euthymic and non-psychotic) were compared with 13 control subjects on the magnitude of startle habituation, startle-alone response, and inhibition of startle following a 60 or 120-ms prepulse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both groups displayed startle inhibition by a prepulse, with no significant between-group differences on the magnitude of inhibition after the 60- or 120-ms prepulse. In addition, there were no between-group differences on habituation or baseline startle response. PPI level was not significantly correlated with mood symptoms and did not differ based on comorbid attention deficit hyperactivity disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A lack of PPI deficits in our pediatric bipolar sample contrasts with previous results in adult bipolar and schizophrenic samples. These negative results may reflect the fact that our sample was medicated and was neither acutely manic nor psychotic. Deficits in sensorimotor gating may not be implicated in the emotional and behavioral dysregulation in pediatric BPD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Brendan A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Pediatrics and Developmental Neuropsychiatry Branch, Unit on Affective Psychophysiology, Mood and Anxiety Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1255, USA. brendanrich@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinton</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Grillon</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bhangoo</LastName><ForeName>Robinder K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001767" MajorTopicYN="N">Blinking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006185" MajorTopicYN="N">Habituation, Psychophysiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="Y">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009801" MajorTopicYN="N">Oculomotor Muscles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012678" MajorTopicYN="N">Sensation Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15762862</ArticleId><ArticleId IdType="pii">BDI183</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2005.00183.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25187262</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Dorsolateral prefrontal hemodynamic responses during a verbal fluency task in hypomanic bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>172-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12252</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Neuroimaging studies have suggested prefrontal dysfunction in response to cognitive activation in bipolar disorder (BD). However, its characteristics in manic states have not been well understood. Thus, we compared prefrontal hemodynamic responses during a cognitive task between hypomanic and depressive states in BD. We then longitudinally compared hypomanic and subsequent euthymic states.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The prefrontal function of 27 patients with BD (11 hypomanic and 16 depressed) and 12 age- and gender-matched healthy controls (HCs) was evaluated using near-infrared spectroscopy (NIRS) during a verbal fluency task (VFT). Hypomanic symptoms were assessed using the Young Mania Rating Scale. Among the 11 hypomanic patients, eight participated in the second NIRS measurement after their hypomanic symptoms resolved.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">VFT performance did not differ among hypomanic, depressed, and HC groups. Both BD groups exhibited significantly lower activation during the VFT than HCs in the broader bilateral prefrontal cortex. Hemodynamic changes in the left dorsolateral prefrontal cortex (DLPFC) in the hypomanic patients with BD were significantly larger than those in the depressed patients. In addition, hypomanic symptom severity was positively correlated with activation in the left DLPFC and frontopolar cortex in patients with BD. Follow-up measurement of the hypomanic patients revealed that prefrontal activation was decreased after hypomanic symptoms resolved.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combining cross-sectional and longitudinal assessments, the present results suggest that prefrontal hemodynamic responses associated with cognitive activation differ between hypomanic and depressive states in BD. NIRS measurement could be a useful tool for objectively evaluating state-dependent characteristics of prefrontal hemodynamics in BD.</AbstractText><CopyrightInformation>Â© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Yukika</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo; Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Katsuyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ohtani</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ikeda-Sugita</LastName><ForeName>Reina</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kasai</LastName><ForeName>Kiyoto</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Okazaki</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="Y">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">executive function</Keyword><Keyword MajorTopicYN="N">hypomanic symptoms</Keyword><Keyword MajorTopicYN="N">near-infrared spectroscopy (NIRS)</Keyword><Keyword MajorTopicYN="N">prefrontal cortex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25187262</ArticleId><ArticleId IdType="doi">10.1111/bdi.12252</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18163039</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12 Suppl 20</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Bipolar depression: best practices for the outpatient.</ArticleTitle><Pagination><MedlinePgn>1-14</MedlinePgn></Pagination><Abstract><AbstractText>Although certain aspects of bipolar disorder are well understood, there is a need for more information concerning management of acute bipolar depression, the effect of comorbid conditions, and long-term management of bipolar disorder. The outpatient presenting with bipolar disorder often presents with many of the key problems related to the long-term course of the disorder, including misdiagnosis and treatment non-adherence. Depressive symptoms are also prevalent during the course of bipolar disorder, with studies finding that depression can cause a low-grade "darkness" that longitudinally affects outpatients with bipolar disorder. These variable and persistent depressive symptoms may cause severe functional impairment and increased suicidality. Pharmacologic treatment of bipolar disorder typically includes anti-manic and mood-stabilizing medication. Although some studies find antidepressants have some positive effect, researchers have found that antidepressants, including selective serotonin reuptake inhibitors, when used as monotherapy or in conjunction with mood stabilizers, have little benefit for the treatment of bipolar disorder and may increase the likelihood of a switch into mania, hypomania, or mixed episodes. For long-term outpatient treatment, lamotrigine and lithium are proven to be highly effective. However, clinicians should also stress psychosocial treatment approaches, such as cognitive-behavioral therapy, as a principle of chronic disease management for long-term outpatients. Data on pharmacotherapy and psychosocial treatments are emerging, and clinicians should integrate these two treatment options into the standard of care. This expert roundtable supplement focuses on the treatment and management of the bipolar outpatient at risk for a depressive relapse as well as patients experiencing both acute and long-term symptoms of the disorder. Two case studies are presented to elucidate the best practices for the varying clinical states of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="N">Periodicity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18163039</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10442791</PMID><DateCompleted><Year>1999</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Secondary mania in patients with HIV infection.</ArticleTitle><Pagination><MedlinePgn>353-60</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to identify a cohort of patients with mania secondary to HIV infection, to describe the clinical and radiological features of HIV-related mania, and to describe the treatment outcome of the patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">All patients referred to the HIV consultation-liaison psychiatry service over the 29-month period from January 1993 to June 1995 were screened for the presence of manic symptoms. Diagnosis of mania was made according to DSM-III-R. Cases were defined as secondary mania if there was no clear history of mood disorder, and no family history of mood disorder. Cases were interviewed by the treating psychiatry registrar and psychiatrist to obtain information regarding present and past psychiatric history and family history of psychiatric disorder. The psychiatry registrar and consultant determined treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-three patients with mania were identified; 19 were considered to have secondary mania. The prevalence of secondary mania over the 29 months was 1.2% for HIV-positive patients, and 4.3% for those with AIDS. The clinical characteristics and response to treatment appeared to be similar to mania associated with bipolar affective disorder (primary mania). Neuroradiological abnormalities were common, occurring in 10 of the 19 patients, but did not appear to be clinically relevant. Cognitive impairment developed in five of the 15 patients where follow-up was possible.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mania occurring in advanced HIV disease appears to be more common than expected from epidemiological data regarding bipolar affective disorder. Differentiating secondary from primary mania has implications for the management and prognosis of mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellen</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia. sellen@austin.unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judd</LastName><ForeName>F K</ForeName><Initials>FK</Initials></Author><Author ValidYN="Y"><LastName>Mijch</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Cockram</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014739" MajorTopicYN="N" Type="Geographic">Victoria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10442791</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1614.1999.00574.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15556120</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>10</Issue><PubDate><Year>2004</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinicians' assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients.</ArticleTitle><Pagination><MedlinePgn>757-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Suicide is a major risk for those with bipolar disorder, a risk amplified by comorbid substance abuse in some, but not all, previous studies. To further explore the relationships of substance abuse, suicide, and bipolarity as they present in clinical practice, we analyzed standardized clinical data from a large acute psychiatric inpatient service.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Standardized clinical evaluations of 7819 patients with diagnoses of bipolar depression (n=990), bipolar mania (n=948), unipolar depressive episode (n=3626), or schizophrenia-schizoaffective disorders (n=2255) were analyzed to evaluate the relationship between current substance-use problems, substance-induced symptoms, and a current suicide crisis, as well as lifetime suicide attempts, with logistic regressions adjusting for age, gender, and ethnicity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Across the combined groups, current substance-use problems were significantly associated with a lifetime suicide attempt (odds ratios [ORs] 1.6-2.5) and to a lesser degree to the admission suicide crisis (ORs 1-2.2). Among bipolar (depressed/manic) patients, but not other diagnostic groups, those with both current substance-use problems and substance-induced symptoms had even higher rates of a recent suicide crisis (ORs 1.5-3.1) and of a lifetime attempt (ORs 2.5-3.4).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In bipolar patients, substance use disorder doubled and substance use disorder plus substance-induced symptoms tripled the suicidal risk. Implications for future research are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Comtois</LastName><ForeName>Katherine Anne</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington 98104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Joan E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Roy-Byrne</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ries</LastName><ForeName>Richard K</ForeName><Initials>RK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014861" MajorTopicYN="N" Type="Geographic">Washington</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15556120</ArticleId><ArticleId IdType="pii">S0006-3223(04)01062-5</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2004.10.003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26222302</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2238-0019</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><MedlineDate>2015 Apr-Jun</MedlineDate></PubDate></JournalIssue><Title>Trends in psychiatry and psychotherapy</Title><ISOAbbreviation>Trends Psychiatry Psychother</ISOAbbreviation></Journal><ArticleTitle>Where does her mood come from? An organic approach to a once functional patient.</ArticleTitle><Pagination><MedlinePgn>100-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/2237-6089-2014-0053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2237-60892015000200100</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report the rare development of manic symptoms in a patient with schizophrenia and discuss its differential diagnosis.</AbstractText><AbstractText Label="CASE DESCRIPTION" NlmCategory="METHODS">Diagnostic criteria were based on the International Classification of Diseases, 10th edition (ICD-10). A 63-year-old female (diagnosed with schizophrenia since she was 28) was brought to the emergency room with symptoms consistent with manic episode and physical examination suggestive of thyrotoxicosis. Graves' disease was confirmed by subsequent laboratory tests. She was treated successfully with radioiodine ablation, leading to full remission of manic symptoms.</AbstractText><AbstractText Label="COMMENTS" NlmCategory="CONCLUSIONS">Schizophrenia is a chronic disease that affects about 1% of the population worldwide. The main symptoms of the disorder are altered affection, delusions, and hallucinations. Graves' disease is an autoimmune condition in which antibodies increase the production and release of thyroid hormones. There are reports about the development of mood symptoms in patients with Graves' disease that remit with adequate treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dutra</LastName><ForeName>Pablo Eduardo Pereira</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Centro PsiquiÃ¡trico do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurgel</LastName><ForeName>Wagner de Sousa</ForeName><Initials>Wde S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Centro PsiquiÃ¡trico do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higa</LastName><ForeName>Renato Alves</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Centro PsiquiÃ¡trico do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, CÃ­rculo PsicanalÃ­tico do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Trends Psychiatry Psychother</MedlineTA><NlmUniqueID>101610695</NlmUniqueID><ISSNLinking>2237-6089</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006111" MajorTopicYN="N">Graves Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26222302</ArticleId><ArticleId IdType="pii">S2237-60892015000200100</ArticleId><ArticleId IdType="doi">10.1590/2237-6089-2014-0053</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2078211</PMID><DateCompleted><Year>1990</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><PubDate><Year>1990</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Life events and the onset of mania.</ArticleTitle><Pagination><MedlinePgn>508-14</MedlinePgn></Pagination><Abstract><AbstractText>Thirty manic in-patients were interviewed in hospital using the LEDS, and 24 were re-interviewed 6-12 months after discharge. Data for life events were analysed by: comparing events before onset of mania and before re-interview; and comparing these manic patients with patients in other studies which examined life events and the onset of schizophrenia and depression. No relationship was found between life events and the onset of mania in this preliminary study. Previous studies reporting a link between events and the onset of mania have serious methodological flaws, and definitive data have yet to be produced.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sclare</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oldham and District General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creed</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1990 Sep;157:450-1</RefSource><PMID Version="1">2078229</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2078211</ArticleId><ArticleId IdType="pii">S0007125000178705</ArticleId><ArticleId IdType="doi">10.1192/bjp.156.4.508</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27017320</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>May</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Emotional and impulsive dimensions in bipolar disorder and borderline personality disorder].</ArticleTitle><Pagination><MedlinePgn>199-204</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(16)00039-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2016.02.007</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies have shown that patients with borderline personality disorder are often misdiagnosed to have bipolar disorder and conversely. Indeed, a number of characteristics common to both disorders could explain this problem: emotional instability as well as impulsivity represent confounding factors and contribute to the risk of misdiagnosis. However, it appears that these characteristics manifest themselves in different ways according to the pathology. The aim of the study is to show differences between affective lability, emotional intensity and impulsivity dimensions. The clinical aim is to refine bipolar disorder and borderline personality disorder diagnosis, to improve psychological care for these patients in the long-term.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We compared the emotional and impulsive dimensions in two groups of patients: a group of 21 patients with bipolar disorder and a group of 19 patients with borderline personality disorder. Tools: ALS, a self-report questionnaire to evaluate affective lability, AIM, a self-report questionnaire to see affective intensity, and UPPS, a self-report questionnaire to measure impulsivity according to several dimensions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results indicate that borderline patients scored significantly higher than bipolar patients at the ALS and AIM scales. Regarding the UPPS, borderline patients scored significantly higher than bipolar patients for the dimensions "lack of premeditation" and "lack of perseverance"; however, bipolar patients had significantly higher scores than borderline patients for the dimension "negative emergency".</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study shows that bipolar disorder and borderline personality can be differentiated thanks to emotional dimensions as well as different dimensions of impulsivity: borderline patients appear to have an affective lability and intensity more important than bipolar patients; it also appears that impulsivity manifests itself differently according to the disorder.</AbstractText><CopyrightInformation>Copyright Â© 2016 L'EncÃ©phale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de psychologie clinique Ã©valuation clinique des troubles psychopathologiques et des psychothÃ©rapies (EVACLIPSY), universitÃ© Paris Ouest, 92000 Nanterre-La-DÃ©fense, France. Electronic address: leblanc-amelie@hotmail.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarroir</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de psychologie clinique Ã©valuation clinique des troubles psychopathologiques et des psychothÃ©rapies (EVACLIPSY), universitÃ© Paris Ouest, 92000 Nanterre-La-DÃ©fense, France; Centre hospitalier Fernand-Widal, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorspan</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre hospitalier Fernand-Widal, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre hospitalier Fernand-Widal, AP-HP, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leveillee</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UniversitÃ© des Trois-RiviÃ¨res, QuÃ©bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de psychologie clinique Ã©valuation clinique des troubles psychopathologiques et des psychothÃ©rapies (EVACLIPSY), universitÃ© Paris Ouest, 92000 Nanterre-La-DÃ©fense, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Dimensions affectives et impulsives dans le trouble bipolaire et le trouble de la personnalitÃ© borderline.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="Y">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Affective intensity</Keyword><Keyword MajorTopicYN="N">Affective lability</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Borderline personality disorder</Keyword><Keyword MajorTopicYN="N">Impulsivity</Keyword><Keyword MajorTopicYN="N">ImpulsivitÃ©</Keyword><Keyword MajorTopicYN="N">IntensitÃ© affective</Keyword><Keyword MajorTopicYN="N">LabilitÃ© affective</Keyword><Keyword MajorTopicYN="N">Trouble bipolaire</Keyword><Keyword MajorTopicYN="N">Trouble de la personnalitÃ© borderline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27017320</ArticleId><ArticleId IdType="pii">S0013-7006(16)00039-7</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2016.02.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15708417</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>84</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Irritable-hostile depression: further validation as a bipolar depressive mixed state.</ArticleTitle><Pagination><MedlinePgn>197-207</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">"Hostile depression" has unofficially long been described as a depressive subtype, but since DSM-III, the affect has been made a defining characteristic of borderline personality disorder. The related affect of irritability in DSM-IV-TR subsumes various hostile nuances and is included in the stem question for mood disorders--especially for hypomanic episodes; in children, it is nonetheless a sign of depression. Then, there is the unofficial more general concept of depression with anger attacks, until recently ostensibly a "unipolar" (UP) disorder. A veritable tower of Babel indeed. In the present analyses, our aim was to extend previous research on irritable-hostile depression to more specific parameters of bipolarity and depressive mixed state (DMX).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive 348 bipolar-II (BP-II) and 254 unipolar (UP) major depressive disorder (MDD) outpatients (off psychoactive agents, including substances of abuse), were interviewed with the Structured Clinical Interview for DSM-IV, the Hypomania Interview Guide, and the Family History Screen. Borderline personality, a confounding variable, rare in the FB setting, was excluded. Irritability was defined according to DSM-IV-TR, which includes various features of hostility and anger. Depressive mixed state (DMX) was defined as a major depressive episode (MDE) plus three or more concurrent intradepressive hypomanic symptoms, whether it occurred in BP-II or MDD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MDE with irritability was present in 59.7% (208/348) of BP-II and in 37.4% (95/254) of MDD (p=0.0000). In BP-II, MDE with, versus MDE without, irritability had significantly younger index age, higher rates of axis I comorbidity, atypical depressive features, and DMX. Upon logistic regression, we found a significant independent association between BP-II MDE with irritability and DMX. In UP, MDE with, versus without, irritability had significantly younger age and age at onset, higher rates of atypical depression, DMX, and bipolar family history. Logistic regression revealed a significant independent association between MDE with irritability and DMX. Given that we had excluded patients with borderline personality, the high prevalence of irritable-hostile depressives in this outpatient population means that hostility cannot be considered the signature of that personality. Factor analysis revealed independent "psychomotor activation" and "irritability-mental activation" factors. Odds ratios of irritability for DMX were highest in the "UP" MDD group (=12.2); for predicting DMX, irritability had the best psychometric profile of sensitivity of 66.3% and a specificity of 86.1% for this group as well.</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">We did not use specific instruments to measure irritable, hostile, and angry affects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These analyses show that irritable-hostile depression is distinct from agitated depression. Whether arising from a BP-II or MDD baseline, irritable-hostile depression emerges as a valid entity with strong links to external bipolar validators, such as bipolar family history. Irritable-hostile phenomenology in depression appears to be a strong clinical marker for a DMX. Irritable-hostile depression as a variant of DMX deserves the benefit of what seems to work best in practice, i.e., anticonvulsant mood stabilizers and/or atypical antipsychotics. Formal treatment studies are very much needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>E. Hecker Outpatient Psychiatry Center, Ravenna, Italy; Department of Psychiatry, National Health Service, Forli, Italy. FrancoBenazzi@FBenazzi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006791" MajorTopicYN="Y">Hostility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="Y">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>02</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15708417</ArticleId><ArticleId IdType="pii">S0165-0327(04)00252-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.07.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28559123</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Biological dysrhythm in remitted bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>218-224</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(17)30006-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2017.05.012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent treatment guidelines support treatment of biological rhythm abnormalities as a part of treatment of bipolar disorder, but still, literature examining various domains (Sleep, Activity, Social, and Eating) of biological rhythm and its clinical predictors are less.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The main aim of our study is to compare various domains of biological rhythm among remitted bipolar I subjects and healthy controls. We also explored for any association between clinical variables and biological rhythm among bipolar subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">40 subjects with Bipolar I disorder and 40 healthy controls who met inclusion and exclusion criteria were recruited for the study. Diagnoses were ascertained by a qualified psychiatrist using MINI 5.0. Sociodemographic details, biological rhythm (BRIAN-Biological Rhythm Interview of assessment in Neuropsychiatry) and Sleep functioning (PSQI- Pittsburgh Sleep Quality Index) were assessed in all subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age of the Bipolar subjects and controls were 41.25Â±11.84years and 38.25Â±11.25 years respectively. Bipolar subjects experienced more biological rhythm disturbance when compared to healthy controls (total BRIAN score being 34.25Â±9.36 vs 28.2Â±6.53) (p=0.002). Subsyndromal depressive symptoms (HDRS) had significant positive correlation with BRIAN global scores(r=0.368, p=0.02). Linear regression analysis showed that number of episodes which required hospitalization (Î²=0.601, t=3.106, P=0.004), PSQI (Î²=0.394, t=2.609, p=0.014), HDRS (Î²=0.376, t=2.34, t=0.036) explained 31% of variance in BRIAN scores in remitted bipolar subjects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Biological rhythm disturbances seem to persist even after clinical remission of bipolar illness. More studies to look into the impact of subsyndromal depressive symptoms on biological rhythm are needed.</AbstractText><CopyrightInformation>Copyright Â© 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Aishwarya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PSG Institute of Medical Sciences and Research (PSG IMS &amp; R), Coimbatore, Tamilnadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palaniappan</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>PSG Institute of Medical Sciences and Research (PSG IMS &amp; R), Coimbatore, Tamilnadu, India. Electronic address: http://mailto:drpradeeppal@yahoo.co.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRIAN</Keyword><Keyword MajorTopicYN="N">Biological rhythm</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Circadian rhythm</Keyword><Keyword MajorTopicYN="N">Sleep functioning</Keyword><Keyword MajorTopicYN="N">Social rhythm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28559123</ArticleId><ArticleId IdType="pii">S1876-2018(17)30006-0</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2017.05.012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19252157</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><Volume>194</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial.</ArticleTitle><Pagination><MedlinePgn>260-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.bp.107.040485</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The long-term efficacy of psychological interventions for bipolar disorders has not been tested.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This study assessed the efficacy of group psychoeducation to prevent recurrences and to reduce time spent ill for people with bipolar disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A randomised controlled trial with masked outcome assessment comparing group psychoeducation and non-structured group intervention during 5-year follow-up. One hundred and twenty people with bipolar disorders were included in the study and 99 completed 5-year follow-up. Time to any recurrence, number of recurrences, total number of days spent ill, frequency and length of hospitalisations were the main outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the 5-year follow-up, time to any recurrence was longer for the psychoeducation group (log rank=9.953, P&lt;0.002). The psychoeducation group had fewer recurrences (3.86 v. 8.37, F=23.6, P&lt;0.0001) of any type and they spent less time acutely ill (154 v. 586 days, F=31.66, P=0.0001). The median number of days of hospitalisation per hospitalised participant was also lower for the psychoeducation group (45 v. 30, F=4.26, P=0.047).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Six-month group psychoeducation has long-lasting prophylactic effects in individuals with bipolar disorders. Group psychoeducation is the first psychological intervention showing such a long-term maintained efficacy in people with bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic of Barcelona, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>SÃ¡nchez-Moreno</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Palomino-Otiniano</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>MartÃ­nez-ArÃ¡n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Br J Psychiatry. 2009 Jun;194(6):571</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2009 Nov;12(4):110</RefSource><PMID Version="1">19854772</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="Y">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19252157</ArticleId><ArticleId IdType="pii">S0007125000249179</ArticleId><ArticleId IdType="doi">10.1192/bjp.bp.107.040485</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19727533</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-9285</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Social psychiatry and psychiatric epidemiology</Title><ISOAbbreviation>Soc Psychiatry Psychiatr Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Social and clinical comparison between schizophrenia and bipolar disorder type I with psychosis in Costa Rica.</ArticleTitle><Pagination><MedlinePgn>675-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00127-009-0118-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Schizophrenia (SC) and bipolar disorder (BP) are two of the most severe and incapacitating mental disorders. It has been questioned whether these two conditions designate distinct illnesses with different etiologies or whether they represent different ends of a clinical spectrum with a common etiology.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This study compares social and clinical characteristics of 84 SC and 84 BP subjects from the Costa Rican Central Valley (CRCV) using information from the DIGS, FIGS and psychiatric records. Each of these subjects had a best estimate lifetime consensus diagnosis of either bipolar type I or SC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with SC differed from subjects with BP in social adjustment measures like marital and employment status, and number of children. Both groups were very similar in years of education, age of onset of their illness, history of other psychiatric co-morbidities, and treatment received.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The high percentage of psychosis in the BP group (97.6%) may largely explain the similarities found between groups in their clinical characteristics.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The differences in social and functional decline support the original dichotomy described by Kraepelin based on chronicity and periodicity between these two psychotic disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Biology Research Center, University of Costa Rica, Sabanilla, Costa Rica. adrianapac@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barguil</LastName><ForeName>Marcela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Contreras</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dassori</LastName><ForeName>Albana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Escamilla</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>RaventÃ³s</LastName><ForeName>Henriette</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Soc Psychiatry Psychiatr Epidemiol</MedlineTA><NlmUniqueID>8804358</NlmUniqueID><ISSNLinking>0933-7954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003364" MajorTopicYN="N" Type="Geographic">Costa Rica</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19727533</ArticleId><ArticleId IdType="doi">10.1007/s00127-009-0118-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 Jul;3(4):337-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9702743</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2007 Jan;97(1):68-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17138910</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2007 Jun;190:521-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17541113</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1994 Mar 10;330(10):681-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8107719</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7944874</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2005 May;2(5):e141</Citation><ArticleIdList><ArticleId IdType="pubmed">15916472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Jan 1;53(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11728836</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):350-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15133590</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9989552</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Jan;36(1):57-68</Citation><ArticleIdList><ArticleId IdType="pubmed">16202191</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Jun;152(6):869-75</Citation><ArticleIdList><ArticleId IdType="pubmed">7755116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):117-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9858071</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Nov;154(11):1544-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9356562</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1997 Oct;32(7):416-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9383973</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Mar;31(2-3):130-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10719141</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Jul;102(1-3):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">18514488</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2005 Mar;9(9):1-156, iii-iv</Citation><ArticleIdList><ArticleId IdType="pubmed">15774232</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Oct;165(4):466-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7804660</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1995 Apr;91(4):222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7625201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 2000;78(4):413-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10885160</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Apr;58(1):75-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10760561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1987 Dec 26;2(8574):1483-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2892048</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Jun;85(6):423-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1642123</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2008 Aug;43(8):673-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18427703</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Jul-Aug;44(4):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12923703</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2001 Aug;3(4):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11470041</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2007;69(3):587-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17379426</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2000;250(6):286-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11153963</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Mar;155(3):355-64</Citation><ArticleIdList><ArticleId IdType="pubmed">9501745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):565-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12796219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Jul;42(9):708-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18331741</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Aug;39(8):879-83</Citation><ArticleIdList><ArticleId IdType="pubmed">7103676</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2004 Apr 28;2:13</Citation><ArticleIdList><ArticleId IdType="pubmed">15115547</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 2001 Apr;40:s60-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Jan;61(1):28-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14706941</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14601037</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Jun;156:842-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2207514</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Genet. 2001 Jan;17(1):35-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11163920</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1999 Dec;34(12):617-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10703270</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):531-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11018225</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Feb;162(2):257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15677588</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1988 Jan-Feb;1(1):3-18</Citation><ArticleIdList><ArticleId IdType="pubmed">3154503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>